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This dissertation contains six chapters regarding the biochemical studies of the chain 
initiation, HMG β-branching, halogenation, cyclopropanation and decarboxylative chain 
termination in the curacin A pathway (see next page for the structure of this dissertation). 
Chapter 1 is an introduction to the whole project, and some sections are partially adapted 
from our NIH proposal and an ecology manuscript submitted to Applied and 
Environmental Microbiology. Chapter 2 is mainly adapted from our paper published in 
Science regarding the chain initiation steps (Science 2007, 318, 970-974). Chapter 3 is 
adapted from our two papers focused on the polyketide β-branching modification (Journal 
of the American Chemical Society, 2006, 128, 9014-9015; Journal of Biological 
Chemistry, 2007, 282, 35954-35963). Chapter 4 is adapted from our manuscript submitted 
to Nature, which is currently in revision. It tells a story about the cyclopropane formation 
and the vinyl chloride formation in the curacin and jamaicamide pathways, respectively. 
Chapter 5 describes a part of the work on the unusual chain termination, and this work is 
in preparation for publication. In chapter 6, I summarize some points we plan to discuss in 
a review article. Due to the limitation of space, results from some other projects I 
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1.1  BACKGROUND 
1.1.1  Natural Products from Marine Cyanobacteria 
Natural products have been playing a crucial role in the development of all classes of 
new pharmaceuticals, especially in the area of oncology. For example, of all cancer drugs 
available during the period 1940-2002, 40% are natural products or natural product derived, 
10% are biologics or vaccines, 20% are synthetics that mimic natural product 
pharmacophores, and just 30% are of unique synthetic origin (1). Representatives for the 
National Cancer Institute’s Developmental Therapeutics Program “strongly advocate 
expanding, not decreasing, the exploration of nature as a source of novel active agents that 
may serve as the leads and scaffolds for elaboration into desperately needed efficacious 
drugs for a multitude of disease indications.” 
Marine cyanobacteria are extraordinarily rich in their production of 
biologically-active and structurally-unique natural products, directly reflecting the 
amazing biosynthetic capacities of these organisms (2, 3). A number of these secondary 
metabolites represent lead compounds in drug discovery programs aimed at providing 
new therapies to treat cancer, bacterial infections, inflammatory responses and in crop 
protection to kill harmful microbial pathogens and insects. The major theme in 
cyanobacterial chemistry is the production of polypeptides modified with various lipid 
components to make diverse lipopeptides. Unusual functional groups are introduced into 
these lipopeptide scaffolds by action of numerous tailoring reactions, including those that 
form heterocyclic rings, oxidations at unusual positions, and halogenation reactions utilizing 
both bromine and chlorine, and occasionally, iodine. 
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The natural products isolated from both aquatic and marine cyanobacteria have been 
one of the richest sources of new clinical candidates and lead compounds for the treatment 
of cancer, and several of these exert their activity through modulation of microfilament 
polymerization processes. For example, a Curaçao collection of Lyngbya majuscula yielded 
a highly potent antitubulin agent, curacin A, which binds at the colchicine binding site on 
tubulin (4, 5). Curacin A has shown significant in vivo antitumor effects in human 
xenografts. However, significant problems with the instability and poor water solubility of 
curacin A have hindered its development as an anticancer lead compound (6). Wipf and his 
colleagues have been applying combinatorial synthesis methods to produce more stable and 
efficacious curacin A analogs (6). 
1.1.2  Chemical Diversity of Lyngbya Natural Products 
The genus Lyngbya consists of filamentous cyanobacteria that cause periodic, but in 
some cases long lasting, blooms in shallow tropical and sub-tropical marine and estuarine 
environments (7, 8). Lyngbya species are prolific producers of secondary metabolites, 
primarily lipopeptides, cyclic peptides, and depsipeptides. Currently, the largest number of 
marine cyanobacterial metabolites comes from diverse strains of a single species, L. 
majuscula (Figure 1-1), obtained at tropical locations worldwide that produce collectively 
over 200 different compounds. Dissection 
of the biosynthetic subunits (e.g. amino 
acids, sugars, fatty acids) that comprise 
these metabolites indicates a range of 1 to 5 
units per molecule, with about 25% of the 
precursors of these compounds derived 
from polyketides or fatty acids, another 
25% from amino acids, and 25% from 
methyl groups likely deriving from 
S-adenosylmethionine (SAM). The 
remaining 25% of the biosynthetic subunits derive from terpenes and sugars, or are of 
uncertain origin. The amino acids are predominately aliphatic (70%), of L stereochemistry, 
N-methylated, and very rarely involve charged side chain residues. For example, many 
Figure 1-1. Lyngbya majuscula. 
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marine cyanobacterial metabolites contain the unique “signature” amino acid, N, 
O-dimethyltyrosine. It can thus be concluded that the roughly 200 metabolites currently 
known from L. majuscula strains form an extraordinarily diverse set of natural product 
structures (3). As such, L. majuscula provides us an intriguing model system for genetic and 
biochemical studies towards understanding the evolution of the biosynthetic genes as well as 
metabolic diversification of natural products. 
Many Lyngbya-derived bioactive secondary metabolites confer competitive 
advantage to the cyanobacteria by deterring grazers, allowing the cyanobacteria to 
overgrow other organisms in benthic habitats (9). In addition to rendering Lyngbya spp. 
unpalatable, bioactive peptides in L. spp. may have additional impacts, such as 
allelopathy against sympatric benthic organisms (9, 10). Also several bioactive 
compounds isolated from L. spp. have been well studied for their pharmaceutical and 
biotechnological applications, but very little is known about their ecological impacts on 
marine environments. Lyngbyatoxin A, an indole alkaloid first isolated from a Hawaiian 
strain of L. majuscula (11), is one of a few compounds subjected to extensive 
investigation for their ecological roles. It was proved to be a protein kinase C activator 
that causes contact dermatitis in humans and acts as a tumor promoter in mice (12, 13). In 
the marine habitat, it acts as a feeding deterrent to generalist grazers, but it stimulates 
feeding in the specialist grazer Stylocheilus striatus (14). Lyngbyatoxin A may have 
detrimental health impacts for generalist marine grazers that come into contact with the 
Lyngbya (15), and as a tumor promoter, it may be involved in fibropapillomatosis, a 
disease of marine turtles that causes internal and external tumorous masses (16). Thus, a 
better understanding of chemical diversity of Lyngbya has many implications for both 
ecosystem and human health. 
1.1.3  Cyanobacterial PKS and NRPS Gene Clusters 
Marine cyanobacteria frequently combine polyketide synthase (PKS) and 
non-ribosomal peptide synthetase (NRPS) pathways to create an amazingly diverse set of 
natural product structures, generally characterized as “lipopeptides”(2, 3, 17). The 
biosynthetic gene clusters recently isolated from marine cyanobacteria by the Sherman and 
 4
Gerwick labs confirm the highly integrated use of PKS and NRPS pathways, and provide 
information about the unique biosynthetic machinery used by these microbes to introduce 
branching methyl groups, modified amino acids, and halogen atoms to produce diverse 
functionalities. To date, the Sherman and Gerwick labs have been involved in the complete 
cloning, sequencing and biochemical characterization of seven cyanobacterial pathways; 
barbamide (bar) (18) curacin A (cur) (19) cryptophycin (crp) (20), carmabin (car) (Jia et al., 
unpublished), lyngbyatoxin (ltx) (21) jamaicamide (jam) (22), and hectochlorin (hec) (23) 
(Figure 1-2). 
With each new pathway, additional insights were developed into the unique nature of 
the secondary metabolite pathways of these organisms. They contain a wealth of novel gene 
sequences, gene cluster architectures and chain termination motifs. For example, in the 
curacin A and jamaicamide pathways (19, 22), a novel gene cassette was identified to be 
responsible for introduction of a branching carbon to a β-carbonyl compound (e.g. a diketide 
or a ketide-extended amino acid). According to protein database analysis, this eight open 
reading frame (ORF) cassette spanning ~10 kb of DNA is most closely related to an 
HMG-CoA synthase, enoyl-CoA hydratase along with several PKS-associated proteins, 





























































Figure 1-2. Cyanobacterial metabolites with their biosynthetic pathways identified by the 
Sherman and Gerwick labs. 
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the feeding experiments, this novel gene arrangement condenses C-2 of an acetate unit with 
the β-carbonyl of a nascent polyketide, and by steps that remain largely undefined at present, 
catalyze the decarboxylation of C-1 resulting in the formation of a cyclopropyl ring in the 
case of curacin A,(19) and a vinyl chloride in the case of jamaicamide (22). Accordingly, 
literature review of known marine natural products provides evidence for the role of this 
gene cassette in the construction of over 50 cyanobacterial metabolites, introducing a wide 
range of functionalities in a pendant carbon atom (cyclopropyl, carbinol, secondary methyl, 
hydroxy methyl, vinyl methyl, terminal vinyl, and terminal vinyl chloride). 
1.2  PRIOR WORK 
Curacin A is a unique polyketide/non-ribosomal peptide natural product discovered 
in 1994 (26). This marine cyanobacterial natural product has attractive features as an 
anticancer lead candidate and was shown (27) to have potent anti-proliferative and 
cytotoxic activity against colon, renal, and breast-cancer derived cell lines. Curacin A has 
been studied extensively for its ability to inhibit tubulin polymerization through 
interaction at the colchicine binding site, and thereby exert its antiproliferative effects on 
cells (4). Simultaneously, there has been considerable interest to produce curacin A by 
total synthesis (28), and to produce synthetic as well as semi-synthetic analogs to explore 
structure-activity relationships (27). Most recently, an elegant combinatorial synthesis 
approach has been applied that has resulted in a chemically-stabilized curacin A 
derivative with improved water solubility characteristics, yet it retains the remarkable 
biological effect of curacin A on microtubules (6). 
Analysis of the precise biosynthetic origin of curacin A has been of great interest, 
and has provided key information to enable a complete genetic analysis of the curacin 
metabolic system (19). Precursor labeling studies using cultured Lyngbya majuscula 
demonstrated that the biosynthetic units for curacin A are acetate and cysteine (29). 
Notable structural features include a cyclopropane ring, thiazoline unit, cis-double bond 
and a terminal alkene residue. Each functional group is introduced by an intriguing set of 
biochemical steps, a subset of which we plan to study and then develop for 


























Recently, we identified and characterized a gene cluster (cur) whose architecture 
and domain organization correlates directly with that expected for curacin A (19). A 
compelling feature of the system is its co-linear set of catalytic domains including a 
loading domain, a series of 14 ORFs (spanning ~75 kb) whose deduced sequences are 
consistent with biochemical elaboration of a cyclopropane ring, a single mixed 
PKS/NRPS bimodular unit, and a series of seven PKS monomodules with a terminal 
thioesterase (TE) domain (Figure 1-3). The cur cluster is unique in that each of the PKS 
multifunctional proteins is monomodular, a feature found in the final two modules of the 
pikromycin PKS (30). We plan to focus on several unique features of the curacin 
pathway. First, we are interested in several early steps including the sequence motif 
(Figure 1-3, Cur A (Hal-ACPI-ACPII-ACPIII), CurB, C, D, E, CurF (ECH-ER)) that likely 
prescribes synthesis of the cyclopropane ring and includes a stand-alone ACP, a putative 
HMG-CoA synthase-like enzyme (CurD), a ketosynthase and two enoyl-CoA hydratases 
(CurE ECH1, CurF ECH2 domain). The ability to understand the mechanistic basis for 
C-2 insertion reactions that provide variant functional group placements in natural 
product systems will be an important component of our planned biochemical studies of 
the jamaicamide system as well due to its identical architecture and extremely high level 
of amino acid sequence identity throughout this motif. Secondly, we are interested in 
understanding the chain initiation process which is most likely mediated by a domain 
showing homology to GNAT superfamily. Finally, we will propose experiments that 
focus on determining the basis for terminal double bond formation and release of curacin 
A, specified by the terminal catalytic domains of CurM. 
1.3  SPECIFIC AIMS 
1. To investigate the unusual polyketide chain initiation in the curacin A 
pathway. By collaboration with the Smith group in Life Sciences Institute, we will try to 
understand the catalytic mechanisms of the corresponding enzymes. 
2. To investigate the cyclopropane formation in the curacin A pathway and the 
vinyl chloride formation in the jamaicamide pathway. We need to establish the 
biochemistry of polyketide β-branching, halogenation and cyclopropanation. By 
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collaboration with the Smith group in Life Sciences Institute, we will try to understand 
the catalytic mechanisms of the corresponding enzymes. 
3. To investigate the decarboxylative chain termination in the curacin A 
pathway. By collaboration with the Wipf group at the University of Pittsburgh, we will 
synthesize the substrates for the enzyme assays. By collaboration with the Smith group in 
Life Sciences Institute, we will try to understand the catalytic mechanisms of the 
corresponding enzymes. 
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GNAT-LIKE STRATEGY FOR POLYKETIDE CHAIN 
INITIATION 
2.1  SUMMARY 
In this chapter, a new biochemical strategy for chain initiation is described for the 
loading module of the curacin A polyketide synthase, an anti-cancer lead derived from 
the marine cyanobacterium Lyngbya majuscula. A central GNAT domain bears 
bifunctional decarboxylase/S-acetyltransferase activity, both unprecedented for the 
GNAT superfamily. A CurA loading tridomain consisting of adaptor-GNAT-acyl carrier 
protein was assessed biochemically, revealing that GNATL catalyzes decarboxylation of 
malonyl-CoA to acetyl-CoA, and direct S-acetyl transfer from acetyl-CoA to ACPL. 
Moreover, the N-terminal AR domain was shown to facilitate acetyl group transfer. 
Crystal structures of GNATL were solved at 1.95Å (ligand-free form) and 2.75Å 
(acyl-CoA complex), showing distinct substrate tunnels for acyl-CoA and holo-ACPL 
binding. Modeling and site directed mutagenesis experiments demonstrated that His389 
and Thr355 at the convergence of the CoA and ACP tunnels participate in malonyl-CoA 
decarboxylation, but not in acetyl transfer. Decarboxylation precedes acetyl transfer, 
leading to acetyl-ACPL as the key curacin A starter unit. 
2.2  INTRODUCTION 
Modular polyketide synthases (PKSs) are large biosynthetic machines that assemble 
structurally diverse secondary metabolites with a broad spectrum of biological activities. 
Multifunctional enzymes catalyze programmed metabolic pathways to assemble 
short-chain acyl-CoA building blocks into complex polyketide products by one step of 
chain initiation followed by multiple steps of chain elongation and processing. Polyketide 
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chain elongation steps are catalyzed by extension modules minimally comprised of three 
essential domains, ketosynthase (KS), acyltransferase (AT) and acyl carrier protein 
(ACP), plus auxiliary processing domains (e.g. ketoreductase, dehydratase, enoyl 
reductase). As in fatty acid synthases (FASs), PKSs catalyze chain extension by a 
decarboxylative condensation reaction. Polyketide chain initiation is catalyzed by a 
loading module that, in all characterized PKSs, consists of domains homologous with 
domains of the minimal extension module. A loading acyltransferase domain (ATL) uses 
an acyl-CoA substrate to load an adjacent ACP domain (ACPL). Typically, the ATL 
substrate is an α-carboxylated acyl-CoA, like the substrate for chain extension, and acyl 
transfer is followed by decarboxylation by a “KSQ” domain within the loading module (1, 
2). Alternatively, in the well studied erythromycin PKS, a trans-acting 
methylmalonyl-CoA decarboxylase acts on α-carboxylated acyl-CoA prior to acyl 
transfer by ATL (3, 4). 
Curacin A, a marine cyanobacterial metabolite from Lyngbya majuscula, is a mixed 
polyketide-non-ribosomal peptide natural product with potent anti-proliferative and 
cytotoxic activity against colon, renal, and breast-cancer derived cell lines (5). The recent 
identification and partial characterization of the biosynthetic pathway for curacin A (6) 
revealed an atypical loading module, in which only the ACP domain (ACPL) resembled 
typical PKS domains. Similar loading modules also occur in the biosynthetic pathways 
for pederin (7), its structural analogues onnamide/theopederin (8), myxovirescin A (9), 
and rhizoxin (10). In these natural product gene clusters, the chain initiation modules are 
structured as: N-terminal ~180 amino acid region of unknown function (referred to 
hereafter as adapter domain (AR), not present in OnnB for onnamide), a variable-length 
linker region, a domain showing homology to GCN5-related N-acyltransferase (GNAT) 
(hereafter referred to as GNATL), and an acyl carrier protein (ACPL) (Figure 2-1). The 
predicted function of all of these GNATL-containing modules was to load an acetyl group 
onto the PKS assembly line (6-10), but the mechanism of this process remained unclear. 
GNAT is a superfamily of N-acetyltransferase enzymes that catalyze acyl transfer to 
a primary amine and function in diverse pathways in prokaryotes and eukaryotes 
including antibiotic resistance, gene regulation, and hormone synthesis (11, 12). 
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Typically, prokaryotic and eukaryotic GNATs have separate binding sites for the acyl 
donor and acceptor substrates, and catalyze direct acyl transfer in the absence of a 
covalent intermediate on the enzyme (11). GNATs are mechanistically and structurally 
distinguished from the polyketide and fatty acid synthase acyltransferase domains that 
function as S-acyltransferases, employ a covalent enzyme intermediate, and belong to the 
α/β hydrolase superfamily (13-16). Thus, acyl transfer to an ACP thiol group represents 
an unprecedented reaction for GNAT enzymes. 
2.3  RESULTS 
2.3.1  Biochemical Assays of AR-GNATL-ACPL Tridomain 
To investigate the atypical PKS chain initiation process, we cloned and 
overexpressed fragments of curA encoding the N-terminal tridomain, AR-GNATL-ACPL. 
  
 
Figure 2-1. Initiation modules containing GNATL and compounds produced by the PKS 
pathways. All GNATL containing modules are predicted to catalyze the loading of an acetyl 
group. AR, adapter domain; GNATL, GNAT decarboxylase. Due to the high similarity of 
pederin, onnamides and theopederin, only onnamide A is shown as the prototype example. 
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Several expression constructs were made to include the three components in various 
combinations (Figure 2-2A and Figure 2-S1A, B). Constructs containing ACPL were 
generated in holo form by co-expression with a plasmid encoding phosphopantetheinyl 
transferase (Sfp) from B. subtilis (17); without this plasmid, E. coli produced ACPL in the 
apo form. All constructs lacking the AR domain were readily produced as soluble 
polypeptides, but those including AR (AR-GNATL and AR-GNATL-ACPL) had 
substantially decreased solubility, and the excised AR domain was not obtained in 
 
Figure 2-2. Biochemical assays of curA initiation module. (A) Expression constructs for curA 
initiation module. (B) Substrate loading of (apo and holo) GNATL-ACP, AR-GNATL-ACP and 
DEBS ATL-ACPL. Proteins (30 μM) were incubated with 90 μM CoA substrates, in 50 mM 
MOPS, pH 7.0, at room temperature. The SDS-PAGE gel images for Coomassie blue staining 
are shown above and autoradiography below. (C) FTICR mass spectrum (left) showing the ACP 
serine-containing peptide from the trypsin digested (holo) AR-GNATL-ACP loaded with 
malonyl-CoA, and partial IRMPD spectrum (right) showing the PPant ejection product with 
covalently-linked acetyl group. (D) Partial FTICR mass spectra showing (holo) ACPL-SH (left) 
and (holo) ACPL-NH2 (right) loaded with acetyl-CoA. The N-terminal His-tag of ACPL was 
removed. 10 μM (holo) ACPL-SH (or ~1.5 μM (holo) ACPL-NH2) and 2 μM AR-GNATL-ACPL 
were incubated with 50 μM acetyl-CoA at room temperature for 30 min. 
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soluble form under any conditions tested. Interestingly, solubility was significantly 
greater for the AR-GNATL-ACPL (holo) tridomain than for the apo counterpart (Figure 
2-S1A), suggesting that the phosphopantetheine (PPant) arm of ACPL (holo) stabilizes 
the AR domain. The 63.3-kDa AR-GNATL-ACPL polypeptide is monomeric (Figure 
2-S1C). 
To assess the initiation behavior of the CurA starter unit, the apo and holo forms of 
the CurA tridomain (AR-GNATL-ACPL) and didomain (GNATL-ACPL) were treated 
with radio-labeled acyl-CoAs and analyzed by SDS-PAGE (Figure 2-2B). The holo 
forms of both the tridomain and didomain incorporated radiolabel, whereas the apo forms 
were not labeled, indicating transthioesterification of the acyl group from CoA to the 
PPant arm of ACP. Thus the N-terminal domains of CurA catalyze acyl loading and 
additional proteins are not required. Lack of radiolabeling of the apo forms also indicates 
that loading does not proceed through a covalent enzyme intermediate, consistent with 
the direct-transfer mechanism established for other GNAT family members (3, 11). This 
is in contrast to the “canonical” PKS loading module, typified by DEBS ATL-ACPL (3), 
in which a covalent intermediate is observed for the apo form (Figure 2-2B). The ability 
of the GNATL-ACPL (holo) didomain to load an acyl group demonstrated that the 
catalytic machinery for chain initiation resides within the GNATL domain and not the AR 
domain, which is also supported by the fact that selected mutations within GNATL 
affected the loading behavior of AR-GNATL-ACPL both in cis (Figure 2-S2) and in trans 
(Figure 2-S6) (see below). However, the increased level of acyl-group loading activity by 
the AR-GNATL-ACPL (holo) tridomain (Figure 2-2B and Figure 2-S3) suggests that AR 
is required for efficient acyl transfer. Unexpectedly, both malonyl-CoA and acetyl-CoA 
functioned as substrates for the AR-GNATL-ACPL (holo) tridomain with similar 
efficiency (Figure 2-S2). 
To investigate further the CurA AR-GNATL-ACPL tridomain components, we 
analyzed the products covalently tethered to the PPant arm of ACPL. This was 
accomplished by interrogating mass changes on AR-GNATL-ACPL for in cis acyl 
transfer, or by employing the excised ACPL as the in trans acyl-group acceptor (Figure 
2-2C). Excised ACPL and trypsin-digested AR-GNATL-ACPL samples were examined by 
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Fourier-transform ion cyclotron resonance mass spectrometry (FTICR-MS) and infrared 
multiphoton dissociation (IRMPD) methods (18). First, the ACPL 
phosphopantetheinylation site was established as Ser477 by MS analysis of the 
trypsin-digested AR-GNATL-ACPL (Figure 2-S3), and by generating the corresponding 
S477A ACPL mutant protein. Remarkably, for both malonyl-CoA and acetyl-CoA 
substrates, only an acetyl group was detected on the PPant arm of AR-GNATL-ACPL 
(holo) (Figure 2-2C and Figure 2-S3) or ACPL (holo) (Figure 2-2D and Figure 2-S4A). 
Thus, the CurA GNATL loading module catalyzes both decarboxylation and acyl transfer 
of carboxyl-acyl-CoA substrates. These data reveal a gain-of-function for a GNAT-type 
polypeptide, as well as a divergence from all other characterized PKS loading modules, 
in which the acyl transfer and decarboxylation are catalyzed by separate domains (1, 4). 
Further analysis by HPLC and FTICR-MS demonstrated that all constructs containing 
GNATL (GNATL, GNATL-ACPL and AR-GNATL-ACPL) catalyzed decarboxylation of 
malonyl-CoA, methylmalonyl-CoA, and malonyl-ACPL to generate acetyl-CoA, 
propionyl-CoA (Figure 2-S5) and acetyl-ACPL (Figure 2-S4B).   
Next, kinetic parameters for decarboxylation were measured by HPLC for 
malonyl-CoA and methylmalonyl-CoA and by radio-assay for [1,3-14C]malonyl-ACPL 
(Table 2-S1). The steady-state analysis indicated that malonyl-CoA is the preferred 
substrate. The kcat for malonyl-CoA was ~1.8 s-1, which is ~6-fold and ~49-fold higher 
than those for methylmalonyl-CoA and malonyl-ACPL, respectively. Similarly, the 
catalytic efficiency, kcat/KM, for malonyl-CoA was ~5.25 mM-1s-1, which is ~3-fold and 
~6-fold higher than those of methylmalonyl-CoA and malonyl-ACPL, respectively. 
With clear evidence for a relatively rapid decarboxylation step catalyzed by GNATL, 
we sought to measure the rate of acyl loading by AR-GNATL-ACPL. The in cis acetyl 
transfer rate of AR-GNATL-ACPL (holo) was determined by using [1-14C]acetyl and 
[2-14C]malonyl-CoA substrates. The kcat and KM values were derived by measuring the 
intramolecular acyl transfer rate at a series of acyl-CoA concentrations (Table 2-S1). The 
kcat or KM values for acetyl transfer were similar for acetyl-CoA and malonyl-CoA 
substrates. In contrast, the kcat for acetyl-group transfer was ~780-fold slower than the kcat 
for decarboxylation of malonyl-CoA, suggesting that decarboxylation and acetyl transfer 
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are separated by a slow tri-domain conformational change that leads to effective binding 
of the ACPL PPant arm in the active site (k2 in Figure 2-S7). Taken together with the 
decarboxylation kinetic data, these results confirm that malonyl-CoA decarboxylation 
precedes acetyl transfer to ACPL (holo). In addition, the apparent KM of acetyl-CoA or 
malonyl-CoA for acyl transfer is 80-90 fold lower than the KM of malonyl-CoA for 
decarboxylation, and is dependent on the ratio of rate constants (k1-k6 in Figure 2-S7). 
Since previously described GNAT enzymes catalyze various N-acetylation reactions, 
we tested whether CurA GNATL retained a similar residual activity. We synthesized a 
CurA ACPL-phosphopantetheine analog bearing a terminal NH2 in place of native (holo) 
ACPL-SH (refer to SOM), and tested it for in trans acetyl transfer catalyzed by 
AR-GNATL-ACPL (apo) to excised CurA (holo) ACPL-NH2 (monitored by FTICR-MS). 
A convenient internal standard was supplied by low levels of ACPL-SH in the ACPL-NH2 
preparation (Figure 2-2D), likely due to the activity of endogenous E. coli ACP synthase 
or EntD (19). In contrast to the significant level of acetyl loading on ACPL-SH (Figure 
2-2D), only a trace amount of acetyl-NH-ACPL was detected. In addition, simple alkyl 
amines (e.g. ethylenediamine, butylamine) were tested as substrates for acetyl transfer by 
CurA GNATL, but no N-acetyl transferase activity was detected for any of them. Thus, 
the N-acetyltransfer activity typically associated with GNAT enzymes is almost 
completely attenuated in the Cur AR-GNATL-ACPL chain initiation module.  
2.3.2  GNATL Structure and Site-Directed Mutagenesis 
To advance our understanding of GNATL function and to identify active site 
residues, we determined crystal structures of the excised CurA apo GNATL (ligand free) 
domain and of the corresponding GNATL with added malonyl-CoA (Table 2-S2). 
GNATL (CurA residues 219-439) possesses the GNAT superfamily fold, consisting of a 
central mostly anti-parallel β-sheet flanked by α-helices (Figure 2-3A) (11, 12), and is 
most similar to serotonin N-acetyltransferase (RMSD = 1.9Å for 160 Cα atoms) (20). 
The crystal structures of CurA GNATL provide key insights into the function of this 
unique member of a large and ubiquitous protein family. Two tunnels from opposite faces 
of the protein converge at a position corresponding to the active sites of homologous 
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GNATs (Figure 2-3B). Presumably these tunnels are the binding sites for the 
phosphopantetheine (PPant) arms of the CoA and ACP substrates. To distinguish the two 
tunnels, crystals of GNATL were soaked with malonyl-CoA (Table 2-S2). New electron 
density was observed in only one tunnel, hereafter called the CoA binding tunnel (Figure 
2-S8). The location of the tunnel and the mode of CoA binding, in which the nucleotide 
lies in a surface cleft and the PPant arm extends into the tunnel, are consistent with 
structures of other members of the GNAT superfamily (11, 12). In CurA GNATL, 
 
 
Figure 2-3. Structure of GNATL domain. (A) Structural fold of GNATL domain. (B) 
Substrate tunnels with models (black carbons) of acetyl-CoA (wheat) and PPant arm of 
holo-ACP (orange). Residues Trp249, His389, Thr355, and Arg404 are shown in green carbons. 
(C) Stereo diagram of modeling results overlaid with observed structure showing interaction 
of His389 and Thr355 with thioester carbonyl of acetyl-CoA. Coloring is identical to (B). 
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selectivity for CoA over ACP is imparted by a 5'-diphosphate binding loop (residues 
327-332) and by Arg387 recognition of the 3'-phosphate. Neither of these recognition 
features exists in FeeM, a GNAT superfamily member that uses an acyl-ACP donor 
substrate (21). Compared to the strong density for the CoA nucleotide, density for the 
PPant arm was weaker and indicative of multiple conformations, perhaps due to presence 
of both the malonyl-CoA substrate and the acetyl-CoA decarboxylation product in the 
crystal. No new electron density was observed in the second tunnel, which we designate 
the ACP-binding tunnel. The side chain of conserved Arg404 forms one wall of the 
putative ACP-binding tunnel (Figure 2-3C and Figure 2-S9), and a series of water 
molecules extending to the protein exterior form the opposite wall. The designated 
ACP-binding tunnel overlays well with the acetyl group acceptor site in other GNATs, is 
well matched in length to the fully extended PPant arm of holo ACP (~15Å), and likely 
forms the ACPL PPant arm binding site (Figure 2-3B). The two tunnels meet at conserved 
Trp249, just as many other GNAT family members have their two binding sites separated 
by an aromatic residue (Figure 2-3B and Figure 2-S9). 
We searched for potential catalytic residues for decarboxylation and found His389 
and Thr355 at the junction of the two tunnels (Figure 2-S9 and Figure 2-3C). These 
residues are precisely positioned by hydrogen bonds of His389 to Tyr419, and of the Thr355 
backbone to the Arg404 side chain. All four of these residues are invariant among 
GNATL-containing PKS loading modules (Figure 2-S9). To test the role of His389 and 
Thr355, H389A, H389N and T355V variant proteins were assayed for decarboxylase and 
acetyltransferase activity (Table 2-S1). Decarboxylation was severely impaired by 
substitutions at either site. Specifically, the His389 and Thr355 variants resulted in at least 
100-fold reduction in kcat for decarboxylation of malonyl-CoA to acetyl-CoA and in 
relatively modest changes to KM values. In contrast, substitutions at His389 and Thr355 had 
only modest effects on acetyl transfer activity, demonstrating that these residues do not 
play a critical role in acetyl transfer. 
Based on mutagenesis results and on modeling the PPant arms of acetyl-CoA and 
ACPL (Figure 2-3C and Figure 2-S8), His389 and Thr355 are proposed to stabilize an 
enolate anion intermediate of the decarboxylation reaction. We further propose that the 
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isoenergetic transfer of an acetyl group from acetyl-CoA to ACPL-SH (holo) is catalyzed 
by direct attack of the deprotonated thiolate of ACPL upon acetyl-CoA at the junction of 
the GNATL CoA and ACPL binding tunnels. The buried Arg404 residue at the base of the 
ACPL binding tunnel may facilitate binding of the deprotonated thiol of the acceptor 
PPant arm of ACPL. The N-terminal AR domain, which was stabilized by the PPant arm 
of ACPL, may also assist in delivering (holo) ACPL to GNATL. AR is likely to have a 
common function in GNATL-containing modules based on its highly conserved sequence. 
Based on the studies described above, the mechanism of CurA AR-GNATL-ACPL is 
proposed to involve a series of acyl-CoA-protein, protein-protein, and protein-PPant arm 
interactions (Figure 2-4 and Figure 2-S7) that mediate the unique bifunctional 
decarboxylase/S-acetytransferase activity. It is likely that other novel GNAT members 
will be found with surprising biochemical properties or that previously identified proteins 
will be grouped within this large family. For example, the eryM-encoded 
methylmalonyl-CoA decarboxylase (4) has not been the subject of structural analysis, but 
comparative amino acid sequence analysis now predicts that it contains the GNAT 
scaffold. 
2.4  DISCUSSION 
A significant outcome of the current work is the realization that GNATL-containing 
 
Figure 2-4. Proposed mechanism of the CurA AR-GNATL-ACPL chain initiation module. 
Malonyl-CoA enters the GNATL domain (blue) CoA tunnel (white) and catalyzes 
decarboxylation to acetyl-CoA. The AR domain (light blue) directs the phosphopantetheine arm 
of ACPL (yellow) into the ACP tunnel (yellow) for subsequent acetyl group transfer via 
transthioesterification. 
 20
modules are not uncommon among previously characterized natural product biosynthetic 
gene clusters, and are well represented within bacterial genome sequences. This 
metabolic strategy thus represents an additional widely employed chain initiation process 
for assembly of important biologically active small molecules. At a comparative level, 
the CurA GNATL has a significantly slower S-acetyltransfer activity than the 
erythromycin PKS ATL. However, L. majuscula has a relatively slow growth rate in the 
marine environment as well as in culture (i.e. doubling time of approximately 10 days) 
(22), and a correspondingly low production of curacin A per unit biomass compared to 
yields of other microbial natural products (e.g. erythromycin via the 
6-deoxyerythronolide B aglycone intermediate) by Saccharopolyspora erythraea (23)). 
Thus, the curacin A PKS assembly line has evolved under environmental constraints and 
organismic needs that reflect its reduced efficiency. 
The work described in this report provides clear evidence for an unprecedented 
bifunctional decarboxylase/S-acetyltransferase role for the CurA GNAT scaffold, which 
significantly broadens the chemical reaction inventory of this well known protein 
superfamily. This newly described method of PKS chain initiation enables malonyl CoA 
to serve as the sole precursor to both initiate and extend the carbon chain of curacin A. 
Moreover, by virtue of the greater rate of acetate versus propionate transfer to ACPL 
following decarboxylation, the GNATL strategy for chain initiation provides an additional 
mechanism to insure fidelity of curacin A chain length. 
2.5  MATERIAL AND METHODS 
Chemicals. [1,3-14C]malonyl-CoA (55 mCi/mmol), [2-14C]malonyl-CoA (55 mCi/mmol), 
and [1-14C]acetyl-CoA (55 mCi/mmol) were from American Radiolabeled Chemicals. 
[1-14C]propionyl-CoA (55 mCi/mmol) was from Moravek Biochemicals. The 
terminal-NH2 analog of pantetheine was synthesize by Michael D. Burkart group at UCSD 
(24). All other chemicals were from Sigma-Aldrich. 
Bacterial strains, media and culture conditions. Escherichia coli DH5α MCR 
(Invitrogen) or XL1-Blue (Stratagene) was used for DNA propagation. Escherichia coli 
BL21 (DE3) and Rosetta (DE3) (Invitrogen) transformed with the derivatives of pET24b, 
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pET28b, pET21b (Novagen) and pMCSG7 (25) were used for protein overexpression in 
Luria-Bertani (LB) medium. Ampicillin (100 μg/mL), carbenecillin (100 μg/mL), 
kanamycin (50 μg/mL), chloramphenicol (25 μg/mL), and apramycin (50 μg/mL) were 
used for the corresponding plasmid construct resistance marker selection in E. coli cultures. 
Plasmid construction and site mutagenesis. The primers used for the plasmid 
construction and site mutagenesis are listed in table 2-S3. AR-GNATL-ACPL, AR-GNATL, 
GNATL-ACPL, GNATL, ACPL and AR genes were amplified from cosmid pLM54 
described in our previous study (6). DEBS loading ATL-ACPL gene was amplified from 
cosmid pBK3 previously described (26). AR-GNATL-ACPL, GNATL-ACPL, and ACPL 
genes were inserted into pET28b plasmid. AR-GNATL, GNATL and AR genes were 
inserted into pET24b plasmid. DEBS loading ATL-ACPL gene was inserted into pET21b 
plasmid similarly as reported (3). All of these pET derivatives were constructed with NdeI 
and XhoI restriction sites. H389A, H389N and T355V site mutagenesis for both GNATL 
and AR-GNATL-ACPL was performed using QuikChange site mutagenesis protocol 
(Stratagene). All the constructs and mutations were verified by DNA sequencing. 
Protein overexpression. A) (apo or holo) AR-GNATL-ACPL, GNATL-ACPL, ACPL 
and corresponding mutants: E. coli BL21 (DE3) was transformed by the 
pET28b::AR-GNATL-ACPL, pET28b::GNATL-ACPL or pET28b::ACPL plasmid to 
overexpress N-terminal His-tagged proteins. The proteins in holo-form were produced by 
coexpression with Sfp plasmid pSG701 (untagged Sfp, under T7 control, chloramphenicol 
resistance). Cells were grown at 30oC to an OD (590 nm) = 0.5-0.6, and then cooled to 
16oC prior to the addition of 1 mM isopropyl-β-D-galactopyranoside (IPTG). The cultures 
were grown at 16oC for another 18-20 h before harvesting. B) AR-GNATL, GNATL, and 
corresponding mutants: E. coli BL21 (DE3) was transformed by the 
pET24b::AR-GNATL or pET24b::GNATL plasmid to overexpress C-terminal His-tagged 
proteins. Cells were grown at 35oC to an OD (590 nm) = 0.5-0.6, and then cooled to 18oC 
prior to the addition of 1 mM IPTG. The cultures were grown at 18oC for another 12-15 h 
before harvesting. C) GNATL for crystallization: E. coli BL21(DE3) was transformed by 
the pET28b::GNATL or pMCSG7::GNATL plasmid to overexpress C- or N-terminal 
His-tagged proteins, respectively. Cells were grown at 37 oC to an OD (600 nm) = 0.6-0.8, 
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and then cooled to 18oC prior to the addition of 0.4 mM IPTG. The cultures were grown at 
18oC for another 12-15 h before harvesting. D) (apo or holo) DEBS ATL-ACPL: E. coli 
Rosetta (DE3) (chloramphenicol resistance) was transformed by pET21b::ATL-ACPL 
(ampicillin resistance) to overexpress the C-terminal His-tagged proteins. (Holo) 
ATL-ACPL was generated by coexpression with Sfp plasmid pRSG56 (kanamycin 
resistance) (27). Cells were grown at 37oC to an OD (590 nm) = 0.5-0.6, and then cooled to 
30oC prior to the addition of 1 mM IPTG. The cultures were grown at 30oC for another 
8-10 h before harvesting. E) E. coli CoAA and H. sapiens PPAT–DPCK: E. coli BL21 
(DE3) was transformed by CoAA (kanamycin resistance) or PPAT–DPCK (ampicillin 
resistance) expression plasmid (gift of Prof. Michael D. Burkart, UCSD) to express 
His-tagged proteins (28). Cells were grown at 37oC to an OD (590 nm) = 0.7-0.8, and then 
cooled to 20oC prior to the addition of 0.8 mM IPTG. The cultures were grown at 20oC for 
another 12-15 h before harvesting. 
Protein purification. Protein purifications were performed at 4oC. Generally, the first 
step Ni-affinity purifications for all His-tagged proteins were performed under the same 
conditions. E. coli cells were harvested by centrifugation (4,000 g, 15 min, 4oC), 
resuspended in the ice cold lysis buffer A (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 10 
mM imidazole, 20% glycerol) and disrupted by sonication on ice. The cell debris was 
removed by centrifugation at 15,000 g for 50 min. The supernatant was gently removed 
and loaded onto the 5 mL HisTrap column (GE Healthcare) preequilibrated with lysis 
buffer A. The resin was washed successively with ~ 10 column volumes of the washing 
buffer B (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole, 10% glycerol) to 
remove nonspecifically bound contaminants. Bound proteins were eluted with imidazole 
by a linear gradient of the elution buffer C (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 
250 mM imidazole, 20% glycerol). The eluate was concentrated using Amicon Ultra-15 
(30 kDa, 10 kDa or 5 kDa) centrifugal devices (Millipore). The follow-up purification 
and buffer exchange for different proteins are described below: 
A) (apo or holo) AR-GNATL-ACPL/GNATL-ACPL, AR-GNATL/GNATL and the 
corresponding mutants: the concentrated eluate was loaded onto HiLoad 26/60 Superdex 
200 column (GE Healthcare) equilibrated with the storage buffer D (50 mM PBS buffer, 
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pH 7.5, 200 mM NaCl, 20% glycerol). The fractions were pooled, concentrated, 
flash-frozen in 50-100 μL aliquots in liquid N2, and stored at -80oC for further use. B) 
(apo or holo) DEBS ATL-ACPL: the concentrated eluate was loaded onto HiPrep 26/10 
Desalting column (GE Healthcare) equilibrated with the storage buffer D. The fractions 
were pooled, concentrated, flash-frozen in 50 μL aliquots in liquid N2, and stored at -80oC 
for further use. C) CoAA and PPAT–DPCK: the concentrated eluate was loaded onto 
HiPrep 26/10 Desalting column equilibrated with the storage buffer E (50 mM HEPES, 
pH 7.5, 0.1 M NaCl, 0.5 mM EDTA, 1 mM DTT and 20% glycerol). The fractions were 
pooled, concentrated, flash-frozen in 50 μL aliquots in liquid N2, and stored at -80oC for 
further use. D) His-tag cleaved (apo or holo) ACPL: the N-terminal His-tag of ACPL 
needs to be removed to avoid a 178 Da posttranslational modification in E. coli which 
was reported to be the α-N-6-phosphogluconoylation on N-terminal His-tag (29). Firstly, 
the concentrated eluate was loaded onto HiPrep 26/10 Desalting column equilibrated with 
the storage buffer D. The biotinylated thrombin (Novagen) was added into the pooled 
fractions, and the reaction was incubated at room temperature for overnight to achieve a 
complete cleavage. The reaction mixture was loaded onto 1mL HiTrap Streptavidin HP 
(GE Healthcare) to trap the biotinylated thrombin and the column was successively 
washed with 10 mL storage buffer D. The flow-through fractions were pooled, 
concentrated and reloaded onto HiPrep 26/10 Desalting column equilibrated with the 
storage buffer E. The fractions were pooled, concentrated, flash-frozen in 100 μL aliquots 
in liquid N2, and stored at -80oC for further use. 
The purity of the proteins was analyzed by SDS-PAGE and the protein concentrations 
were determined using the Bradford assay (Bio-Rad). The percentage of the holo form of 
ACPL was analyzed by reverse-phase HPLC using a Jupiter C4 column (250 x 2.0 mm, 5 
μm, 300 Å, Phenomenex). The samples were eluted with a linear gradient from 5% to 
90% of CH3CN (0.1% CF3CO2H)/H2O (0.1% CF3CO2H). According to the HPLC assay, 
60-70% ACPL was converted into holo form by coexpression with Sfp. The holo/apo 
ratio of AR-GNATL-ACPL samples was analyzed by trypsin digestion followed by 
FTICR-MS analysis. More than 90 % AR-GNATL-ACPL was converted into holo form 
by coexpression with Sfp. 
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Preparation of ACPL-NH2. One-pot chemo-enzymatic strategy (28) was used to 
synthesize ACPL-NH2. To simplify the ACPL-NH2 purification, we did not use pyruvate 
kinase and inorganic pyrophosphatase to recycle the ATP. Briefly, a 200 μL reaction 
mixture contains: 20 μL 10x Tris buffer (500 mM, pH 8.0), 20 μL MgCl2 (100 mM), 20 
μL KCl (200 mM), 70 μL His-tag removed apo-ACPL (1 mM), 10 μL recombinant 
Bacillus subtilis Sfp (100 μM), 10 μL ATP (0.2 M), 25 μL terminal-NH2 analogue of 
pantetheine (20 mM), 5 μL CoAA (1.2 mM) and 20 μL recombinant PPAT–DPCK (0.2 
mM). The reaction was incubated at 37oC for 2-3 hours. According to the HPLC analysis 
of the reaction mixture, 10-15% yield of ACPL-NH2 was achieved. 
Two protocols were applied to purify ACPL-NH2 from the reaction mixture. Protocol A: 
The reaction mixture was loaded onto a Source 15PRC reverse phase column (GE 
Healthcare). The protein were eluted with a linear gradient from 30% to 70% of CH3CN 
(0.1% CF3CO2H)/H2O (0.1% CF3CO2H). The ACPL-NH2 fractions was pooled, 
flash-frozen in liquid N2 and lyophilized overnight. The lyophilized ACPL-NH2 was 
redissolved and renatured in the storage buffer D for 1 hour before the assays. Compared 
with protocol B, protocol A has a faster purification and less loss of the protein, but only 
part of lyophilized ACPL-NH2 can be renatured. Protocol B: The reaction mixture was 
loaded onto HisTrap column to trap most of the His-tagged CoAA, PPAT–DPCK and Sfp, 
and the flow-through were pooled, concentrated, diluted 1:5 with 50 mM PBS buffer F 
(pH 8.0, 10% glycerol) and loaded onto 6 mL Resource Q ion-exchange column (GE 
Healthcare). ACPL-NH2 was eluted using a NaCl gradient 50-500 mM over 20 column 
volumes. The purified ACPL-NH2 was desalted by PD-10 column (GE Healthcare) 
equilibrated with storage buffer D, concentrated and checked for purity by SDS-PAGE 
and HPLC. Both protocol A and B can completely remove Sfp, which can interfere with 
the GNATL loading assays. 
HPLC analysis of GNATL decarboxylation of malonyl-CoA. HPLC analysis of the 
decarboxylation was performed using XBridge C18 column (4.6 x 250 mm, 5 μm, Waters) 
on the Gold HPLC system equipped with an autosampler and controlled by 32 Karat 
software (Beckman Coulter). The samples were eluted with a linear gradient from 3% to 
60% of MeOH/H2O (10 mM CH3CO2NH4). For the steady-state kinetic studies, the 
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decarboxylations were examined in 40 μL 50 mM PBS, pH 7.0 at 100 μM, 200 μM, 500 
μM, 1000 μM and 2000 μM malonyl or methylmalonyl-CoA. The GNATL concentrations 
were optimized as 0.11 μM WT, 9.65 μM H389A, 14.6 μM H389N or 12.6 μM T355V 
for malonyl-CoA decarboxylation, and 0.35 μM WT for methylmalonyl-CoA 
decarboxylation. The reactions were incubated at room temperature for 5 min before 
quenched by 40 μL 1M CH3CO2H. 4 μL propionyl-CoA (for malonyl-CoA 
decarboxylation) or 4 μL acetyl-CoA (for methylmalonyl-CoA decarboxylation) was 
added as the internal standard. The reaction mixtures were filtrated by Microcon YM-10 
(Millipore), neutralized by 20 μL 1M NaOH, and stored at -80oC before analyzed by 
HPLC. Control reactions without enzymes were run at the same time. The peak areas of 
the decarboxylation products were normalized based on the internal standards, subtracted 
by the peak areas of the control reactions, and converted to turnovers/second based on 
peak areas of the acetyl or propionyl-CoA standard. 
Radioassays of GNATL decarboxylation of malonyl-ACPL. [1,3-14C]malonyl-CoA (55 
mCi/mmol) were diluted with malonyl-CoA to get 5 mM 20 mCi/mmol 
[1,3-14C]malonyl-CoA. [1,3-14C]malonyl-ACPL was generated by incubating 100 μM 
apo-ACPL with 1 M [1,3-14C]malonyl-CoA (20 mCi/mmol), 4 μM Sfp, 10 mM MgCl2 in 
50 mM Tris-HCl buffer, pH 8.1 at 30oC for 2 h (30). The reaction mixture was desalted by 
PD-10 desalting column equilibrated with storage buffer D and concentrated. The final 
concentration of [1,3-14C]malonyl-ACPL was measured by Bradford assay. The 
steady-state kinetic studies were performed in 20 μL 50 mM PBS, pH 7.0, 1.1 μM WT 
GNATL, at 15 μM, 30 μM, 60 μM, 120 μM and 180 μM malonyl [1,3-14C]malonyl-ACPL. 
The reactions were incubated at room temperature for 5 min before quenched with 60 μL 
30% trichloroacetic acid (TCA) and 60 μL 10 mg/ml bovine serum albumin (BSA). The 
proteins were precipitated by centrifugation, washed twice with 10% TCA, redissolved in 
100 μL formic acid, added into 4 mL scintillation fluid and counted. The amounts of 
radioactivity for the reactions were compared with those of controls and the decreased 
radioactivity were converted to turnovers/second by using [1,3-14C]malonyl-CoA as the 
standard. 
Radioassays of AR-GNATL-ACPL acyl transfer. Acyl transfer of AR-GNATL-ACPL 
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was measured by using acetyl-CoA and (holo) AR-GNATL-ACPL (or the corresponding 
mutants). The kinetic studies were performed in 20 μL 50 mM MOPS, pH 7.0, 1 mM 
DTT, 25 μM (holo) AR-GNATL-ACPL (or the corresponding mutants), at 1 μM, 2.5 μM, 
5 μM, 12.5 μM, 25 μM, 50 μM and 125 μM [1-14C]acetyl-CoA. The (holo) ACPL was 
used in the control reactions to measure the autocatalytic transthioesterification. The 
reactions were incubated at room temperature for 1 min before quenched with TCA. The 
bound radioactivity of AR-GNATL-ACPL and ACPL was measured as above. The bound 
radioactivity of AR-GNATL-ACPL was subtracted by that of ACPL, and converted to 
turnovers/second by using [1-14C]acetyl-CoA as the standard. The acyl transfer rate was 
analyzed by Cleland’s method (31). 
Autoradiographic analyses. The loading of GNATL-ACPL or (DEBS) ATL-ACPL was 
examined by SDS-PAGE followed by autoradiographic analyses. [2-14C]malonyl-CoA 
(55 mCi/mmol) and [1-14C]acetyl-CoA (55 mCi/mmol) were used for AR-GNATL-ACPL 
and GNATL-ACPL loading, and [1-14C]propionyl-CoA (55 mCi/mmol) was used for 
(DEBS) ATL-ACPL loading. The acyl transfer were performed in 50 mM MOPS, pH 7.0, 
1 mM TCEP, 90 μM acyl-CoA, and 30 μM (holo or apo) AR-GNATL-ACPL, 
GNATL-ACPL, or (DEBS) ATL-ACPL. The aliquots were periodically moved from the 
reaction mixture and the proteins were precipitated by TCA, washed by ice-cold acetone 
and dissolved in Tris/glycine/SDS loading buffer. After running the SDS-PAGE, the gels 
were dried and subjected to autoradiography. 
Analysis of ACPL and AR-GNATL-ACPL digestion samples by ESI-FTICR-MS. The 
observed and calculated masses for all the samples were listed in table 2-S4. ACPL 
samples were prepared by loading the reaction mixtures on Source 15PRC reverse phase 
column. The proteins were eluted with a linear gradient from 30% to 70% CH3CN 
(0.05% HCOOH and 0.05% CF3COOH)/H2O (0.05% HCOOH and 0.05% CF3COOH). 
AR-GNATL-ACPL digestion samples were prepared by first removing the CoA thioesters 
from AR-GNATL-ACPL reaction mixtures using Zeba desalt spin column (Pierce) 
equilibrated with the digestion buffer (50 mM NH4HCO3, pH 7.6, 0.1 M NaCl and 10% 
glycerol). 10 μL 2.5 mg/mL AR-GNATL-ACPL sample was digested with 5 μL 0.1 
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mg/mL trypsin (Princeton Separations) at 37oC for 4 hours. The digestion was quenched 
by 0.1% formic acid and desalted by Source 15PRC column. (Performed by Liangcai Gu) 
Mass spectrometric analysis was performed with an actively shielded 7 Tesla 
quadrupole-Fourier transform ion cyclotron resonance mass spectrometer (APEX-Q, 
Bruker Daltonics, Billerica, MA). Target analytes were diluted in an electrospray solution 
(1:1 CH3CN:H2O with 0.1% HCOOH) and directly infused into an electrospray 
ionization (ESI) source (Apollo II, Bruker Daltonics) at a flow rate of 70 µL/h and a 
voltage of - 3.8 kV. A counterflow of hot (240 °C) nitrogen gas was applied to assist 
desolvation of ESI droplets. For accurate mass determination, up to 10 picomoles of 
apomyoglobin (Sigma, St. Louis, MO) was spiked into the ESI solution as internal 
calibrant.  Multiply protonated ions generated from ESI were externally accumulated in 
a hexapole for 1 s and transferred via high voltage ion optics to the ICR cell for analysis. 
All data were acquired with XMASS software (version 6.1, Bruker Daltonics) in 
broadband mode from m/z = 200 to 2000 with 512k data points and summed over 20-30 
scans. Mass spectra were analyzed with the MIDAS analysis software (32). When needed, 
external frequency-to-m/z calibration was performed with a two-term calibration 
equation (33) using two calibration standards (m/z = 622.02895 and 922.00979, from the 
calibration mix G2421A, Agilent Technologies, Palo Alto, CA). For infrared multiphoton 
dissociation (IRMPD), precursor ions were mass-selectively accumulated in a hexapole 
with a 3-5 m/z quadrupole isolation window, transferred to the ICR cell, and irradiated 
for 100-300 ms by 10.6 μm photons at 10 W laser power (25 W CO2 laser, Synrad, 
Mukilteo, WA) for 30-50 scans. (Performed by Bo Wang) 
GNATL preparation and crystallization. In addition to pET24b::GNATL, 
pMCSG7::GNATL was also constructed to facilitate His-tag cleavage (25). 
Selenomethionine-labeled GNATL was produced in BL21(DE3) using SeMet minimal 
media according to the protocol reported (34). The Ni-affinity purification was performed 
in a similar way as mentioned above. The His-tag removal was performed in buffer F (20 
mM Tris pH 7.9, 500 mM NaCl, 20 mM imidazole, 10% glycerol, and 1 mM DTT) by 
incubating GNATL with 2% (w/w) His-tagged TEV protease at 4°C for 24 hr. The 
cleavage mixture was loaded onto HisTrap column, and flow-through fractions were 
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pooled and concentrated. After Ni-affinity purification (or His-tag cleavage), the 
concentrated fractions were loaded onto a HiLoad 16/60 Superdex 75 (GE Healthcare) 
column equilibrated with buffer G (20 mM Tris pH 7.9, 500 mM NaCl, and 10% 
glycerol). Fractions were then combined, concentrated to 13 mg/mL and either flash 
frozen in liquid N2 or stored at 4°C. Crystals were grown in 24-72 hr at 20°C by 
micro-seeding in hanging drops using the vapor diffusion method. Equal volumes were 
mixed of protein solution and mother liquor containing 100 mM Bis-Tris pH 6.8, 100 
mM NaCl, 1.0-1.5 M ammonium sulfate, and 20% glycerol. Apo crystals were harvested 
in loops and directly frozen by plunging into liquid N2. In order to obtain the complex 
structure, apo crystals were grown at 4°C. After crystal growth, malonyl-CoA was added 
to the drop to a final concentration of ~10 mM and incubated for 1 hour before crystal 
mounting and freezing. (Performed by Todd Geders) 
Diffraction Data Collection and Structure Determination. Diffraction data were 
collected at 100 K on GM/CA-CAT beamline 23ID-B at the Advanced Photon Source 
(APS) in Argonne National Laboratory (Argonne, IL). Data were processed using the 
HKL2000 suite (35). Initial phasing was performed using a three-wavelength MAD 
dataset from a single SeMet-labeled protein crystal of His-tagged GNATL. SOLVE was 
used to find the six selenium sites (‹m› = 0.52, score = 37.15) and for MAD phasing 
(overall FOM = 0.53) (36). RESOLVE was used for density modification (overall FOM = 
0.66) and partial automated model building (37, 38). Two CurA molecules were present 
in the asymmetric unit. Modeling was completed manually using COOT (39). 
Refinement was performed using REFMAC5 of the CCP4 suite with TLS (40-42). The 
refined model was used as a probe structure for molecular replacement using PHASER 
with data from malonyl-CoA soaked crystals (43, 44). OMIT density was calculated 
using the program SFCHECK (45). Images and Figures were prepared using PyMOL 
(46). Tunnels were identified by the program CAVER (47). (Performed by Todd Geders) 
Modeling of Acetyl-CoA and ACP PPant Arm into Active Site. Initial atomic 
coordinates and topology files for acetyl-CoA and 4’-phosphopantetheine were generated 
using the PRODRG2 server (48). Acetyl-CoA was positioned into the 1.95Å structure 
using the position of the low-occupancy conformation observed in the malonyl-CoA 
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soaked crystal as a guide. A fully extended 4’-phosphopantetheine was placed within the 
ACP binding tunnel. For both ligands, any overlapping waters were removed before 
energy minimization of an isolated CurA GNATL molecule after the addition of 
hydrogens using the program CNS (49) in 500 steps of conjugate gradient minimization 
using no experimental energy terms and full harmonic restraints. (Performed by Todd 
Geders) 
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2.6  SUPPLEMENTARY FIGUES AND TABLES 
 
Figure 2-S1. Protein expression, purification, and size-exclusion analysis. (A) Expression and 
solubility of GNATL constructs. Protein expression was induced at 20oC for 12 hours. W., whole 
cell lysate; S., supernatant. (B) Constructs after purification. 1. (apo) AR-GNATL-ACPL, 2. (holo) 
AR-GNATL-ACPL, 3. (apo) GNATL-ACPL, 4. (holo) GNATL-ACPL, 5. AR-GNATL, 6. GNATL. 
(C) Analytical size-exclusion chromatography of GNATL constructs. 200 μL ~5mg/mL proteins 
were loaded on Superdex 200 10/300 GL column and eluted by 50 mM PBS, pH 7.5, 0.2 M NaCl 
and 10% glycerol. Partial dimerization of GNATL and GNATL-ACPL was observed, however 




Figure 2-S2. Acyl transfer in cis for (holo) AR-GNATL-ACPL (WT and H389N) and 
GNATL-ACPL. 20 μM holo enzymes were incubated with 100 μM [2-14C]malonyl-CoA or 
[1-14C]acetyl-CoA in 50 mM MOPS, pH 7.0, at room temperature. The autocatalytic acyl-CoA 
loading rate was measured using excised (holo) ACPL (20 μM). The H389N substitution resulted 
in ~3-fold greater kcat (see table S1) for acetyl transfer in comparison to wild type, perhaps by 
creating a stabilizing polar environment for the CoA thiolate intermediate generated immediately 




Figure 2-S3. Partial FTMS spectra showing the mass changes of serine477-containing peptide 





Figure 2-S4. (A) Comparison of the in trans loading activities of AR-GNATL and GNATL for 
acetyl and malonyl-CoAs. 15 μM (holo) ACPL was incubated with or without 2 μM AR-GNATL 
or GNATL in 50 μM CoAs and 50 mM MOPS, pH 7.0 at room temperature for 30 min. (B) 
GNATL catalyzed decarboxylation of malonyl-ACPL. 50 μM malonyl-ACPL was incubated with 
or without 1 μM GNATL in 50 mM PBS, pH 7.0 at room temperature for 15 min. (C) IRMPD 
spectra showing the PPant ejection products for malonyl-ACPL (above) and acetyl-ACPL (below). 




Figure 2-S5. HPLC analysis of GNATL catalyzed decarboxylation. 200 μM 
malonyl-CoA/methylmalonyl-CoA and 1 μM GNATL were incubated in 50 mM PBS, pH 7.0, at 




Figure 2-S6. Comparison of the in trans loading activities of the wild type and H389N 
mutant of AR-GNATL-ACPL. 20 μM (holo) ACPL was incubated with 2 μM AR-GNATL-ACPL 
(WT or H389N) in 100 μM CoAs and 50 mM MOPS, pH 7.0 at room temperature for 30 min. 1: 
ACPL-SH, 2: acetyl-ACPL, 3: malonyl-ACPL. Malonyl-ACPL products (3) were observed for the 
malonyl-CoA loading by H389N mutant, which is likely due to the autocatalytic loading without 
decarboxylation. 
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Figure 2-S7. Partition analysis of the acetyl transfer kcat of AR-GNATL-ACPL (holo) by 
using Cleland’s method. 
 
 
A chain initiation mechanism for AR-GNATL-ACPL is proposed above. This mechanism can be 
reduced to mechanism (1) using net rate constants: 
 1 2 4 6k ' k ' k ' k '1 2 3 4 5E E E E E⎯⎯→ ⎯⎯→ ⎯⎯→ ⎯⎯→  (1) 
The net rate constants are 
 
2 4 6 4 6
1 1 2 4 6 6
3 5 3 6 4 6 5 6
k k k k kk ' = k , k ' = , k ' = , k ' = k
k k  + k k  +k k k  + k
 (2) 
The sum of [E4] and [E5] was measured for the acetyl transfer rate, and thus the acetyl transfer kcat 
can be calculated as: 
 
cat 1 2





1 1=  (assume k >> k ' according to assays)1 1 1 1 1+ + +
k k ' k ' k ' k '





The net rate of acetyl transfer is negatively affected by (a) the slow rate of acetyl transfer (k4), (b) 
the partitioning of E4 between product release and reversal, and (c) the partitioning of E3 between 
E2 and E4. Low occupancy of the GNATL ACP tunnel (k2<k3) can significantly decrease the 




Figure 2-S8. OMIT map density surrounding the CoA binding tunnel. (A) First CurA 
GNATL molecule in the asymmetric unit (ASU) with acetyl-CoA model drawn in white carbons. 
(B) Second CurA GNATL molecule in the ASU with two alternate conformations of acetyl-CoA 
drawn in white and grey carbons. N- and C-termini are labeled for reference. Tan coloring 
indicates portions of the molecule omitted for clarity in inset. Protein surface is colored by 
electrostatic potential. OMIT density calculated from the final refined model is contoured at 1 σ 
(green) and 3 σ (magenta). Clear density observed for the 3’-ribose phosphate, which interacts 
with Arg387 (not drawn), and the diphosphate linker, which is coordinated by backbone amides of 




Figure 2-S9. Multiple sequence alignment of GNATL domains from curacin A (CurA_GNAT), 
onnamide A (OnnB_GNAT, 47.5% identity), myxovirescin A (TaI_GNAT, 44.8% identity), 
rhizoxin (RhiA_GNAT, 43.4% identity), and pederin (PedI_GNAT, 40.7% identity) PKS clusters. 
Secondary structure elements of CurA GNATL are shown above the alignment, colored boxes 
indicate regions designated motifs C, D, A, and B by Neuwald & Landsman, invariant residues 
are red, sites of conservative substitution are blue, and similar residues are green. Every tenth 
residue is underlined. 
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Table 2-S1. Kinetic parameters for decarboxylation and acyl transfer. 
 
Decarboxylation 
GNATL Substrate kcat [s-1] KM [μM] kcat/KM [x103 M-1s-1] 
WT malonyl-CoA 1.8 ± 0.2 340 ± 27 5.25 ± 0.15 
H389A malonyl-CoA 0.018 ± 0.001 238 ± 15 0.077 ± 0.003 
H389N malonyl-CoA 0.025 ± 0.004 1460 ± 140 0.017 ± 0.002 
T355V malonyl-CoA 0.0071 ± 0.002 225 ± 21 0.0031 ± 0.005 
WT methylmalonyl-CoA 0.29 ± 0.07 168 ± 46 1.73 ± 0.07 
WT malonyl-ACP 0.037 ± 0.011 41 ± 13 0.92 ± 0.21 
Acyl transfer  
(holo) AR-GNATL-ACPL Substrate kcat [s-1] KM [μM] kcat/KM [x103 M-1s-1] 
WT acetyl-CoA 0.0023 ± 0.0002 4.3 ± 0.2 0.53 ± 0.02 
H389A acetyl-CoA 0.0019 ± 0.0003 4.2 ± 0.3 0.46 ± 0.03 
H389N acetyl-CoA 0.0067 ± 0.0005 14.0 ± 0.3 0.48 ± 0.03 
T355V acetyl-CoA 0.0031 ± 0.0008 5.7 ± 0.5 0.55 ± 0.07 
WT malonyl-CoA 0.0021 ± 0.0004 3.7 ± 0.6 0.58 ± 0.02 
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Table 2-S2. Data collection and Refinement Statistics. 
 
Table S2A – Data Collection 
Parameter  Apo Peak Inflection Remote  Malonyl- CoA Soak
Space Group  P3121 P3121 P3121 P3121  P3121 
Dimensions (Å) a, c  91.5, 138.9 91.7, 137.5 91.7, 137.5 91.6, 137.5  91.9, 139.5
X-ray source  23ID-B 23ID-B 23ID-B 23ID-B  23ID-B 
Wavelength λ (Å)  0.97939 0.97934 0.97945 0.96112  0.97939 
dmin (Å)  1.95 2.30 2.30 2.30  2.75 
Unique observations  49,929 30,361 30,365 30,327  18,244 
Rmerge(%)a,b  6.9 (55.5) 7.2 (65.5) 7.1 (63.7) 7.2 (66.6)  9.4 (53.4)
‹I/σ›a  28.9 (5.0) 13.5 (1.5) 14.0 (1.5) 13.6 (1.5)  24.5 (4.9)
Completeness (%)a  99.6 (99.2) 100 (100) 100 (99.9) 100 (100)  99.9 (99.9)
Avg. redundancya  11.2 (11.1) 2.9 (2.9) 2.9 (2.8) 2.9 (2.9)  9.7 (9.8) 
aValues in parenthesis are for outer shell 
bRmerge=∑|Ii-‹I›|/∑Ii, where Ii is the intensity of the ith observation and ‹I› is the mean intensity 
 
Table S2B – Refinement Statistics 
Refinement statistics   
  Apo Malonyl-CoA 
soak 
Data range  50-1.95 50-2.75 
R/Rfreea  0.172/0.211 0.207/0.251 
RMSD bond length (Å)  0.013 0.008 
RMSD bond angle (Å)  1.382 1.351 
Avg. Protein B-factor (Å2)  39.5 43.1 
Avg. Solvent B-factor (Å2)  47.4 28.8 
Wilson B (Å2)  31.6 60.3 
Ramachandran plotc    
    Favored  97.7 96.4 
    Allowed  3.3 3.4 
    Disallowed  0.0 0.2 
Protein atoms  3432 3356 
Water molecules  460 4 
Other atoms  33 153 
PDB code  2REE 2REF 
aR = ∑|FO-|FC||/∑|FO| where FO is the observed structure factor and FC is the calculated structure 
factor used in the refinement 
bRfree = ∑|FO-|FC||/∑|FO| where FO is the observed structure factor and FC is the calculated structure 
factor from 5% of reflections not used in the refinement 
cFrom output of MOLProbity (Davis et al. 2004 Nucleic Acids Research 32:W615-W619) 
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Table 2-S3. Primers for the expression constructs and site mutagenesis. 
 
Construction Primers 
Primer name Sequences (5’ to 3’) 
AR-GNATL-ACPL-for CATATGCTAGAGTTAATTAATCGT (NdeI) 
AR-GNATL-ACPL-rev CTCGAGTTACTCTGGCTTTGGTAGTAC (XhoI) 
GNATL-ACPL-for CATATGAGTTTAAATTGTTTTGAAAATAAT (NdeI) 
GNATL-ACPL-rev CTCGAGTTACTCTGGCTTTGGTAGTAC (XhoI) 
AR-GNATL-for CATATGCTAGAGTTAATTAATCGT (NdeI) 
AR-GNATL-rev CTCGAGCTTAGTCTGCCGATTTTTTTC (XhoI) 
GNATL-for CATATGAGTTTAAATTGTTTTGAAAATAAT (NdeI) 
GNATL-rev CTCGAGCTTAGTCTGCCGATTTTTTTC (XhoI) 
ACPL-for CATATGAAACTGACAGAAGATATAGAT (NdeI) 
ACPL-rev CTCGAGTTACTCTGGCTTTGGTAGTAC (XhoI) 
AR-for CATATGCTAGAGTTAATTAATCGT (NdeI) 
AR-rev CTCGAGTTTTTGGACTTTTATCAAAC (XhoI) 
(DEBS)ATL-ACPL-for CATATGGCGGACCTGTCAAAGC (NdeI) 





Mutagenic Primers  










The restriction sites are underlined; the mismatch bases are in red. 
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Table 2-S4. MS analysis for decarboxylation and acetyl transfer. 
 
Masses are in Daltons. Calc., calculated; Obs., observed; ND, not detected 
*The masses ACP derivatives are calculated without the first methionine for the His6-tag removed protein. 
†[469-484] = ALMEMGIES477LELLELR. 
§PPant ejection product for acetyl-NH-ACP was not detected due to the weak signal of acetyl-NH-ACPL. 
ACPL samples 
ESI-FT-ICR-MS IRMPD (PPant ejection product) 
ACPL* Obs. avg mass Calc. avg mass Obs. [M + H]+ Calc. [M + H]+ 
apo-ACPL 10820.7 10821.1   
holo-ACPL 11160.9 11160.7 216.128 261.127 
acetyl-S-ACPL 11202.5 11202.7 303.138 303.137 
malonyl-S-ACPL 11247.4 11247.2 347.128 347.127 
NH2-ACPL 11144.5 11144.7 244.166 244.166 
Acetyl-NH -ACPL 11186.4 11186.7 ND ND 
AR-GNATL-ACPL trypsin digestion samples 
ESI-FT-ICR-MS IRMPD (PPant ejection product) 
[469-484 + 2H]2+ Obs. mass Calc. mass Obs. [M + H]+ Calc. [M + H]+ 
apo- 1845.97 1845.95   
holo- 2186.05 2186.04 261.127 261.127 
acetyl- 2228.06 2228.05 303.138 303.137 
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POLYKETIDE HMG β-BRANCHING 
3.1  SUMMARY 
This chapter contains two successive studies towards understanding the mechanisms 
of polyketide HMG β-branching in the curacin A pathway. The first study describes the 
functional identification of a pair of mechanistically diverse enzymes that catalyze the 
successive dehydration (CurE ECH1) and decarboxylation (CurF ECH2) of 
(S)-HMG-ACP to generate a 3-methylcrotonyl-ACP intermediate, the presumed 
precursor of the cyclopropyl ring in curacin A. The reactions catalyzed by ECH1 and 
ECH2 are found in a broad cross-section of microbial natural product gene clusters and 
participate in the introduction of carbon chain branch points and functional group 
diversity as key steps in the HMG-CoA synthase mediated addition of C-2 from acetate 
to the α-carbonyl group of polyketide chains. The second study provides structural 
insights into CurF ECH2 decarboxylation in polyketide chain β-branching. The crystal 
structure of the CurF N-terminal ECH2 domain establishes that the protein is a crotonase 
superfamily member. Ala78 and Gly118 form an oxyanion hole in the active site, which 
includes only three polar side chains as potential catalytic residues. Site-directed 
mutagenesis and a coupled ECH1/ECH2 dehydration/decarboxylation assay established 
critical functions for His240 and Lys86, whereas Tyr82 was non-essential. A 
decarboxylation mechanism is proposed in which His240 serves to stabilize the substrate 
carboxylate and Lys86 donates a proton to γ-C of the acyl-ACP enolate intermediate to 
form the α,β unsaturated isopentenoyl-ACP product. CurF ECH2 substrates were 
synthesized enzymatically, and used in a direct ECH2 assay to show a 20-fold selectivity 
for ACP- over CoA-linked substrates. Specificity for ACP-linked substrates has not been 
reported for any other crotonase superfamily decarboxylase. Tyr73 may select against 
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CoA-linked substrates by blocking a contact of Arg38 with the CoA adenosine 
5'-phosphate. 
3.2  INTRODUCTION 
Polyketides and non-ribosomal peptides are important secondary metabolites 
possessing an array of biological activities and considerable chemical diversity (1-4). 
Type I modular polyketide synthase (PKS) and non-ribosomal peptide synthetase (NRPS) 
systems sequentially elongate and modify a growing ketide or peptide chain as it is 
passed from module to module. The biosynthetic machinery generates tremendous 
chemical diversity in these compounds by use of specific reductive domain combinations 
within modules and/or gene cassettes that encode proteins capable of producing unique 
functionalities. 
Curacin A (1, Figure 3-1A), a marine cyanobacterial metabolite from Lyngbya 
majuscula, is a mixed polyketide-non-ribosomal peptide natural product with potent 
anti-proliferative and cytotoxic activity against colon, renal, and breast-cancer derived 
cell lines (5). Because of its unusual structure, which includes a cyclopropane group, 
thiazoline moiety, cis-alkenyl group, and terminal double bond, we were motivated to 
characterize the unique enzymes responsible for the curacin A assembly.  
Recently, we identified and characterized a gene cluster (cur) from Lyngbya 
majuscula L19 whose architecture and domain organization correlates directly with that 
expected for curacin A biosynthesis (6). Within the cur gene cluster that spans ~65 kbp is 
an ~8 kbp region (CurA-CurF) with striking similarity (80-95% amino acid identity) to a 
comparably-sized section of the jamaicamide 2 (jam) biosynthetic pathway (JamE-JamJ) 
(7). The genes from this region are translated into a set of enzymes containing a predicted 
α-ketoglutarate dependent halogenase (8), a set of three tandem ACPs, and a 
3-hydroxy-3-methylglutaryl (HMG)-CoA synthase (HCS)-like gene cassette that 
collectively are likely involved in the introduction of the cyclopropane group in curacin 
A and the vinyl chloride substituent in jamaicamide (6, 7). The HCS-like gene cassette 
encodes five biosynthetic enzymes: an acyl carrier protein (CurB), a putative 
ketosynthase (CurC), an HMG-CoA synthase (CurD), and two putative enoyl-CoA 
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hydratases (CurE ECH1 and CurF ECH2). This novel cassette has recently been identified 
in several additional gene clusters, including the jam pathway from L. majuscula, the 
mupirocin 3 (Mup) pathway from Pseudomonas fluorescens, and the “PksX” pathway 
from Bacillus subtilis (6-9), and is proposed to catalyze addition of C-2 from acetate onto 
the polyketide chain to generate a pendant functional group (Figure 3-1A). 
In the first study (10), we provided evidence for the specific function of the 
CurE/CurF ECH1-ECH2 enzyme pair (Figure 3-1A) in curacin A biosynthesis, and 
demonstrated that they catalyze the successive dehydration and decarboxylation of 
(S)-HMG-ACP 5 to generate a 3-methylcrotonyl-ACP 7 intermediate for the subsequent 
formation of the cyclopropane ring in 8 (Figure 3-1B). Significantly, it is now evident 
from bioinformatic analysis that the ECH1-ECH2 enzyme pair exists widely in different 
 
 
Figure 3-1. HMG enzyme cassettes. A) HMG gene cassettes are proposed to introduce a 
pendant carbon (indicated by red asterisk) from C-2 of acetate to the polyketide chains. 
Amino acid identities of enzymes are shown (%), and acetate labeling patterns are 
highlighted in blue. B) Proposed mechanism for the HMG β-branching in curacin A 
pathway. 
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microbial species and is not necessarily limited to HCS-like gene cassettes (Figure 3-S1). 
Therefore, we believe that the ECH1-ECH2 of the curacin A system represents an 
excellent example of chemistry-directed enzyme evolution, giving rise to “mechanistic 
diversity”(11) within a single protein family. 
Enoyl-CoA hydratases belong to the crotonase superfamily, consisting of a wide 
variety of mechanistically diverse enzymes that exhibit various activities, such as 
hydratase (12), dehalogenase (13), decarboxylase (13, 14), isomerase (15-17), hydrolase 
(14), and carbon-carbon bond formation (14) or cleavage (18, 19). The common 
mechanistic theme of this low-sequence-identity superfamily is the stabilization of an 
enolate anion intermediate of phosphopantetheine-linked substrates by two backbone 
amide groups forming an oxyanion hole (20). A unique feature of the ECH2-like enzymes 
involved in natural product biosynthesis is that they are thought to depend exclusively on 
ACP-linked substrates in vivo. Structural clues that enable these enzymes to discriminate 
between CoA and ACP-linked substrates will increase our understanding of the 
evolutionary changes that have occurred to favor one substrate over another, as well as to 
control functional group diversity in the final natural product. 
In the second study (21), we solved the 1.85Å crystal structure of the wild-type, 
N-terminal ECH2 domain of CurF and the 1.65Å structure of the corresponding Y82F 
variant. Modeling of the substrate of CurF ECH2 was performed and Tyr82, Lys86, and 
His240 were identified as potential catalytic or substrate-binding residues. Site-directed 
mutagenesis in a coupled ECH1/ECH2 dehydration/decarboxylation assay with 
ACP-linked substrates demonstrated that CurF ECH2 His240 and Lys86 are critical to 
catalysis. 
3.3  RESULTS AND DISCUSSION 
3.3.1  Functional Identification of ECH1 and ECH2 Enzyme Pair 
In the cur gene cluster, ECH1 is encoded by curE, and the ECH2 gene is embedded 
in curF as the first domain of the CurF hybrid PKS/NRPS bimodular polypeptide (Figure 
3-1A). Although the sequence identity between cur ECH1 and ECH2 is only 17%, they 
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are predicted to belong to the crotonase superfamily, and contain two consensus 
sequences (Figure 3-S1) essential for the “oxyanion hole” to stabilize enolate anions (20). 
In contrast, the sequence identities in the ECH1 and ECH2 groups compared from various 
biosynthetic systems (Figure 3-S1) are generally above 40%, which suggests that ECH1 
and ECH2 have different functional roles. To identify their precise function, we reasoned 
that the HCS motif would follow a path involving initial assembly of HMG-ACP via the 
reaction of C-2 of acetyl-ACP with acetoacetyl-ACP 4 (catalyzed by HMG-CoA synthase 
(CurD)). The co-linearity of the Cur biosynthetic pathway suggested that the ECH1-ECH2 
pair would operate in late stage construction of the presumed acyl-ACP precursor for 
cyclopropane ring formation. 
To probe the function of ECH1, curE was cloned, overexpressed and purified as a 
30.5 kDa N-His-tagged fusion protein. Next, we sought to excise a functional form of 
ECH2 from the amino terminus of the CurF multifunctional enzyme. This was 
accomplished by choosing an optimized cutting site in the linker region of ECH2 (259 
amino acids) to yield a 29.5 kDa C-His-tagged fusion protein. Additionally, curB was 
cloned, overexpressed and purified in the apo-CurB (acyl carrier protein) form as an 11 
kDa N-His-tagged fusion protein. ECH1, ECH2 and apo-CurB were isolated in soluble 
form from E. coli and purified by Ni-NTA agarose resin. The apo-CurB protein (75 μM) 
was subsequently loaded using HMG-CoA via in vitro phosphopantetheinylation through 
in situ incubation with (R,S)-HMG-CoA (500 μM) and Sfp (4 μM) (22). The 
HMG-holo-CurB was dialyzed against ECH assay buffer to adjust pH and remove excess 
HMG-CoA. 
The in vitro activity of ECH1 and ECH2 were investigated by incubating ECH1, 
ECH2 or both (2 μM each) with (R,S)-HMG-holo-CurB (50 μM) in a series of buffers at 
37oC. ESI-FTMS (Apex-Q instrument, Bruker Daltonics) was applied to detect mass 
change of the acyl group covalently linked to the holo-CurB. We found that in the 
presence of ECH2 alone (Figure 3-2A, c), no new reaction products were observed. In 
contrast, in the presence of ECH1, a peak corresponding to 18 Da loss in molecular mass 
occurred (Figure 3-2A, b), and when both ECH1 and ECH2 were employed, two peaks 
corresponding to 18 Da and 62 Da loss in molecular mass were observed (Figure 3-2A, d). 
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These results suggest that ECH1 catalyzes dehydration of HMG-ACP 5 to 
3-methylglutaconyl-ACP 6 (Figure 3-1B), and ECH2 catalyzes subsequent 
decarboxylation to 7. 
Next, we also demonstrated that ECH1 and ECH2 are able to accept and catalyze 
dehydration and decarboxylation of (R,S)-HMG-CoA (Figure 3-2B), which suggests that 
 
 
Figure 3-2. ECH1 and ECH2 assays for the substrates in CoA and ACP forms. A) 
FTICR spectra, 50 μM (R,S)-HMG-ACP, 2 μM ECH1, ECH2, or both, at 37oC for 3 h. 
Experimental most abundant mass: 5-ACP, 11325.8; 6-ACP, 11307.8; 7-ACP, 11264.8. B) 
UV 275 nm traces of (a) standards: 5-CoA and 7-CoA (MC-CoA), 0.5 mM (R,S)-5-CoA 
treated with (b) 2 μM ECH1, (c) 2 μM ECH2, (d) 2 μM ECH1 and ECH2 at 37oC for 3 h. The 
CoA peak shoulders and the following minor peaks are possibly due to CoA aggregation. 
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the two enzymes recognize the phosphopantetheine arm from CoA as well as holo-ACP. 
Importantly, this finding facilitated structural identification of the dehydration and 
decarboxylation products from the reaction. Specifically, 0.5 mM (R,S) HMG-CoA was 
incubated with the ECH1, ECH2 or both (2 μM each) in 30 mM Bis-Tris buffer, pH 6.5 at 
37 oC for 3 hours, and the reaction mixtures were analyzed by HPLC equipped with a 
photodiode array detector and an ESI-LTQ mass spectrometer (ThermoFinnigan). UV 
spectral analysis of the HMG-CoA substrate, and the following dehydration and 
decarboxylation steps, revealed a significant absorption increase at 260 nm for both 
dehydration and decarboxylation products (Figure 3-S2). This increase is consistent with 
an α,β C=C bond formation in an acyl-CoA thioester (23). In addition, MS/MS analysis 
confirmed that the dehydration product was 6-CoA, and we did not pursue the further 
clarification of the C=C configuration. To determine regiochemistry of the double bond 
in the decarboxylation product, we synthesized 3-methyl-3-butenoyl-CoA and used 
commercially available 7-CoA (Sigma) as authentic standards. HPLC co-injection 
showed that the decarboxylation product is 7-CoA (Figure 3-S3A). 
Finally, we investigated the substrate preference of ECH1 by comparing the 
conversion ratio of (R,S)-HMG-CoA and (S)-HMG-CoA which was generated by 
HMG-CoA reductase (24). Based on HPLC traces, the conversion ratio of (S)-HMG-CoA 
is 2-fold higher than that of (R,S)-HMG-CoA (Figure 3-S3B), which indicates that 
(S)-HMG is the natural ECH1 substrate (25). 
In summary, the CurE/CurF ECH1-ECH2 enzyme pair from the curacin A 
biosynthetic pathway was functionally identified as a mechanistically diverse enzyme 
pair. We demonstrated that CurE ECH1 catalyzes dehydration of (S)-HMG-ACP 5 to 
form 3-methylglutaconyl-ACP 6, and CurF ECH2 catalyzes decarboxylation of 6 to 
generate 3-methylcrotonyl-ACP 7, the presumed precursor for cyclopropyl-ACP 8 
formation in curacin A. The detailed steps leading from 3-methylcrotonyl-ACP to the 
cyclopropane ring are the subject of ongoing studies in our laboratory. It is noteworthy 
that, to date, only two members of crotonase enzyme superfamily, methylmalonyl-CoA 
decarboxylase (MMCD) (26) and CarB (27) were reported to catalyze loss of carbon 
dioxide. Thus, identification of the reaction catalyzed by CurF ECH2 provides a new 
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example of this novel biotin-independent decarboxylase in secondary metabolism. 
3.3.2  Structural Insights into ECH2 Decarboxylation 
Structure Determination  Initial crystal screening with a polypeptide including 
residues 1-257 of CurF produced crystals that diffracted to only ~3.8Å, but an N-terminal 
truncation including residues 17-257 yielded crystals that diffracted to beyond 2Å. The 
structure was solved by MAD phasing using selenomethionyl CurF ECH2 (Table 3-S1). 
The resulting model was refined against the 2.0Å dataset in crystal form I and used to 
solve the structures by molecular replacement in crystal form II (Table 3-S2). 
Structure of the N-terminal ECH2 Domain of CurF  The CurF ECH2 domain 
possesses the crotonase core fold (residues 17-209) consisting of a central mostly parallel 
beta sheet flanked by alpha helices (Figure 3-3A). Roughly perpendicular to the main 
beta sheet (β1, β2, β3, β5, β7) are short beta strands (β4, β6, β8) that are a hallmark of 
the crotonase superfamily. Crotonase superfamily members can be classified into one of 
three structural classes based on the conformation of the helical C-terminus (14, 20). The 
helical C-terminus (α9, α10, α11) of CurF ECH2 has the “self-association” fold seen in at 
least eight other crotonase family members (15-17, 19, 28), including the two with 
biotin-independent decarboxylase activities, methylmalonyl CoA decarboxylase (MMCD) 
(26) and carboxymethylproline synthase (CarB) (14). 
Quaternary Structure of the ECH2 Domain of CurF  The trimer structure 
fundamental to the crotonase superfamily occurs in both crystal forms of ECH2 (Figure 
3-3B). Subunit contacts are virtually identical in the two crystal forms. A total of 15% of 
the solvent-accessible surface area of the monomer is buried in the ECH2 trimer (total 
buried surface area per monomer = 1050 Å2). The extensive buried surface and the lack 
of water in the subunit interface together indicate that the trimeric association observed in 
the crystal structure reflects a true quaternary structure for the protein. However, in 
solution CurF ECH2 also displayed concentration-dependent dissociation (Figure 3-S4), 
indicating a dynamic equilibrium between trimeric and lower oligomeric states. 
Active site  Despite less than 20% sequence identity with other crotonase family 
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members of known structure, strong structural similarity of the CurF ECH2 domain to 
 
Figure 3-3. CurF ECH2 structure. A), stereo diagram of the monomer of the CurF ECH2 
domain with the active site chamber indicated by an asterisk. B), trimeric structure of the 
CurF ECH2 domain with the active site chamber indicated by an asterisk. C), multiple 
sequence alignment of ECH2-like decarboxylases from gene clusters encoding the 
biosynthesis of curacin (CurF), bacillaene (PksI, 44% identity), virginiamycin M (VirE, 36% 
identity), myxovirescin A (TaY, 43% identity), mupirocin (MupK, 39% identity), 
jamaicamide (JamJ, 59% identity), pederin (PedI, 36% identity), and sequences of the two 
structurally characterized crotonase superfamily decarboxylases (CarB [17% identity] and 
MMCD [15% identity]). Secondary structure elements of CurF are shown above the 
alignment, residues of the oxyanion hole are indicated by triangles below the alignment, 
invariant residues are red, sites of conservative substitution are blue, and similar residues are 
green. Every tenth residue is underlined.aggregation. 
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crotonase superfamily members enabled us to align the structures and to identify critical 
elements of the active site, including the substrate binding tunnel, active site oxyanion 
hole, and active site chamber. Structural alignments with several other crotonase family 
members (Figure 3-S5) clearly indicate that the backbone amides of residues Ala78 and 
Gly118 form the oxyanion hole. These residues follow conserved Gly77 and Gly117, which 
have backbone conformations only accessible to glycine. In this manner, the peptide 
planes of residues 77-78 and 117-118 are oriented so their amides can stabilize the 
 
 
Figure 3-4. Active site of CurF ECH2. A) refined 2Fo - Fc electron density contoured at 1 σ 
from wild type CurF ECH2 domain. The water molecule present in the oxyanion hole is shown 
with dashed lines to the backbone amides of Ala78 and Gly118. Residues His240, Lys86, and 
Tyr82 are shown in the foreground. B) stereo diagram of substrate (gray) modeling results 
highlighting polar residues within8Åofthe modeled substrate carboxylate group. The loop 
connecting helices α2 and α3 covers the active site. 
55 
proposed enolate anion intermediate by hydrogen bonding. In the crystal structures, a 
water molecule occupies the oxyanion hole (Figure 3-4A). Attempts to obtain crystal 
structures of complexes with product analogues were unsuccessful. The substrate of CurF 
ECH2 was then modeled into the active site (see Methods). Only three polar side chains 
(Tyr82, Lys86 and His240) are present within the primarily hydrophobic active-site chamber 
(Figure 3-4B). 
Decarboxylase Activity with ACP-linked substrate  Based on the active site and 
substrate modeling, residues Tyr82, Lys86 and His240 were selected for mutagenesis. 
Proteins possessing Y82F, K86A, K86Q H240A, or H240Q were produced and assayed 
for activity against ACP-linked substrates in a coupled ECH1/ECH2 assay (10). 
Substitution of Tyr82 by Phe led to two-fold reduction in product formation in comparison 
to wild-type (Figure 3-5), indicating that Tyr82 plays little or no role in catalysis. On the 
other hand, product formation was reduced more than 20-fold in the K86A, K86Q, 
H240A, and H240Q variants compared to wild-type. FT-ICR mass spectrometry 
confirmed that the ECH1 and ECH2 products were produced from the ACP-linked 
substrate (Figure 3-5C, Figure 3-S6) (10). The 1.65Å crystal structure of the Y82F 
variant of CurF ECH2 showed a similar position for the phenyl ring within an otherwise 
undisturbed structure. Although stable, the CurF ECH2 K86A, K86Q, H240A, and 
H240Q variants have not yielded crystals. 
Decarboxylase Activity Preference for ACP-linked Substrates over CoA-linked 
Substrates  CurE ECH1 activity towards (R,S)-HMG-CoA or (R,S)-HMG-ACP yielded 
very similar 3-methylglutaconyl-ACP and 3-methylglutaconyl-CoA yields (Figure 3-6). 
CurF ECH2 activity towards 3-methylglutaconyl-ACP or 3-methylglutaconyl-CoA 
yielded significantly better activity with the ACP-linked substrate (~3% CoA conversion 
versus >70% conversion, respectively) (Figure 3-6). 
The N-terminal ECH2 domain of CurF possesses the crotonase superfamily fold. As 
is seen with the two other structurally characterized crotonase family members 
possessing biotin-independent decarboxylase activity (CarB (14) and MMCD (26)), the 
C-terminal helical domain folds back upon the monomer in a “self association” fold (15). 
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Thus the active site chamber is formed exclusively by residues within one monomer of 
the trimer. 
The diversity of chemical reactions catalyzed by crotonase family members and 
their highly divergent sequences result in little if any conservation within the active site 
chamber. Nevertheless, the close structural similarity with other crotonase family 
members suggests strongly that Ala78 and Gly118 form the oxyanion hole of CurF ECH2 
(Figure 3-S5). The site-directed mutagenesis results show that Lys86 and His240 play 
crucial roles in catalysis (Figure 3-5). We propose a decarboxylation mechanism in which 
 
 
Figure 3-5. ECH1/ECH2 coupled enzymatic assays for ECH2 wild type and mutants. A) 
HPLC chromatograms showing the (R,S)-HMG-CurA-ACP(II) and associated species before 
and after ECH1/ECH2 coupled reactions at 37°C for 1 h; the peaks correspond to 
(R,S)-HMG-CurA-ACP(II) (peak 1), 3-methylglutaconyl-CurA-ACP(II) (peak 2), and 
3-methylcrotonyl-CurA-ACP(II) (peak 3). B) comparison of the peak areas of 
3-methylcrotonyl-CurA-ACP(II) for ECH2 wild type and mutants. The data were subjected to 
normalization and base-line subtraction before the peak area calculation, and the assays were 
duplicated. C) FTICR-MS identification of the ACP-linked substrate and products. Only the 
preferred substrate for ECH1,(S)-HMG-ACP, is shown in the reaction scheme. 
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the oxyanion hole anchors the substrate in the active site and stabilizes the enolate anion, 
His240 hydrogen bonds with the substrate carboxylate, and Lys86 is the proton donor to the 
C-4 position of the decarboxylated substrate (Figure 3-7). The hydrophobic environment 
of the active site chamber enhances the reactivity of these groups. 
Other than Lys86 and His240, Tyr82 is the only polar side chain within the active site 
chamber. However, elimination of the phenolic hydroxyl by substitution with Phe had 
 
 
Figure 3-6. Comparison of ACP and CoA substrate preference of ECH1 and ECH2. A) 
CoA-dependent activities. HPLC traces were monitored at 254 nm. 50 µM (R,S)-HMG-CoA 
or 3-methylglutaconyl-CoA was treated with 2 µM ECH1 or ECH2. B) ACP-dependent 
activities. HPLC traces at 280 nm. 50 µM (R,S)-HMG-ACP or 3-methylglutaconyl-ACP was 
treated with 2 µM ECH1 or ECH2. Peak 1,(R,S)-HMG; peak 2, 3-methylglutaconyl; peak 3, 
3-methylcrotonyl. The yields of CoA (A, peak 2) or ACP (B, peak 2) for the reactions of CoA 
(A, peak 1)/ACP (B, peak 1) treated with ECH1 are similar ( 10-15% conversion of substrate 
to product), but the yields of CoA (A, peak 3) and 3-ACP (B, peak 3) treated with ECH2 are 
significantly different ( 3% for the CoA substrate and >70% for the ACP substrate). 
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only a two-fold effect on product formation, indicating that Tyr82 does not play a major 
role in substrate hydrogen bonding or proton donation. Interestingly, Tyr140 of MMCD 
was proposed to hydrogen bond with the carboxylate group of methylmalonyl CoA in a 
mechanism analogous to that outlined above (26). Tyr82 of CurF ECH2 and Tyr140 of 
MMCD are not in analogous parts of the protein structures. Significantly, Tyr82 is not 
conserved among sequences of decarboxylases in the crotonase superfamily (Figure 
3-3C). 
His240 is conserved in all decarboxylases encoded by HCS cassettes and also in 
carboxymethylproline synthase (CarB) (Figure 3-3C). His240 is in an excellent position to 
assist catalysis by hydrogen bonding with the carboxylate leaving group (Figure 3-7A). 
In liganded CarB, His229 is in an identical position to His240 of CurF ECH2, and also was 
proposed to function as a general base in decarboxylation (14). The importance of His240 
in catalysis was demonstrated in the H240A and H240Q variants of CurF ECH2, in which 
catalysis was severely impaired (Figure 3-5). His240 of CurF ECH2 is the only invariant 
polar residue within the active site chamber, and we propose that it acts as a general base 
here and in all other ECH2-like decarboxylases of HCS cassettes (Figure 3-3C). An 
analogous His does not exist in MMCD. The equivalent helix to α10 of CurF ECH2, 
which contains His240, is further from the active site chamber in MMCD and forms 
extensive trimer contacts with the adjacent monomer. 
After decarboxylation, proton donation to the substrate C-4 carbon to form 
 
 
Figure 3-7. Proposed CurF ECH2 mechanism. His240 stabilizes the substrate 
carboxylate (A), and Lys86 donates a proton to the decarboxylated intermediate (B) to 
form the product (C). The oxyanion hole is formed by the backbone amides of Ala78 
and Gly118. 
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isopentenyl-ACP is necessary for enolate collapse to the ∆2 unsaturated product (Figure 
3-7B). Lys86 is the most likely proton donor in CurF ECH2, given the relatively fixed 
position of the enolate anion in the oxyanion hole during substrate binding and the 
hydrophobic nature of the active site chamber. Lys86 resides on helix α2, and has the 
necessary flexibility and reach to accommodate proton donation at the C-4 carbon of the 
substrate (Figure 3-4B). His240 is not a candidate proton donor because it appears unable 
to reach the C-4 carbon of the decarboxylated intermediate, as required for subsequent 
product formation, and also unable to move closer to the C-4 carbon. Its backbone is held 
in place as part of the long helix α10 and its side chain is positioned by a hydrogen bond 
with the carbonyl of Thr147 (Figure 3-4A) deep within the active site chamber. In contrast, 
Lys86 is located on helix α2, the most mobile part of the CurF ECH2 structure as seen in 
distinctly higher crystallographic temperature factors. This region of the crotonase fold is 
generally mobile and is completely disordered in some structures. 
Proton addition to the C-4 carbon following decarboxylation should produce an α,β 
unsaturated product, whereas proton addition to C-2 should yield the β,γ product (Figure 
3-7). Examples of both reaction routes exist, based on the structures of the PKS products. 
Thus, the mechanism of ECH2 is a key determinant of the regiochemistry of the ultimate 
product of each pathway. The active site chambers of other ECH2-like decarboxylases 
appear equally as hydrophobic as the CurF ECH2 active site with the exception of the 
loop between helices α2 and α3 (residues 89-95 of CurF, Figure 3-3C). This region 
covers the active site (Figure 3-4B), but differs in length and sequence among the ECH2 
decarboxylases (Figure 3-3C). It is uncertain whether all residues aligned with CurF 
89-95 constitute the α2-α3 loop in these decarboxylases, or whether some of them are 
part of a longer helix α3, as in CarB and MMCD (Figure 3-S5). Variability in the α2-α3 
loop is expected among the ECH2 decarboxylases. Each enzyme must possess a unique 
conformation to accommodate its substrate, often bulkier than the methyl group of the 
CurF ECH2 substrate. In addition, a unique proton donor must be positioned to generate 
specifically an α,β or β,γ unsaturated product. Candidate proton donors include Lys80, 
Asp83 or Asp84 of PksI, His68, Asp73 or Asp77 of VirE, Cys74 or Asp75 of TaY, Asp79 or 
Asp82 of MupK, Glu88, Glu89, Lys92 or Asp95 of JamJ, and Asp2949, Lys2954, Asp2962 or 
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Glu2963 of PedI (Figure 3-3C). 
The CurF ECH2 domain is the first structurally characterized crotonase family 
member that acts preferentially upon ACP-linked substrates. Product formation in vitro 
with a CoA-linked substrate was significantly less robust than with an ACP-linked 
substrate (Figure 3-6), but the effect of each amino acid substitution was identical in 
ACP- and CoA-based assays (data not shown). Despite the strong preference for 
ACP-linked substrates by CurF ECH2, structure alignment with other crotonase 
superfamily enzymes having CoA ligands (Figure 3-S5) revealed remarkably few 
structural changes in the CoA-binding region. Structural motifs that would recognize the 
adenine ring and overall backbone conformation around the adenosine portion of CoA are 
identical to other structurally characterized crotonase enzymes. One notable difference in 
CurF ECH2 is the position of the Tyr73 side chain. In the CoA-dependent enzymes, a 
basic side chain occupies this space and interacts with the 4-phosphate of pantothenic 
acid and the 5'-phosphate of the adenosine portion of CoA. In the ECH2-like 
decarboxylases from HCS cassettes that operate with presumed ACP-linked substrates, 
Tyr73 of CurF is conserved as a bulky phenylalanine or tyrosine residue (Figure 3-3C), 
whereas in the CoA-dependent enzymes the analogous position is always a smaller 
alanine, serine, or valine residue. Thus it appears that CoA is a poorer substrate of CurF 
ECH2 in part because the Tyr73 side chain has displaced a basic side chain (Arg38 in CurF) 
from the CoA binding site. CurF ECH2 containing an alanine substitution at the Tyr73 site 
was not soluble and has frustrated efforts to directly test this hypothesis. The relatively 
small number of changes and persistent structural conservation implies a relatively recent 
evolution of protein function towards ACP-linked substrates. 
An intriguing outcome of the CurF ECH2 structure is the apparent symmetry 
mismatch between its trimeric structure and the fundamentally dimeric structure of 
several downstream domains in the CurF polypeptide (enoyl reductase, ketosynthase, 
dehydratase) (6, 29). The CurF ECH2 domain possesses the crotonase “self-association” 
fold with the active site fully formed by each monomer and also demonstrates a capacity 
for trimer dissociation in solution (Figure 3-S4). Thus, the ECH2 domain may be 
monomeric in the context of full-length CurF, similar to the bacterial fatty acid 
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β-oxidation multienzyme complex in which an N-terminal monomeric crotonase domain 
is fused to a dimeric dehydrogenase domain (28). Nevertheless, existence of the classical 
crotonase trimer in the isolated ECH2 domain (Figure 3-3B) is strongly suggestive of a 
trimeric ECH2 within full-length CurF. This could be accomplished in either of two ways. 
CurF could be a hexamer containing two ECH2 trimers flexibly tethered to three dimers 
of the downstream domains. Alternatively, CurF could be a dimer in which ECH2 forms a 
heterotrimer with ECH1 (CurE). Determination of the oligomeric organization of CurF is 
an ongoing investigation. 
In summary, the crystal structure of the N-terminal ECH2 domain of CurF 
PKS-NRPS multifunctional protein from Lyngbya majuscula possesses a crotonase fold. 
Structural alignments identified Ala78 and Gly118 as forming the oxyanion hole, whereas 
substrate modeling identified His240, Lys86, and Tyr82 as potential catalytic residues. Site 
directed mutagenesis and functional analysis using a coupled ECH1/ECH2 
dehydration/decarboxylation assay demonstrated that His240 and Lys86 are critical for 
catalytic activity. Based on assay results, sequence conservation with decarboxylases 
from other HCS cassette-containing biosynthetic systems and comparisons with other 
structurally characterized crotonase decarboxylases, His240 is proposed to be the general 
base involved in decarboxylation and Lys86 is proposed to donate a proton to the C-4 
position of product. These structural features enable CurF ECH2 to specifically generate 
the α-β alkene regiochemistry in formation of the key isopentenyl-ACP product during 
curacin A biosynthesis. 
3.4  MATERIAL AND METHODS 
Chemical synthesis of 3-methyl-3-butenoyl-CoA. 3-methyl-3-butenoic acid was prepared 
by oxidizing 3-methyl-3-buten-1-ol (Fluka) using CrO3/H2SO4. Analytical data: 1H NMR 
(300 MHz, CD3Cl): δ =1.83 (s, 3H), 3.06 (s, 2H), 4.88 (s, 1H), 4.94 (s, 1H). 
3-methyl-3-butenoyl-CoA was generated by the thioesterification reaction of coenzyme A 
(protocol from Professor Christopher T. Walsh). 6.5 μL 3-methyl-3-butenoic acid solution 
(100 mg/mL acid in THF), 200 μL (benzotriazol-1-yloxy) tripyrrolidinophosphonium 
hexafluorophosphate (PyBOP) suspension (66.5 mg/mL in THF) and 8.87 μL 
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N,N-diisopropylethylamine (DIPEA) were combined before adding 200 μL CoA solution 
(50 mg/mL). Reaction mixture was stirred for 3-5 hours at room temperature. The mixture 
was loaded onto a preparative C18 column, and eluted with the gradient of 5-50% 
CH3OH/H2O (10 mM NH4OAc). Further purification was performed using a 
semipreparative C18 column and the gradient of 5-40% CH3OH/H2O (10 mM NH4OAc). 
Analytical data: ESI-MS (-ve): expected [M-H]-: 848.2, found: 848.3. 
Enzymatic synthesis of (S)-HMG-CoA. (S)-HMG-CoA was enzymatically generated 
using HMG-CoA reductase as previously described (24). The 15 ml reaction mixture 
contained 60 mM Tris-HCl, pH 7.9, 60 mM (R,S)-mevalonate, 5 mM NAD+, 1 mM CoA 
and 150 mM HMG-CoA reductase. 60 mM pyruvate and lactate dehydrogenase (200 units) 
were added to regenerate NAD+. The reaction was stirred at room temperature for 3 hours 
and monitored at UV 340 nm. The precipitate and enzymes were removed from the 
solution using a 10 kDa cutoff membrane (Amicon Ultra, Millipore). The filtrated solution 
was applied to a preparative C18 column using the elution gradient of 3-60% CH3OH/H2O 
(10 mM NH4OAc). The collected fraction containing (S)-HMG-CoA was evaporated and 
lyophilized. (S)-HMG-CoA was further purified by a semipreparative C18 column using the 
elution gradient of 3-30% CH3OH/H2O (10 mM NH4OAc). Analytical data: ESI-MS (-ve): 
expected [M-H]-: 910.2, found: 910.3. 
Bacterial strains, media and culture conditions. Escherichia coli DH5α MCR 
(Invitrogen) was used for DNA propagation. Escherichia coli BL21 (DE3) (Invitrogen) 
transformed with the derivatives of pET24b and pET28b (Novagen) was used for protein 
overexpression in Luria-Bertani (LB) medium. Ampicillin (100 μg/mL), Kanamycin (50 
μg/mL), Chloramphenicol (25 μg/mL), and Apramycin (50 μg/mL) were used for the 
corresponding plasmid construct resistance marker selection in E. coli cultures. 
Cloning, site-directed mutagenesis and protein overexpression. CurB, CurE and 
CurF-ECH2 (1-259 amino acid) genes were amplified from cosmid pLM54 described in 
our previous study (6) and inserted into pET24b and pET28b plasmids by the NdeI and 
XhoI restriction sites. The oligo pairs used for PCR amplification are the following: CurB 
((F) 5’-ATT GGA GTT CAT ATG AGC AAA GAA CAA GTA-3’, (R) 5’-CAA CAA 
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CTC GAG CAA TTT TGC TGC AAA TCA G-3’), CurE ((F) 5’-GAA CAC TAT CAT 
ATG TAT TAC AAA ACC ATA-3’, (R) 5’-GAT TCA CTC GAG GTT CTG CCA TGG 
GTA ATA-3’) and CurF-ECH2 ((F) 5’-CAT ATG GCA GAA CTG AAT TTG AAT-3’, 
(R) 5’-CTC GAG AAA CTC TTG CTG AAT ACG ACT-3’). The plasmid constructions 
were sequenced to confirm that they contained no errors. E. coli BL21 (DE3) was 
transformed by the expression plasmids, pET28b::CurE, pET24b::CurF-ECH2 and 
pET28b::CurB, to express N-His-tagged CurE, C-His-tagged CurF-ECH2, and 
N-His-tagged CurB. 0.8 liter cultures were inoculated with 8 ml of an overnight culture 
grown at 37oC. For CurB and CurF-ECH2, the cultures were grown at 35oC to an OD (600 
nm) = 0.5, and then cooled to 18oC prior to the addition of 
isopropyl-β-D-galactopyranoside (IPTG) (final concentration is 1 mM). The cultures were 
grown at 18oC for another 10-12 h. In order to increase the solubility of CurE, the pG-KJE8 
chaperone system (TaKaRa) was used to coexpress the chaperones in E. coli according to 
the instruction manual. 2.0 mg/mL L-arabinose and 5 ng/mL tetracycline were added to the 
culture to induce the chaperone expression. The culture was grown at 30oC to an OD (600 
nm) = 0.3-0.4, and cooled to 22oC before the addition of IPTG (0.5 mM). The culture was 
grown at 18oC for another 7-8 h prior to harvesting.  
The plasmid pMCSG7::CurFd17 was generated by PCR amplification of coding 
sequence corresponding to residues 17-257 of CurF from the pML9 cosmid DNA (6) and 
inserted into the vector pMCSG7 (30). The plasmid pMCSG7::CurFd17 was transformed 
into BL21(DE3) and grown at 37°C in 2xYT media to an OD600 of 0.6-0.8 in 2 L baffle 
flasks. The cultures were adjusted to 18°C, IPTG was added to final concentration of 0.4 
mM, and allowed to grow 8-16 h with shaking. Cells were harvested by centrifugation 
and cell pellets were frozen immediately at -20°C. SeMet-labeled protein was produced 
in BL21 (DE3) using SeMet minimal media according to the protocol of Guerrero et al. 
(31). Site-directed mutagenesis was performed by QuikChange method (Stratagene) with 
the primers: Y82F: (F) 5’-CAT CAG GGG CTA GCA AAG AAT TTT TAA TTA GAA 
AGA CTA GGG GTG AA AG-3’, (R) 5’-CTT CAC CCC TAG TCT TTC TAA TTA 
AAA ATT CTT TGC TAG CCC CTG ATG-3’; K86A: (F) 5’-GGG GCT AGC AAA 
GAA TAT TTA ATT AGA GCG ACT AGG GGT GAA GTA GAA G-3’, (R) 5’-CTT 
CTA CTT CAC CCC TAG TCG CTC TAA TTA AAT ATT CTT TGC TAG CCC C-3’; 
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K86Q: (F) 5’-GGG GCT AGC AAA GAA TAT TTA ATT AGA CAG ACT AGG GGT 
GAA GTA GAA G-3’,(R) 5’-CTT CTA CTT CAC CCC TAG TCT GTC TAA TTA 
AAT ATT CTT TGC TAG CCC C-3’; D95A: (F) 5’-GGG GTG AAG TAG AAG TTC 
TTG CTT TAT CAG GGT TGA TAC-3’, (R) 5’-GTA TCA ACC CTG ATA AAG CAA 
GAA CTT CTA CTT CAC CCC-3’; D95N: (F) 5’-GGG GTG AAG TAG AAG TTC 
TTA ATT TAT CAG GGT TGA TAC-3’, (R) 5’-GTA TCA ACC CTG ATA AAT TAA 
GAA CTT CTA CTT CAC CCC-3’; H240A: (F) 5’-GAA GCT ATC AAA AAA GAA 
CTA GAA ATA GCC CAG GTA ACC TTT AAC CAA CC-3’, (R) 5’-GGT TGG TTA 
AAG GTT ACC TGG GCT ATT TCT AGT TCT TTT TTG ATA GCT TC-3’; H240Q: 
(F) 5’-GAA GCT ATC AAA AAA GAA CTA GAA ATA CAA CAG GTA ACC TTT 
AAC CAA CC-3’, (R) 5’-GGT TGG TTA AAG GTT ACC TGT TGT ATT TCT AGT 
TCT TTT TTG ATA GCT TC-3’. All constructs were verified by DNA sequencing. 
CurA (2057-2146)-ACPII with a C-terminal His6-tag was constructed by inserting 
synthetic DNA (a kind gift from Christopher Calderone and Christoper T. Walsh, 
Harvard Medical School) into pET29a using NdeI and XhoI restriction sites. Protein 
overexpression of CurA ACPII was performed as described for CurB ACP. 
Protein purification. Protein purification was performed at 4oC. E. coli cells bearing an 
expression construct were harvested by centrifugation (4,000 x g, 15 min, 4oC), 
resuspended in the lysis buffer (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 10 mM 
imidazole, 20% glycerol) and disrupted by sonication. The cell debris was removed by 
centrifugation at 15,000 × g for 50 min. The supernatant was gently removed and loaded 
onto at the Ni-NTA agarose column pre-equilibrated with lysis buffer. The resin was 
washed successively with at least 5 column volumes of the washing buffer (50 mM PBS 
buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole) to remove nonspecifically bound 
contaminants. Bound proteins were eluted with the elution buffer (50 mM PBS buffer, 
pH 8.0, 300 mM NaCl, 250 mM imidazole). The eluate was concentrated using Amicon 
Ultra centrifugal devices (Millipore) and immediately loaded onto the PD10 desalting 
column (GE Healthcare) pre-equilibrated with the storage buffer (50 mM PBS buffer, pH 
7.5, 200 mM NaCl, 20% glycerol). The proteins were flash-frozen in liquid N2 and stored 
at -80oC for further use. The purity of the protein was analyzed by SDS-PAGE and the 
protein concentrations were determined using the Bradford assay (Bio-Rad Protein assay, 
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Bio-Rad). 
The protein purification for X-ray structural studies was performed in a similar way. The 
cell pellet from 1 L of culture was resuspended in 35 mL of buffer A (20 mM Tris pH 7.9, 
500 mM NaCl, 10% glycerol, 20 mM imidazole). Cellytic Express (200-300 mg) was 
added prior to lysis by sonication (Sigma-Aldrich). Lysate was cleared by centrifugation 
at >38,000 x g for 45 minutes. Supernatant was filtered by 0.45 μm filter, loaded onto a 5 
ml HisTrap (GE Healthcare) Ni-NTA resin column, and washed with 10 column 
volumes of buffer A. Protein was eluted with ~200 mM imidazole by a linear gradient of 
buffer B (20 mM Tris pH 7.9, 500 mM NaCl, 10% glycerol, 750 mM imidazole). For 
His-tag removal, fractions were pooled, buffer exchanged with buffer A containing 1 mM 
DTT, and incubated at 4°C for 24-72 h with 2% (w/w) His-tagged TEV protease. The 
reaction mixture was reloaded onto the HisTrap column and flow-through fractions were 
pooled, concentrated, and loaded onto a HiLoad 16/60 Superdex 75 (GE Healthcare) 
column equilibrated with 20 mM Tris pH 7.9, 500 mM NaCl, and 10% glycerol. 
Fractions were then combined, concentrated to 20 mg/ml and either flash frozen in liquid 
N2 or stored at 4°C. 
FTMS analysis. Multiply protonated (R,S)-HMG-CurB ACP with or without ECH1 
and/or ECH2 treatment was generated by electrospray ionization (ESI) at 70 µL/h (Apollo 
ion source, Bruker Daltonics, Billerica, MA) of a solution containing 2.5 μM 
(R,S)-HMG-CurB (1:1 CH3CN:H2O with 0.05% HCOOH and 0.05% CF3COOH). To 
accurately determine the masses of HMG-CurB ACP and the species associated with the 
loss of H2O and (H2O + CO2) from (R,S)-HMG-CurB ACP a calibration standard 
(G2421A, Agilent Technologies, Palo Alto, CA) was mixed with the sample (30-fold 
dilution of the standard) for internal calibration. All mass spectra were collected with an 
actively shielded 7 Tesla quadrupole-Fourier transform ion cyclotron resonance (FT-ICR) 
mass spectrometer (APEX-Q, Bruker Daltonics). Ions produced by ESI were externally 
accumulated in a hexapole for 1 s, transferred via high voltage ion optics, and captured in 
an Infinity ICR cell (32) by gated trapping. This accumulation sequence was looped 32 
times. The ESI capillary voltage was set to -3.8 kV. Nitrogen drying gas (200-250°C) 
was employed to assist desolvation of ESI droplets. The collision cell gas pressure (Ar) 
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was kept at 4.5 × 10-6 mbar, which is slightly lower than the standard pressure used for 
this instrument (6-7 × 10-6 mbar). All data were acquired with XMASS software (version 
6.1, Bruker Daltonics) in broadband mode from m/z = 200 to 2000 with 512k data points 
and summed over 16 or 32 scans. Mass spectra were analyzed with the MIDAS analysis 
software (33) Internal frequency-to-mass calibration was performed by Microsoft Excel 
with a two-term calibration equation (34) using the masses of two peaks (m/z = 
622.02895 and 922.00979) resulting from the calibration standard. The theoretical and 
calculated masses are listed in table 3-S3. (Performed by Haichuan Liu) 
HPLC and mass spectrometry analysis. The ECH activity assays using HMG-CoA 
substrate were performed by incubating 500 μM HMG-CoA and 2 μM ECH1, ECH2 or 
both in 30 mM Bis-Tris-HCl buffer, pH 6.5 at 37oC for 5 h. Before the LC-MS analysis, 
the reaction mixtures were filtered using a 10 kDa cutoff membrane (0.5 ml, Amicon 
Microcon, Millipore) to remove the enzymes. The filtered mixtures were analyzed by 
HPLC using a reverse-phase column chromatography (XBridge C18, 3.5 μm, 2.1x150 
mm, Waters). The LC-MS was performed on the ThermoElectron Surveyor HPLC 
system equipped with the ThermoElectron Finnigan ESI-LTQ mass spectrometer. The 
isolation width for MS/MS-fragmentation was 1.5 and the normalized energy was set to 
28%. 
Crystallization. Crystals were grown in 24-72 h at 4°C by micro-seeding in hanging 
drops using the vapor diffusion method. Equal volumes were mixed of protein solution 
and mother liquor containing 1.3-1.8 M sodium malonate pH 7.0, 50 mM HEPES pH 6.8, 
and 0-25 mM 2-ethanamidoethyl 3-methylbut-2-enethioate. Crystals were harvested in 
loops and directly frozen by plunging into liquid N2. Both trigonal (P321) and 
rhombohedral (R32) crystals grew in the above crystallization condition from the same 
seed stock. (Performed by Todd Geders) 
Data collection and structure determination. Diffraction data were collected at 100 K 
on GM/CA-CAT beamlines 23ID-B and 23ID-D at the Advanced Photon Source (APS) 
in Argonne National Laboratory (Argonne, IL). Data were processed using the HKL2000 
suite (35). Initial phasing was performed using a three-wavelength MAD dataset from a 
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single trigonal wild-type SeMet-labeled protein crystal. SOLVE was used to find the four 
selenium sites and for MAD phasing (‹m› = 0.47, score = 25.07) (36). RESOLVE was 
used for density modification (overall FOM = 0.69) and partial automated model building 
(37, 38). In both crystal forms, one ECH2 subunit was present in the asymmetric unit. 
Modeling was completed manually using COOT (39). Refinement was performed using 
REFMAC5 of the CCP4 suite with TLS (40-43). The refined model was used as a probe 
structure for molecular replacement using PHASER with data from rhombohedral 
crystals (43, 44). (Performed by Todd Geders) 
Sequence and structure analysis. Sequence alignments were performed by T_COFFEE 
(40). Figures and structure alignments were generated with PyMOL (45). Surface area 
calculations were calculated using AREAIMOL (46). Identification of structural 
neighbors was performed by a DALI search (47). (Performed by Todd Geders) 
Structure alignment and substrate modeling. Cα atoms of the crotonase core domain 
of CurF ECH2 (residues 18-222) were aligned with the analogous core region of liganded 
crotonase family members carboxymethylproline synthase ((14), PDB code 2A81, 
RMSD=2.3Å for 167 Cα), methylmalonyl-CoA decarboxylase ((26), PDB code 1EF9, 
RMSD=1.7Å for 153 Cα), 1,4-dihydroxy-2-naphthoyl-CoA synthase ((48), PDB code 
1Q51, RMSD=1.6Å for 138 Cα), rat enoyl-CoA hydratase ((12), PDB code 1DUB, 
RMSD=1.8Å for 156 Cα), and 4-chlorobenzoyl-CoA dehalogenase (13), PDB code 
1NZY, RMSD=2.0Å for 163 Cα) (Figure 3-S5). Initial atomic coordinates and topology 
files for the substrate 3-methylglutaconyl moiety attached to 4-phosphopantetheinic acid 
were generated using the PRODRG2 server (49). Using the conformation of 
4-phosphopantethenic acid bound to rat ECH as a guide (PDB code 1DUB), the substrate 
thioester oxygen was fixed at the position of a water molecule in the oxyanion hole of 
wild-type CurF ECH2. Three water molecules overlapping the modeled substrate were 
removed. The model was refined by energy minimization using the program CNS (50) in 
500 steps of conjugate gradient minimization with no experimental energy terms, no 
crystallographic symmetry restraints, and fixed main chain positions after addition of 
polar hydrogens. (Performed by Todd Geders) 
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ECH1/ECH2 coupled enzymatic assay. The activities of the CurF ECH2 wild type and 
variants were measured in the ECH1-ECH2 coupled assay, as previously reported (10). In 
brief, 50 μM (R,S)-HMG-CurA-ACPII was incubated with 2 μM ECH1 and ECH2 (WT or 
variants) in 50 mM Tris-HCl (pH 7.5) at 37oC for 1 h. The reactions were terminated by 
10% formic acid immediately before loading the reaction mixture on the Jupiter C4 (5μ, 
300 A) reverse phase column (Phenomenex) and the proteins were eluted with CH3CN 
(0.05% HCOOH and 0.05% CF3COOH)/H2O (0.05% HCOOH and 0.05%CF3COOH). 
The chromatogram peaks were normalized by 32 Karat software (Beckman Coulter) and 
subjected to base-line subtraction before peak-area calculations. 
Preparation of 3-methylglutaconyl-CoA and ACP. In order to separate the dehydration 
and decarboxylation steps catalyzed by ECH1 and ECH2, 3-methylglutaconyl-CoA was 
prepared by enzymatic dehydration of (R,S)-HMG-CoA. (R,S)-HMG-CoA was incubated 
with ECH1 at 37oC for 5 h, and the dehydration product was isolated using XBridge Prep 
C18 column (Waters, 10 x 250 mm, 5 μm) under the similar HPLC conditions reported 
(10). The fractions were pooled and lyophilized. ~0.5 mg 3-methylglutaconyl-CoA was 
generated from 6 mg (R,S)-HMG-CoA. 3-methylglutaconyl-ACP was prepared with the 
Sfp protocol (10). 
ECH1 and ECH2 assays for ACP and CoA substrates. (R,S)-HMG-CoA/ACP and 
3-methylglutaconyl-CoA/ACP were employed to test the ECH1 and ECH2 activities. 2 
μM ECH1 or ECH2 was incubated with 50 μM ACP or CoA substrates in 50 mM 
Tris-HCl (pH 7.5) at 37oC for 1 h. The CoA samples were analyzed by XBridge Prep C18 
column (Waters, 4.6 x 250 mm, 5 μm) and eluted with MeOH/H2O (10 mM 
CH3COONH4), and ACP samples were analyzed by Jupiter C4 column and eluted with 
CH3CN (0.05% HCOOH and 0.05% CF3COOH)/H2O (0.05% HCOOH and 0.05% 
CF3COOH). 
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Figure 3-S1. Partial sequence alignments of ECH1 (A) and ECH2 (B) from different 
microorganisms. The two consensus sequences highlighted in red were reported to contribute to 
the formation of the oxyanion hole in the crotonase superfamily. The identical amino acids are 
highlighted in green. CurE, F: Lyngbya majuscula; JamI, J: Lyngbya majuscula; MupJ, K: 
Pseudomonas fluorescens; PksH, I: Bacillus subtilis; Bpse6_01000426, 01000427, Burkholderia 
pseudomallei; BpseP_02004602, 02004603: Burkholderia pseudomallei; BPSS1000, 1001: 
Burkholderia pseudomallei; BTH_II1668, 1669: Burkholderia thailandensis; Npun02005238, 









Figure 3-S2. Mass spectra (A) and UV spectra (B) of CoA compounds. 5, (HMG)-CoA (a), 6, 
(3-methylglutaconyl)-CoA (b) and 7, (3-methylcrotonyl)-CoA (c). The mass spectra and UV 
spectra were recorded at the retention times of the corresponding HPLC peaks after the 
background subtraction. 
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Figure 3-S3. ECH1 substrate specificity and ECH2 regiochemical control. A) HPLC 
chromatograms at 260 nm for ECH1 and ECH1 assays and co-injection with the standards. (a) 
Authentic standards: 7 (3-methylcrotonyl)-CoA and 3-methyl-3-butenoyl-CoA; (b). ECH1/ECH2  
coupled assay using (R,S)-HMG-CoA; (c) the co-injection of (b) and 7-CoA. B) HPLC 
chromatograms at 275 nm for ECH1 assays using (R,S)-HMG-CoA and (S)-HMG-CoA. Reaction 






Figure 3-S4. Analytical size-exclusion chromatography of the CurF ECH2. Change in 
apparent molecular weight is seen at loading concentrations below 5 mg/mL. Normalized A280
 absorbance trace is shown for a 100 μL injection onto a 24 mL Superdex 200 10/300 GL column 
at the indicated protein concentration: black (10 mg/mL), blue (5 mg/mL), magenta (1 mg/mL), 
and red (0.25 mg/mL). Elution volumes for molecular weight standards are shown at the top. 
Similar elution patterns are seen with trimeric rat mitochondrial Δ3-Δ2-enoyl-CoA isomerase (1,2) 
and 4-hydroxycinnamoyl-CoA hydratase/lyase from Pseudomonas (3,4).  
1. Palosaari, P. M., Kilponen, J. M., Sormunen, R. T., Hassinen, I. E., and Hiltunen, J. K. (1990) 
J. Biol. Chem. 265(6), 3347-3353  
2. Hubbard, P. A., Yu, W., Schulz, H., and Kim, J. J. (2005) Prot. Sci. 14(6), 1545-1555  
3. Mitra, A., Kitamura, Y., Gasson, M. J., Narbad, A., Parr, A. J., Payne, J., Rhodes, M. J., Sewter, 
C., and Walton, N. J. (1999) Arch Biochem. Biophys. 365(1), 10-16  
4. Leonard, P. M., Brzozowski, A. M., Lebedev, A., Marshall, C. M., Smith, D. J., Verma, C. S., 





Figure 3-S5. Superposition of CurF ECH2 with other crotonase family members. A, Stereo 
diagram of the superposition of wild-type CurF ECH2 (green) with MMCD (magenta), CarB (yellow), MenB (pink), rat ECH (grey), 4-chlorobenzoyl CoA dehalogenase (blue). The 
4-phosphopantetheine arms observed in the structures are shown in stick representation. The view 
is from the same orientation as Figure 3-4, with helix α3 present in front. B, Wild-type CurF 
ECH2 is shown in cartoon representation (green). The water molecule in the oxyanion hole is shown as a red sphere with yellow dashed lines to backbone amides. The phosphopantetheine arm 
portion of the ligand from each structure in the superposition is shown with carbon coloring 
corresponding to the structure shown in A.  
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Table 3-S1. Data Collection. 
 
  Crystal Form I  Crystal Form II 
Parameter  SeMet wt Peak Inflection Remote  SeMet wt Y82F 
Space Group  P321 P321 P321 P321  R32  R32 














X-ray source  23ID-B 23ID-B 23ID-B 23ID-B  23ID-D 23ID-D 
Wavelength λ (Å)  1.0332 0.97942 0.97956 0.95373  1.0332 1.0332 
dmin (Å)  2.0 2.30 2.40 2.30  1.85 1.65 
Unique 
observations 
 20,390 13,394 11,842 13,379  22,402 31,221 
Rmerge(%)a,b  6.3 (68) 10.1 (66) 10.2 (71) 8.8 (67)  7.2 (57) 6.1 (61) 





100 (100) 100 (100) 100 (100)  100 (100) 99.9 
(100) 
Avg. redundancya  11.0 
(10.4) 
5.9 (5.8) 5.9 (5.8) 5.9 (5.6)  11.0 
(10.3) 
10.9 (9.6)
aValues in parenthesis are for outer shell 
bRmerge=∑|Ii-‹I›|/∑Ii, where Ii is the intensity of the ith observation and ‹I› is the mean intensity 
 
 
Table 3-S2. Refinement Statistics 
 
Refinement statistics  Form I Form II 
  SeMet wt SeMet wt Y82F 
Space Group  P321 R32 R32 
Data range  50-2.0 50-1.85 50-1.65 
R/Rfreea  0.202/0.250 0.169/0.206 0.167/0.204 
RMSD bond length (Å)  0.011 0.012 0.012 
RMSD bond angle (Å)  1.245 1.249 1.316 
Average Protein B-factor 
(Å2) 
 29.6 22.8 21.5 
Average Solvent B-factor 
(Å2) 
 44.6 41.0 40.0 
Wilson B (Å2)  33.2 25.6 23.6 
Ramachandran plotc     
    Favored  98.8% 99.2% 98.3% 
    Allowed  1.2% 0.8% 1.7% 
    Disallowed  0.0% 0.0% 0.0% 
Protein atoms  1899 1895 1894 
Water molecules  145 184 307 
PDB code  2Q2X 2Q34 2Q35 
aR = ∑|FO-|FC||/∑|FO| where FO is the observed structure factor and FC is the calculated structure 
factor used in the refinement 
bRfree = ∑|FO-|FC||/∑|FO| where FO is the observed structure factor and FC is the calculated structure 
factor from 5% of reflections not used in the refinement 





Table 3-S3. Mass calibration results for A) HMG-ACP (CurB), B) HMG-ACPII and their 
associated peaks corresponding to the loss of H2O and (H2O + CO2). The masses of the most 
abundant isotopes of the 8+-15+ charge states were used for mass calculation. 
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HALOGENATION, CYCLOPROPANATION AND 
POLYKETIDE DIVERSIFICATION 
4.1  SUMMARY 
The chemical diversity of natural products is fueled by the emergence and ongoing 
evolution of biosynthetic pathways in secondary metabolism (1-5). However, the 
co-evolution of enzymes as functional assemblies for metabolic diversification is not well 
understood, especially at the biochemical level. Here, two parallel enzyme assemblies 
with an extraordinarily high sequence identity, including a halogenase domain (Hal), a 
3-hydroxy-3-methylglutaryl (HMG) enzyme cassette and an enoyl reductase domain (ER) 
in the curacin A (Cur) and jamaicamide (Jam) pathways catalyze the formation of 
β-branched cyclopropane and vinyl chloride moieties respectively, in their final products. 
Bioinformatic analysis indicated that their corresponding genes were inserted into 
modular polyketide synthases (PKSs) via acyltransferase (AT) domain replacement. The 
Hal from CurA, and dehydratases (ECH1s), decarboxylases (ECH2s) and ERs from both 
Cur and Jam were biochemically assessed to determine the mechanism of cyclopropane 
and vinyl chloride group formation. In the Cur pathway, ECH1, ECH2 and ER were 
presumed to catalyze successive dehydration, decarboxylation, and α,β C=C (enoyl 
thioester) saturation from an (S)-HMG substrate tethered to a tandem acyl carrier protein 
tridomain (ACP3), to generate isovaleryl-ACP3. Unexpectedly, this polyketide 
β-branching scheme was modified by introduction of a γ-chlorination step on (S)-HMG 
group mediated by Cur Hal, a non-haem FeII, α-ketoglutarate (α-KG)-dependent 
halogenase (6). CurF ER was found to specifically catalyze an unprecedented 
cyclopropanation reaction of the chlorinated substrate. In contrast, regiochemical control 
by Jam ECH2 selectively generates the β,γ C=C (enoyl thioester) of the 
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3-methylglutaconyl-ACP3 decarboxylation product, thus forming a vinyl chloride, and 
rendering the Jam ER redundant. Moreover, site-directed mutagenesis experiments 
demonstrated that Tyr82 of Cur ECH2 is crucial for regiochemical control. Thus, the 
combination of chlorination and polyketide β-branching, coupled with mechanistic 
diversification of ECH2 and ER leads to formation of the cyclopropane and vinyl chloride 
functional groups. These results show how the unique interplay of modular PKS domain 
integration and β-branching enzyme evolution generates functional group diversity in 
secondary metabolites. 
4.2  INTRODUCTION 
The tremendous biosynthetic capability of nature is well exemplified by structurally 
diverse secondary metabolites that help their hosts, typically microorganisms and plants, 
to survive and thrive in particular environmental niches by mediating a broad range of 
ecological and physiological interactions (1-5). The biosynthesis of secondary 
metabolites is “diversity-oriented” (1, 5, 7), targeting the variable environment by 
producing a vast array of complex chemical structures (8). This enormous productivity is 
largely fueled by the rapid evolution of biosynthetic genes and functional alteration of the 
corresponding enzymes (3, 4). As such, the evolutionary history of metabolic gene 
assemblies informs the origin of their biosynthetic diversity. However, tracing the 
ancestral forms of multiple genes as a functional collective is elusive, especially when 
they are dispersed in the genome. Biosynthetic genes from microbial hosts are usually 
clustered in their genomes, and as such are ideal for evolutionary and functional studies 
(4). To date, our understanding of the evolution of biosynthetic systems is largely limited 
to the genetic level. Recently, an expansion of sequencing information is providing rapid 
access to natural product biosynthetic enzymes, which is enabling efforts to trace the 
origin of metabolic diversity and to exploit biochemical diversity. 
Modular PKSs originated from fatty acid synthases (FASs) and serve as a paradigm 
for secondary metabolic systems that are successful in natural selection to expand 
chemical diversity. These giant biosynthetic machines are modularized assembly-lines 
catalyzing highly programmed metabolic pathways. The chain extension modules 
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minimally comprise three essential domains—ketosynthase (KS), AT, ACP—plus 
auxiliary processing domains (e.g., ketoreductase (KR), dehydratase (DH), and ER) for 
β-keto group modification. Chemical diversity of the final products tends to be generated 
by introduction of variation in chain initiation, extension and termination steps (9-11). 
Similar to other enzymes in secondary metabolism, PKS catalytic domains show 
significant substrate tolerance to expand pathway chemical diversity (9). Moreover, PKS 
systems are prone to form hybrids with other biosynthetic elements, such as 
nonribosomal-peptide synthetase (NRPS) modules, and recently reported HMG enzyme 
cassettes (12, 13). The metamorphic properties shown in these composite systems drive 
metabolic diversification, but, remain poorly understood.  
The curacin and jamaicamide marine cyanobacterial metabolites from Lyngbya 
majuscula are mixed-polyketide nonribosomal-peptide natural products with potent 
anticancer and sodium channel blocking activities, respectively (14, 15). The parallel 
components of the Cur and Jam biosynthetic pathways (Figure 4-1a) provide an unusual 
opportunity to investigate the biosynthetic origin of chemical diversity, in the form of 
cyclopropane ring formation for curacin and vinyl chloride formation for jamaicamide 
(14, 16). Studies on the function and selectivity of these highly parallel biosynthetic 
systems form the subject of this report. 
4.3  RESULTS 
4.3.1  Two Highly Similar Enzyme Assemblies 
The two parallel, highly conserved Cur and Jam pathway enzyme assemblies are 
incorporated into the early PKS modules, and are predicted to catalyze β-branching type 
modification of the growing chain elongation intermediate (14, 16). These unusual 
embedded domains and discrete enzymes span from CurA to CurF and from JamE to 
JamJ, and are grouped into three subsets (Figure 4-1a): (1) Hals embedded in CurA and 
JamE; (2) HMG enzyme cassettes containing ACP3 tridomains (tandem ACPI, ACPII and 
ACPIII) embedded in CurA and JamE, discrete CurB and JamF ACPIVs, CurC and JamG 
KSs, CurD and JamH HMG-CoA synthase-like enzymes (HCSs), CurE and JamI ECH1s, 
ECH2s embedded in CurF and JamJ; and (3) ERs embedded in CurF and JamJ 
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immediately adjacent to ECH2s (Figure 4-1a). Comparative analysis of these Cur and Jam 
 
 
Figure 4-1. Comparison of enzyme assemblies in the Cur and Jam pathways. a, 
Formation of cyclopropane and vinyl chloride functional groups. b, Comparative sequence 
identities of the HMG-type enzyme assemblies. The aligned DNA sequences are located at the 
boundaries of these two highly related regions. c, Formation of 3-ACP3 in the Cur pathway, 
and hypothesized reactions for 4-ACP3, 5-ACP3 and 6-ACP3. The β-branching carbon atoms 
are highlighted in red. 
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enzymes revealed that the sequence identities of the Hals, ACP3s, ACPIVs, KSs, HCSs 
and ECH1s are extraordinarily high (~90%), whereas the ECH2s and ERs show 
significantly lower sequence identity (~60%) (Figure 4-1b). 
Cur and Jam Hals show low homology (less than 20% sequence identity) to the 
α-KG-dependent non-haem enzyme superfamily, the members of which usually catalyze 
oxidation reactions (17). Some recently characterized halogenases belong to this 
superfamily (18-20) and are able to catalyze halogenation of unactivated carbon atoms 
(19-23) through a non-haem FeIV=O intermediate (24, 25). The presence of a β-branched 
vinyl chloride in the jamaicamide structure suggested that Jam Hal was responsible for 
the key halogenation step. By analogy, it suggested that transient halogenation might be 
crucial for curacin cyclopropane ring formation (6, 19). 
HMG enzyme cassettes have been demonstrated to catalyze polyketide β-branching 
to generate a pendant methyl or ethyl group from a polyketide β-carbonyl (12, 13, 26). As 
shown for curacin A (Figure 4-1c), the AT loads a malonyl group from malonyl-CoA to 
CurB ACPIV, and the KS catalyzes subsequent decarboxylation of malonyl-ACPIV to 
acetyl-ACPIV. HCS then catalyzes condensation of C-2 from acetyl-ACPIV and 
acetoacetyl-ACP3, to form (S)-HMG-ACP3 (1-ACP3). As we have shown previously, 
ECH1 catalyzes dehydration of 1-ACP3 to 3-methylglutaconyl-ACP3 (2-ACP3), followed 
by ECH2 mediated decarboxylation to generate 3-methylcrotonyl-ACP3 (3-ACP3) (12). 
Notably, chain elongation intermediates on ACP3 are presumed to undergo multiple 
modification steps before transfer as substrates to downstream enzymes. Presumably, the 
tridomain ACP3 facilitates metabolic efficiency, as suggested in other FAS and PKS 
systems bearing tandem ACPs (27, 28). 
Sequence analysis of Cur and Jam ERs (Figure 4-1b) suggested that each functions 
with the adjacent HMG enzyme cassette based on a presumed ability to catalyze 
reductive conversion of α,β C=C (enoyl thioester) in 3-ACP3 to isovaleryl-ACP3 
(4-ACP3). They show ~50% sequence identity to the other PKS ERs in Cur and Jam 
pathways, and belong to the acyl-CoA reductase family that catalyzes 
NADPH-dependent reduction of α,β C=C (enoyl thioester) in acyl-CoAs or acyl-ACPs 
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(29). These two ERs are located upstream of CurF and JamJ KS, an unusual location as 
ERs typically reside between AT and ACP domains in PKS modules. A similar location 
was reported for TaO ER in the myxovirescin A biosynthetic pathway, also predicted to 
catalyze reduction of the α,β C=C (enoyl thioester) of the corresponding ECH2 
decarboxylation product (30). Thus, the Cur and Jam HMG cassette enzymes including 
ACP3, ACPIV, KS, HCS, ECH1, ECH2 and ER comprise an integrated functional 
assembly for polyketide chain β-branching. Some HMG-type cassettes in other pathways 
lack one or more enzymes, and are occasionally found to have a dispersed architecture 
(31-33). 
Our previous work on Cur ECH1 and ECH2 revealed enzymatic formation of 
3-ACP3 (12, 34), a presumed precursor for (1R, 
2S)-2-methylcyclopropane-1-carboxyl-ACP3 (5-ACP3) (Figure 4-1c), but the precise 
steps leading to cyclopropane ring formation remained to be established. This initial 
study raised a number of additional questions: (1) What is the timing and regiochemistry 
of the presumed Hal reaction, and what is the specific substrate?  (2) Is Cur ER involved 
in reduction of 3-ACP3?  (3) How is the pendant vinyl chloride formed in the Jam 
pathway, and what is the key control point for the introduction of this functional group?  
As previously proposed, could 3-methyl-3-butenoyl-ACP3 (6-ACP3) be generated from 
3-ACP3 isomerization (6) or by differential regiochemical control of double bond 
formation during ECH2 decarboxylation (34)? 
4.3.2  AT Replacement-Mediated PKS Hybridization 
Bioinformatic analyses of cur and jam cluster sequences suggested that the DNA 
fragment that encompasses the parallel Cur and Jam 
AT-Hal-ACPI-ACPII-ACPIII-ACPIV-KS-HCS-ECH1-ECH2-ER-KS-AT gene assembly 
might have been introduced into the polyketide pathway by AT domain replacement 
(Figure 4-1b). Based on the DNA and amino acid alignments of CurA—CurF and 
JamE—JamJ regions, we found that the highly similar regions, with clear demarcation in 
their DNA and protein sequences, extend from the N-termini of the ATs in CurA and 
JamE, through the C-terminal “post-AT linkers” (35) of the ATs in CurF and JamJ 
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(Figure 4-1b). Moreover, the two sites that delimit these regions are conserved for the 
ATs from the sequenced cur and jam gene clusters isolated from unique strains of L. 
majuscula (Figure 4-S1). Recent bioinformatic studies indicate that these highly similar 
sequences could promote AT domain replacement by homologous recombination (36, 37). 
Thus, this gene assembly could have been introduced by a “di-AT replacement”, which 
could represent a prevalent strategy for pathway expansion or contraction in modular 
PKS systems. 
To further probe our hypothesis, we constructed phylogenetic trees for KSs, ATs 
and DHs of the sequenced pathways from L. majuscula. The CurF and JamJ KSs within 
the proposed di-AT replacement are most closely related, but in contrast the CurA and 
JamE KSs outside this region are distant (Figure 4-S2). CurA and JamE ATs as well as 
CurF and JamJ ATs reveal extraordinarily high similarity (86% and 79% sequence 
identities, respectively). As expected, the CurF and JamJ DHs, which are outside the 
di-AT replacement region, show a relatively distant relationship, with the JamJ DH being 
most similar to DHs from the putative carmabin pathway (~70% sequence identity). 
Overall, this phylogenetic analysis is consistent with the di-AT replacement hypothesis. 
4.3.3  HMG β-Branching with ER Saturation 
To assess CurF ER function as a putative reductase, the embedded domain was 
excised and cloned as an N-terminal GST-tagged fusion protein. We also overexpressed 
and purified the CurA ACP3 tridomain and each excised single domain (ACPI, ACPII and 
ACPIII) as apo proteins (Figure 4-S3). 1-ACPs were generated as previously described12, 
and substrate loading was examined by HPLC (Figure 4-S4). The ACPI, ACPII and 
ACPIII have nearly identical amino acid sequences, and each was efficiently loaded with 
the HMG substrate. Thus, for convenience we chose excised CurA ACPII, as well as 
ACP3, for subsequent enzyme assays. 
Fourier transform ion cyclotron resonance mass spectrometry (FTICR-MS) and 
infrared multiphoton dissociation (IRMPD) methods were applied to detect mass changes 
to the HMG substrate covalently linked to the ACP phosphopantetheine (PPant) arm (38). 
Cur ER function was assessed by coupling it with the Cur ECH1 and ECH2 reactions. As 
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reported, Cur ECH1 catalyzed the reversible dehydration of 1-ACPII to generate 2-ACPII, 
and Cur ECH2 catalyzed decarboxylation of 2-ACPII to generate 3-ACPII, corresponding 
 
Figure 4-2. Halogenation and cyclopropanation in the Cur pathway. a, Partial 
FTICR mass spectra (12+ change state of ACPII) for Cur Hal, ECH1, ECH2 and ER 
reactions. 1-ACPII was incubated with Hal for 2 h to generate the γ-Cl-1-ACPII 
substrate. Reactions were incubated at 30oC for 2 h for the 1-ACPII substrate and 30 
min for the γ-Cl-1-ACPII substrate. Asterisks denote unidentified species. b, IRMPD 
spectra for the PPant ejection products (PEPs) of 3-ACPII and 4-ACPII. c, IRMPD 
spectrum for the PEP of γ-Cl-1-ACPII and its theoretical isotopic distribution. d, 
IRMPD spectra for the PEPs of  γ-Cl-3-ACPII and 5-ACPII. e, GC-MS analysis of the 
enzyme products after butylamine cleavage, and comparison with authentic standards. 
For optimal sensitivity, the chromatograms were recorded at selective ion mode (SIM) 
by monitoring 55, 57, 83, 115, 155 and 157 atomic mass unit (amu). Retention times 
of the products were confirmed by co-injection with authentic standards. 
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to 18- and 62-Dalton mass losses from 1-ACPII, respectively (Figure 4-2a). Cur ECH1 
shows substrate preference for (S)-HMG-ACPII over (R)-HMG-ACPII (Figure 4-S5), 
which is consistent with our previous results using the CoA-linked substrates (12). With 
Cur ER and NADPH, a 2-Dalton mass addition was observed for 3-ACPII (Figure 4-2a 
and 2b), corresponding to saturation of the α,β enoyl thioester to generate 4-ACPII. No 
saturation product was detected by using Cur ER and NADH as cofactor. 
To confirm the structure of the Cur ER reaction product tethered to ACP3, we 
cleaved it from the PPant arm with butylamine to generate the corresponding butylamide 
derivative. Gas chromatography (GC)-MS analysis was performed and the readily 
separable isomers were compared and correlated with authentic standards (39). We used 
1-ACPII and 1-ACP3 as substrates for Cur ECH1, ECH2 and ER reactions. According to 
the retention time and mass spectrum of the product, its structure was confirmed as 4 
(Figure 4-2e). These experiments demonstrated that a reductive step catalyzed by Cur ER 
is included in the polyketide β-branching series of reactions and that ER is a component 
of the HMG enzyme cassette. Based on this analysis, 4-ACPII had been assumed to be a 
direct precursor of 5-ACPII, which was disconfirmed by the results shown below. 
4.3.4  Halogenation and Cyclopropane Ring Formation 
In assessing the role of Cur Hal in cyclopropane ring formation we considered the 
more evident role for the Hal in the analogous Jam pathway. In this system, chlorination 
evidently occurs on the pendant carbon generated by β-branching. Thus for Cur Hal, we 
reasoned that cyclopropane ring formation likely involves transient halogenation as in 
coronatine biosynthesis, where the chloride serves as a leaving group for intramolecular 
nucleophilic substitution (19). However, timing of the chlorination event remained to be 
established, and the identity of the Cur pathway ring-forming enzyme was not evident 
from bioinformatic analysis. 
An important clue about the timing of chlorination at the β-branching carbon came 
from previous precursor-incorporation studies in curacin A biosynthesis. NMR data on 
curacin A labeling by [2H3,2-13C]acetate indicated that the β-branching carbon that forms 
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cyclopropane was labeled by only one deuterium atom (α-isotope chemical shift at C20, 
0.295) (16), which was previously interpreted as an anomalous result. Reconsideration of 
these data revealed that chlorination should occur before ECH2 catalyzed decarboxylation. 
Otherwise, the pendant carbon atom would be labeled by either one or two deuterium 
atoms by 2:1 ratio (Figure 4-S6). 
To identify the function of Cur Hal, we constructed the single-domain Hal and the 
tetradomain Hal-ACP3 as N-terminal His-tagged proteins (Figure 4-S3). Cur Hal eluted 
as a dimer from an analytical size-exclusion column. Following His-tag removal by 
thrombin cleavage, the metal content of Hal was analyzed by inductively coupled plasma 
(ICP)-MS. After reconstitution with a mixture of metal ions and α-KG, more than 90% of 
Hal was bound exclusively to Fe2+, which indicated that it functions as an FeII-dependent 
enzyme. Thus, anaerobic purification coupled with α-KG/FeII-reconstitution was 
employed, as was previously reported to retain optimal activities of α-KG-, O2- and 
FeII-dependent halogenases (19-21). 
We tested seven acyl-ACP substrates to establish the substrate identity for Cur Hal, 
including malonyl-ACPIV, acetyl-ACPIV, 1-ACPII, 2-ACPII, 3-ACPII, 4-ACPII and 
6-ACPII. Consistent with the [2H3,2-13C]acetate precursor incorporation experiment noted 
above, we observed the formation of the mono-chlorinated species exclusively on 
1-ACPII to generate γ-Cl-1-ACPII. The chlorinated product was confirmed by FTICR-MS 
and IRMPD (Figure 4-2a and 2c) analysis, and corroborated by GC-MS (Figure 4-3c, see 
below). Moreover, Cur Hal showed evident chirality preference toward the 
(S)-HMG-ACPII (1-ACPII) substrate, as expected based on previous studies of Cur ECH1 
substrate selectivity (Figure 4-S5). In the absence of α-KG or O2, no chlorinated product 
was detected with Cur Hal in the presence of HMG substrate (Figure 4-S5). 
Next, we sought to investigate how chlorination of 1-ACPII affects efficiency of the 
downstream reaction sequence with the HMG cassette enzymes. 1-ACPII was converted 
to γ-Cl-1-ACPII by Hal and reacted sequentially with Cur ECH1, ECH2 and ER. ECH1 
dehydrated γ-Cl-1-ACPII and the γ-Cl-2-ACPII product was decarboxylated by ECH2 to 
generate γ-Cl-3-ACPII (Figure 4-2a). Unexpectedly, no saturation product was observed 
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for Cur ER. Instead, we saw a 34-Dalton mass reduction from γ-Cl-3-ACPII (Figure 4-2a 
and 2d), demonstrating the elimination of chlorine in the product. This result suggests 
that the product could be 3-ACPII, 5-ACPII or 6-ACPII. These experiments also revealed 
that the ECH1/ECH2-coupled dehydration and decarboxylation rate was significantly 
increased with the chlorinated substrate (Figure 4-S7), which might be due either to the 
electron-withdrawing effect of the γ-chlorine atom which stabilizes the negative charge 
on the intermediate of ECH2 decarboxylation or to a more effective binding position of 
the chlorinated versus non-chlorinated substrate in the ECH2 active site. 
The experimental design to determine the final product in the presence of both Hal 
and HMG-cassette enzymes was streamlined by developing a one-pot reaction using Cur 
Hal-ACP3, ECH1, ECH2 and ER. Cur (apo) Hal-ACP3 was loaded with 1-CoA, desalted, 
and mixed with Cur ECH1, ECH2 and ER in an anaerobic environment. The reaction was 
initiated by exposing the mixture to air. To confirm the structure of the final product, we 
cleaved the acyl group from the Hal-ACP3 PPant arms with butylamine and compared the 
derivatives with the authentic standards by GC-MS. Direct correlation was made to a 
single species identified as the cis-2-methylcyclopropane-1-carboxyl compound (Figure 
4-2e), demonstrating the formation of 5-ACP by an unprecedented ER-catalyzed 
cyclopropanation reaction. 
4.3.5  Regiochemical Control by ECH2s 
Ascertaining the role of chlorination in the cyclopropane ring formation during 
curacin biosynthesis strongly suggested that a similar chlorination event occurs in the 
Jam pathway. Given the extraordinarily high similarity between Cur and Jam Hals (92% 
sequence identity), we surmised that the two pathways diverge after chlorination, 
resulting in differential catalytic processes in the terminal step to preserve a vinyl 
chloride moiety in jamaicamide. Compared to Cur and Jam Hals and ECH1s, Cur and Jam 
ECH2s and ERs have lower sequence identities (59% for ECH2s and 65% for ERs), and 
likely function as key branch-point determinants. Accordingly, excised forms of Jam 
ECH2 and ER were constructed, expressed and purified in the same way as the Cur 
enzymes (Figure 4-S3). We also expressed and purified Jam ECH1 to generate substrate 
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for Jam ECH2/ER reactions. We investigated the functions of Jam enzymes with Cur 
substrates starting from 1-ACP or γ-Cl-1-ACPII to establish the key branch-point that 
controls the introduction of the β,γ vinyl chloride group. 
For both 1-ACPII and γ-Cl-1-ACPII substrates, Jam ECH1 and ECH2 catalyzed 
successive dehydration and decarboxylation steps as expected (Figure 4-3a, and Figure 
 
Figure 4-3. Comparison of ECH2s and ERs in Cur and Jam pathways. a, Partial 
FTICR mass spectra for Cur and Jam ECH1, ECH2 and ER reactions with 
γ-Cl-1-ACPII substrate. The reactions were incubated at 30oC for 30 min. b, IRMPD 
spectra for the PEPs of γ-Cl-6-ACPII and γ-Cl-4-ACPII. c, GC-MS analysis to identify 
the structures of Cur and Jam ECH2 products. The chromatograms were recorded at 
selective ion mode (SIM) by monitoring 57, 117, 154 and 189 amu. The retention 
times of products were confirmed by co-injection with authentic standards. d, 
Comparison of catalytic efficiencies for cyclopropanation and saturation by Cur and 
Jam ERs. The product yields were measured by IRMPD-based quantification. 3-ACPII 
was used as substrate for Cur ER saturation, and γ-Cl-3-ACPII was used as substrate 
for Cur ER cyclopropanation and Jam ER saturation. Assays were performed in 
triplicate. 
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4-S8a). However, when Jam ER was added, only ~20% of the saturated product was 
detected for the non-chlorinated substrate (derived from 1-ACPII, Figure 4-S8b). 
Remarkably, no mass change was observed for the corresponding chlorinated substrate 
(derived from γ-Cl-1-ACPII), suggesting that the Jam ECH2 product is not a substrate for 
Jam ER. Based on FTICR-MS and IRMPD results (Figure 4-3a, 3b, and Figure 4-S8), the 
product of Jam ECH2 was consistent with either γ-Cl-6-ACPII (β,γ C=C; enoyl thioester) 
with a vinyl chloride group, γ-Cl-3-ACPII (α,β C=C; enoyl thioester) or a mixture of both.  
To probe the key branching points in these related systems further, we selectively 
exchanged the Cur and Jam ECH1/ECH2/ER enzymes in coupled reactions with the 
γ-Cl-1-ACPII substrate. When Cur and Jam ECH1s were switched in the coupled reaction, 
no change in the product profile was observed. However, when Jam ECH1 and ECH2 
were coupled to Cur ER, only the Jam ECH2 decarboxylation product was detected, in 
accord with the Jam ECH1/ECH2/ER reaction (Figure 4-3a). UV spectral comparison of 
Cur and Jam ECH2 decarboxylation products revealed that their UV absorption patterns 
are slightly different between 250 and 280 nm (Figure 4-S9), which reflects isomeric α,β 
or β,γ C=C (enoyl thioester) functionality in the products (γ-Cl-3-ACPII and 
γ-Cl-6-ACPII). 
To determine the structures of the decarboxylation products, one-pot reactions using 
Cur Hal-ACP3, ECH1 and Cur or Jam ECH2s were performed as described above. After 
butylamine cleavage of the products from the ACP3, each butylamide derivative was 
analyzed by GC-MS and compared with the authentic standards. For the reaction 
including Cur ECH2, the main product contained primarily an α,β C=C in the E 
configuration, with trace amounts of the β,γ C=C products (Figure 4-3c) quantified to be 
~3% (Figure 4-4b, see below). In contrast, reactions using Jam ECH2 showed a high 
regiochemical control to generate exclusively the β,γ C=C product, with ~85% in the E 
configuration and ~15% in the Z configuration (Figure 4-3c). The exclusive E 
configuration of the vinyl chloride C=C in jamaicamide natural products (14) suggests 
that the minor Z configuration product is likely due to utilization of the curacin substrate, 
which is less sterically hindered than the jamaicamide substrate. Notably, Jam ECH2 
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decarboxylation had lower regiochemical control using the non-chlorinated substrate, and 
generated ~80% β,γ C=C and ~20% α,β C=C products, which further explains the partial 
enoyl reduced product observed following Jam ECH1, ECH2 and ER reactions with this 
substrate (Figure 4-S8b). Given the normal function of ER to catalyze only α,β C=C 
(enoyl thioester) saturation, the selective formation of β,γ C=C product by Jam ECH2 
renders Jam ER redundant in the biosynthesis of jamaicamides. In general, α,β C=C 
ECH2 products are energetically preferred and frequently identified or predicted in other 
pathways (13, 26, 30, 40-42), except the pathways of pederin and its structural analogs 
(33, 43) that are predicted to generate β,γ C=C products (Figure 4-S10). 
4.3.6  Functional Differentiation of ERs 
Although Jam ER cannot function with the β,γ C=C thioester substrate, we sought to 
test whether it can catalyze cyclopropanation when presented with γ-Cl-3-ACPII bearing 
an α,β C=C. Thus, Cur ECH1 and ECH2 were coupled to Jam ER, but only the saturated 
product, γ-Cl-4-ACPII, was observed (Figure 4-3a, 3b). Thus Jam ER has the activity of a 
canonical PKS ER, α,β C=C saturation. 
The distinct functions of Cur and Jam ERs, despite the redundant nature of Jam ER 
within the Jam pathway, motivated us to compare the catalytic efficiencies of Cur ER 
cyclopropanation vs. Jam ER saturation of the chlorinated substrate, and the efficiencies 
of cyclopropanation of the chlorinated substrate vs. saturation of the non-chlorinated 
substrate by Cur ER. This was accomplished using time-course studies of catalytic 
efficiencies by measuring product yields under uniform reaction conditions. It was not 
possible to measure enzyme kinetic parameters (kcat and KM) due to the tendency of ER to 
aggregate and the solubility limits of ACP-tethered substrates. Thus, γ-Cl-3-ACPII was 
employed to assess cyclopropanation by Cur ER, compared to reduction by Jam ER, and 
3-ACPII was used to compare reductive efficiency of the Cur and Jam ERs. 
IRMPD-based MS analysis (e.g. peak abundance of PPant ejection products (PEPs) (38)) 
provided a convenient method to quantify the yields of ER saturation products that 
correspond to a 2-Dalton mass change (Figure 4-S11). Similarly, Cur ER-catalyzed 
cyclopropanation was quantified by using 4-ACPII, prepared by loading (apo) ACPII with 
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4-CoA, as an internal standard for 5-ACPII.  
We found that Jam ER saturation and Cur ER cyclopropanation of γ-Cl-3-ACPII are 
faster by ~400-fold and ~50-fold, respectively, than is Cur ER saturation of 3-ACPII 
under identical experimental conditions (Figure 4-3d). For the 3-ACPII substrate, Jam ER 
saturation is ~240-fold faster than is Cur ER saturation (Figure 4-S12). This comparison 
confirmed that Jam ER has retained a canonical α,β enoyl reduction function, in contrast 
to the unprecedented activity of Cur ER cyclopropanation. 
4.3.7  Loss of Regiochemical Control by Mutation 
To understand the regiochemical control of ECH2-catalyzed decarboxylation, the crystal 
structure of Cur ECH2 was solved recently (34). Only three polar residues, Lys86, His240, 
and Tyr82, are present in the nonpolar active site chamber, which is nevertheless water 
accessible (Figure 4-4a). As suggested by modeling with the non-chlorinated substrate 
and further supported by site-directed mutagenesis experiments, Lys86 and His240 are 
critical to catalysis (34). His240 is conserved for all known ECH2s in HMG enzyme 
cassettes, but Lys86 and Tyr82 are located in a hypervariable region (α2–loop–α3, 
residues 82-98) and are not conserved in Jam ECH2 (34). As a follow-up analysis, Cur 
ECH2 was modeled with the chlorinated substrate (Figure 4-4a), and the catalytic 
efficiencies of the wild type (WT) and mutants of Cur ECH2 were compared using the 
chlorinated substrate γ-Cl-2-ACPII. Moreover, we measured the ratios of the two possible 
decarboxylation products, γ-Cl-3-ACP and γ-Cl-6-ACP. 
Similar to our previous assays (34), ECH1/ECH2-coupled dehydration and 
decarboxylation of γ-Cl-1-ACPII was analyzed to compare the catalytic efficiencies of 
WT and mutant Cur ECH2s. It was immediately evident that their catalytic activities were 
significantly increased with the chlorinated substrate (Figure 4-4b) (34), possibly due to 
γ-Cl stabilization of the carbanion intermediate. As we observed previously for the 
non-chlorinated substrate under similar reaction conditions, the K86Q, K86A, H240Q 
and H240A variants had significantly decreased activities (Figure 4-4b). This suggests 
that His240 and/or Lys86 may draw the γ-carboxyl group away from the substrate in the 
transition state of ECH2 decarboxylation through hydrogen-bond formation (Figure 4-4a). 
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The alanine substitutions at Lys86 and His240 had higher activity than the corresponding 
 
 
Figure 4-4. Loss of Cur ECH2-mediated regiochemical control by site-directed 
mutagenesis. a, The hypervariable region (magenta) of Cur ECH2 and the active site 
chamber modeled with the chlorinated substrate. The S-configuration of the γ-carbon 
is preferred based on modeling results. b, Activity and regiochemical control of ECH2 
WT and Cur ECH2 mutants. γ-Cl-1-ACPII was used as the substrate for all reactions. 
(Left) HPLC analysis for ECH1/ECH2 coupled dehydration and decarboxylation. All 
reactions were quenched after 10 min incubation at 30oC. (Right) IRMPD-based 
quantification to measure the percent of β,γ C=C products. The coupled ECH1/ECH2 
reactions were incubated for 45 min before treated with Jam ER for 45 min at 30oC. 
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glutamine substitutions (Figure 4-4b, left panel), possibly due to the small side chain of 
alanine allowing space for water molecules to stabilize the γ-carboxyl group or to donate 
a proton to the presumed enolate intermediate. Cur ECH2 Y82F and Jam ECH2 WT had 
similar activities to Cur ECH2 WT, indicating that Tyr82 is not essential to the 
decarboxylation step. 
Next, we measured the ratio of α,β and β,γ C=C decarboxylation products to 
investigate whether the site-directed mutations can elucidate a basis for double bond 
regiochemical control by Cur ECH2. Changes in the ratio of α,β and β,γ C=C products 
were assessed by measuring UV absorbance ratios (A280nm/A250nm, Figure 4-S9) for HPLC 
peaks corresponding to ECH2 decarboxylation products (Figure 4-4b). Measured peak 
ratios for Cur ECH2 WT, K86Q, K86A, H240Q and H240A are ~1.75, for Jam ECH2 WT 
the ratio is 2.23, but for Cur ECH2 Y82F it is 1.85. The intermediate value for Cur ECH2 
Y82F suggests a mixture of α,β and β,γ C=C products. These products can be 
distinguished directly by using Jam ER as a reagent to selectively reduce α,β C=C 
(Figure 4-3b, and Figure 4-S11) followed by IRMPD to quantitate the product ratios. The 
level of β,γ C=C product (γ-Cl-6-ACPII) for Cur ECH2 WT, K86Q, K86A, H240Q and 
H240A was ~3% of the total product formed, but was ~30% of total product formed by 
Cur ECH2 Y82F (Figure 4-4b). Thus, replacing the Tyr82 hydroxyl group with a hydrogen 
atom resulted in substantially reduced regioselectivity during Cur ECH2 decarboxylation. 
As previously proposed, product regiochemistry is controlled by a protonation step 
leading to collapse of the presumed enolate intermediate (34). While the proton donor has 
not been identified, we propose that a hydrogen bond from the Tyr82 hydroxyl group to 
the Glu92 backbone carbonyl stabilizes the hypervariable loop, thereby blocking the 
entrance of water to protonate the α-C of the substrate to generate the β,γ C=C product 
(γ-Cl-6-ACPII). Regiochemical control of the protonation step for Jam ECH2 remains 
unclear since its crystal structure is not yet available. However, site-directed mutagenesis 
experiments described above suggest that this hypervariable region in ECH2s plays an 
important role for regiochemical control. 
4.4  DISCUSSION 
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The Cur and Jam pathways enable us to witness the remarkable process of metabolic 
pathway evolution based on comparative biochemical analysis of their β-branching 
enzyme assemblies. What determines the evolution of chemical diversity in natural 
product pathways?  This issue is particularly difficult to address in marine environments 
where host-microbe or predator-microbe interactions are poorly understood. In the case 
of a free living marine microorganism such as Lyngbya majuscula, it is clear that their 
large genomes contain high potential for natural product biosynthesis based on the 
presence of many distinct secondary metabolic pathways (22, 44). How these systems 
have developed within an individual cell, and how small or large fragments of DNA 
might participate in horizontal gene transfer remains unknown. However, that these 
events occur is evident by patterns of gene duplication, insertion and mutation, and 
moreover, by the close genetic and biochemical relationship between selected sets of 
biosynthetic components. Despite the structural relationships, subtle changes in amino 
acid sequences of only two members (e.g. ECH2 and ER) of the 10 component 
β-branching enzyme system are ultimately responsible for the divergent chemical 
outcomes (Figure 4-1a). Thus, based on the genomic information and biochemical 
insights gained in the current study, a scenario of pathway evolution can be surmised. As 
a primary event, we propose that horizontal gene transfer resulted in insertion of an HMG 
gene assembly (Figure 4-1b) whose translation results in a full set of β-carbonyl reaction 
chemistry. This preformed metabolic system includes the Hal, discrete ACP (e.g. ACPIV), 
KS, HCS, ECH1, ECH2 and ER, and specifies formation of a saturated β-methyl 
substituent during polyketide chain elongation (Figure 4-5a). The canonical example of 
this process can be found in the myxoveriscin A pathway where the full complement of 
enzymatic activities (except Hal) results in a pendant β-ethyl group at C16 in the 
28-membered ring system (30). 
Based on the initial biochemical characterization of the HMG-cassette multi-step 
process, variation in β-branching biochemistry is observed in a growing number of 
microbial secondary metabolic pathways. The functional group outcome is largely 
predictable from bioinformatic analysis. For example, mupirocin and bacillaene contain 
vinyl methyl substituents that reflect an HCS assembly devoid of an ER domain (13, 41), 
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consistent with the architecture of their respective biosynthetic gene clusters. More 
unusual combinations of HCS assemblies are found in the leinamycin and bryostatin 
biosynthetic gene clusters (31, 32) that diverge considerably from the canonical example, 
where the formation of a β-branched HMG-ACP is followed by further elaboration of 
this intact subunit in the absence of dehydration/decarboxylation, or decarboxylation 
steps, respectively. 
Where do Cur and Jam HMG assemblies reside in the spectrum of current examples 
leading to unique functional group chemistry?  These two systems reveal clear evidence 
for two types of metabolic pathway evolution that result in unique biochemical functions 
and divergent paths for functional group assembly. Both HMG cassettes contain Hal 
domains that were evidently recruited, and embedded in a modular PKS to impart new 
 
 
Figure 4-5. Impact of enzyme assembly evolution on β-branching chemical diversity. a, 
Proposed ancestral forms of the enzyme assemblies in Cur and Jam pathways. b, 
Differential regiochemical control by ECH2. c, The functional diversification of ERs. 
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chemical diversity. Recent studies on this class of α-KG dependent non-haem 
halogenases have been reported as discrete enzymes within natural product pathways (6, 
19-22), but this integrated domain represents an unprecedented example of pathway 
diversification. Although our initial analysis of the ECH1 and ECH2 catalyzed steps 
utilized HMG-ACP as substrate (12), we have demonstrated that the preferred substrate is 
γ-Cl-1-ACP3. This halogenation step represents the point of divergence in the Cur and 
Jam pathways (Figure 4-5a) where substantial amino acid sequence variation is found in 
comparison of the respective ECH2 and ER enzymes (Figure 4-1b). Pathway 
diversification is reflected in select amino acid sequence changes that ultimately control 
alternate double bond regiochemistry in the curacin and jamaicamide products. 
Regiochemical control is the product of a protonation step accompanying enolate 
collapse after ECH2-mediated decarboxylation (Figure 4-5b). In this case, the 
ramifications of pathway evolution inform downstream steps in unexpected ways. 
Specifically, the Cur ER domain with its unusual placement outside a canonical PKS 
module has revealed itself to be a cyclopropanase, where hydride addition to the 
α,β-enoylthioester (γ-Cl-3-ACP3) is followed by nucleophilic displacement of the 
chlorine atom leading to this highly strained and unusual functional group in secondary 
metabolism (Figure 4-5c). In contrast, our results demonstrate that the Jam ER domain, 
although still functional as a traditional reductase on the curacin α,β enoylthioester 
substrate, has evolved into a redundant enzyme on the alternative β,γ-enoylthioester 
substrate thus retaining the vinyl chloride functional group in jamaicamide. These parallel 
yet distinct systems demonstrate the mutability of enzymes within complex metabolic 
pathways, and reveal their metamorphic properties for creating chemical diversity in 
biologically active natural products. 
4.5  MATERIAL AND METHODS 
The chemical synthesis of the butylamide derivatives as GC-MS authentic standards 
is outlined in Figure 4-S13. Butylamide derivatives, 8, 10, 12 and 14 were synthesized 
from carboxylic acids 7, 9, 11 and 13, respectively. 
General Protocol A. Chemical synthesis and spectroscopic data of 
N-butyl-3-methylbutanamide (8). A solution of carboxylic acid 7 (200 mg, 1.96 mmol) 
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in 20 mL of CH2Cl2 was treated with butylamine (160 mg, 2.19 mmol), HOBt (340 mg, 
2.5 mmol), EDC hydrochloride (480 mg, 2.5 mmol) and i-Pr2NEt (1.1 mL, 6.5 mmol). 
The reaction mixture was stirred at room temperature for 15 h, concentrated in vacuo, and 
partitioned between cold (0˚C) 1 N HCl (100 mL) and Et2O (100 mL). The aqueous 
phase was further extracted with Et2O (2 x 100 mL). The combined organic extracts were 
washed with brine (150 mL), dried (MgSO4), concentrated in vacuo, and purified by 
chromatography on SiO2 (1:1, hexane/EtOAc) to provide 8 (250 mg, 80%) as a white 
powder: 1H NMR (400 MHz, CDCl3) δ 3.15 (dd, J = 12.9, 7.1 Hz, 2 H), 1.96-2.09 (m, 1 
H), 1.93 (d, J = 7.6 Hz, 2 H), 1.35-1.41 (m, 2 H), 1.22-1.28 (m, 2 H), 0.85 (d, J = 6.5 Hz, 
6 H), 0.83 (t, J = 7.3 Hz, 3 H); MS (ESI) calculated for [M+H]+ 158.15, found 158.14. 
Spectroscopic data for N-butyl-3-methylbut-2-enamide (10). 1H NMR (400 MHz, 
CDCl3) δ 5.46-5.50 (m, 1 H), 3.18 (dd, J = 13.5, 6.3 Hz, 2 H), 2.06 (s, 3 H), 1.74 (s, 3 H), 
1.37-1.44 (m, 2 H), 1.22-1.31 (m, 2 H), 0.84 (t, J = 6.5 Hz, 3 H); MS (ESI) calculated for 
[M+H]+ 156.13, found 156.12. 
Spectroscopic data for N-butyl-3-methylbut-3-enamide (12). 1H NMR (400 MHz, 
CDCl3) δ 4.87-4.89 (m, 1 H), 4.79-4.81 (m, 1 H), 3.15 (dd, J = 13.6, 6.5 Hz, 2 H), 2.86 (s, 
2 H), 1.70 (s, 3 H), 1.34-1.42 (m, 2 H), 1.21-1.29 (m, 2 H), 0.83 (t, J = 7.3 Hz, 3 H); MS 
(ESI) calculated for [M+H]+ 156.13, found 156.12. 
Spectroscopic data for (1R,2S)-N-butyl-2-methylcyclopropane-1-carboxamide (14) 
and its racemic mixture of cis- and trans-isomers (cis,trans-14). The enantiomerically 
pure acid 13 was a gift from Timothy M. Ramsey (Novartis Institutes for Biomedical 
Research, Inc.). The racemic mixture of cis- and trans-isomers of 14 was generated from 
2-methylcyclopropanecarboxylic acid. Data for 14: 1H NMR (400 MHz, CDCl3) δ 3.15 
(dd, J = 13.7, 6.6 Hz, 2 H), 1.36-1.44 (m, 2 H), 1.21-1.31 (m, 2 H), 1.21-1.31 (m, 1 H), 
0.96-1.04 (m, 1 H), 0.99 (d, J = 6.1 Hz, 3 H), 0.84 (t, J = 7.3 Hz, 3 H), 0.78-0.85 (m, 1 H), 
0.44 (ddd, J = 7.7, 6.1, 3.6 Hz, 1 H); MS (ESI) calculated for [M+H]+ 156.13, found 
156.13. (Performed by Amol Kulkarni) 
Spectroscopic data and chemical synthesis of 
(E)-N-butyl-4-chloro-3-methylbut-2-enamide (18). (E)-4-Bromo-3-methylbut-2-enoic 
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acid (16): To a solution of 3,3-dimethylacrylic acid (200 mg, 2.0 mmol) in CCl4 (10 mL) 
was added freshly recrystallized NBS (391 mg, 2.2 mmol, 1.1 equiv) followed by 
benzoyl peroxide (24.2 mg, 0.05 equiv). The reaction mixture was heated at reflux for 1 h, 
cooled to room temperature, and filtered to remove succinimide. An aliquot was removed 
for 1H NMR analysis, and the remainder of the solution was poured into a separatory 
funnel and washed with H2O (2 x 20 mL) and brine (1 x 20 mL). The organic layer was 
dried (Na2SO4) and the solvent was removed in vacuo to afford a mixture (371 mg) of 
isomeric allylic bromides as a pale yellow oil. A solution of the crude oil (371 mg, 2.07 
mmol) in water (2 mL) containing 82.8 mg (2.07 mmol) of NaOH was stirred at room 
temperature for 1 h and was then extracted with CH2Cl2 (2 x 2 mL). The aqueous layer 
was acidified with 6 N HCl (1 mL) and extracted again with CH2Cl2 (2 x 5 mL). The 
combined organic extracts were washed with brine (5 mL), dried (Na2SO4), and 
concentrated in vacuo to afford the desired carboxylic acid 16 (88 mg, 24%) as a pale 
yellow oil. This compound was carried on to the next step without further purification.  
(E)-4-Chloro-3-methylbut-2-enoic acid (17): A solution of bromo acid 16 (360 mg, 2.01 
mmol, 1.0 equiv) in CH2Cl2 (5 mL) was cooled to 0˚C, treated with t-butyl ammonium 
chloride (1.12 g, 4.02 mmol, 2.0 equiv) and stirred at 0˚C for 24 h. The mixture was 
concentrated in vacuo to afford a viscous pale yellow oil. Purification by chromatography 
on SiO2 (2% MeOH/CH2Cl2 containing 0.5% AcOH) provided the desired acid 17 (215 
mg, 79%) as a colorless oil.  
(E)-N-Butyl-4-chloro-3-methylbut-2-enamide (18): To a solution of carboxylic acid 17 
(40.0 mg, 0.297 mmol) in CH2Cl2 (0.5 mL) was added oxalyl chloride (0.377 g, 2.97 
mmol, 10.0 equiv). The reaction mixture was heated at a gentle reflux for 2 h, allowed to 
cool to room temperature, and concentrated in vacuo to afford a viscous pale yellow oil. 
After addition of THF (0.5 mL), the solution was cooled to 0˚C, treated with a mixture of 
triethylamine (45 mg, 0.45 mmol, 1.5 equiv), butylamine (24 mg, 0.37 mmol, 1.1 equiv) 
and DMAP (1.8 mg, 0.015 mmol, 0.05 equiv), stirred at 0˚C for 15 min, and warmed to 
RT. The reaction mixture was stirred at room temperature for an additional 45 min and 
poured into a separatory funnel containing 1 M HCl (2 mL) and ether (2 mL). The 
organic layer was washed with water (1 x 2 mL) and brine (1 x 2 mL), dried (Na2SO4), 
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concentrated and purified by chromatography on SiO2 to afford the desired butylamide 
derivative 18 (35 mg, 62%) as a pale yellow oil: IR (neat) 3296, 1633, 1548, 1266, 1182 
cm-1; 1H NMR (300 MHz, CDCl3) δ 5.88-5.86 (m, 1 H), 5.73 (br s, 1 H), 4.00 (s, 2 H), 
3.29 (q, 2 H, J = 8.0 Hz), 2.21 (bs, 3 H), 1.50 (app p, 2 H, J = 7.5 Hz), 1.35 (app s, 2 H, J 
= 7.4 Hz), 0.92 (t, 3 H, J = 8.0 Hz); 13C NMR (75 MHz, CDCl3) δ 165.9, 146.6, 121.4, 
50.2, 39.1, 31.6, 20.1, 16.3, 13.7; MS (ESI) calculated for [M+H]+ 189.09, found 189.10. 
(Performed by Amol Kulkarni) 
Spectroscopic data and chemical synthesis of 
(Z)-N-butyl-4-chloro-3-methylbut-2-enamide (21).  
(Z)-4-Chloro-3methylbut-2-enoic acid (20): A solution of an (E,Z)-mixture of allylic 
bromides 19 (0.67 g, 3.74 mmol) in CH2Cl2 was treated at 0˚C with tetrabutyl ammonium 
chloride (2.08 g, 7.49 mmol), stirred at 0˚C for 24 h, and concentrated to afford a pale 
yellow viscous oil. Purification by chromatography on SiO2 (1:99, MeOH/CH2Cl2 
containing 0.5% AcOH) provided the chloroacid (0.402 mg, 79%) as a 1.2:1 mixture of 
(E,Z)- isomers. Further purification by SFC (SiO2 column, 7% MeOH/CO2) led to pure 
(Z)-isomer 20 (retention time = 3.12-3.17 min) (77 mg) as a colorless oil.  
(Z)-N-Butyl-4-chloro-3-methylbut-2-enamide (21): To a solution of the (Z)-acid 20 (40.0 
mg, 0.297 mmol) in CH2Cl2 (0.5 mL) was added oxalyl chloride (0.377 g, 2.97 mmol, 
10.0 equiv). The reaction mixture was heated at reflux for 2 h, cooled to room 
temperature, and concentrated in vacuo. A solution of the viscous pale yellow oily 
residue in THF (0.5 mL) was cooled to 0˚C, treated with a mixture of triethylamine (45 
mg, 0.45 mmol, 1.5 equiv), butylamine (24 mg, 0.33 mmol, 1.1 equiv) and DMAP (1.8 
mg, 0.015 mmol, 0.05 equiv), stirred at 0˚C for 15 min and then allowed to warm to RT. 
The solution was stirred at room temperature for 45 min, and poured into a separatory 
funnel containing 1 M HCl (2 mL) and ether (2 mL). The organic layer was washed with 
water (1 x 2 mL) and brine (1 x 2 mL), dried (Na2SO4) and concentrated. The residue was 
purified by chromatography on SiO2 (1% MeOH/CH2Cl2) to afford butylamide 21 (33 mg, 
59%) as a pale yellow oil: IR (neat) 3424, 1691, 1631 cm-1; 1H NMR (300 MHz, CDCl3) 
δ 5.69 (br s, 2 H) 4.69 (br s, 2 H), 3.29 (br t, 2 H, J = 6.6 Hz), 1.97 (d, 3 H, J = 1.2 Hz), 
1.56-1.46 (m, 2 H), 1.42-1.29 (m, 2 H), 0.93 (t, 3 H, J = 7.2 Hz); 13C NMR (75 MHz, 
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CDCl3) δ 165.4, 146.8, 122.7, 42.8, 39.1, 31.6, 22.4, 20.1, 13.7; MS (ESI) calculated for 
[M+H]+ 189.09, found 189.10. (Performed by Amol Kulkarni) 
Spectroscopic data and chemical synthesis of 
(E)-N-butyl-4-chloro-3-methylbut-3-enamide (25).  
(E)-4-Chloro-3-methylbut-3-enoic acid (24): A solution of Cp2ZrCl2 (1.46 g, 5.0 mmol, 
1.0 equiv) in CH2Cl2 (5 mL) in a 50 mL 3-necked flask was stirred at 0˚C for 15 min and 
then treated with a solution of AlMe3 (1.08 g, 15.0 mmol, 3.0 equiv) in CH2Cl2 (5 mL). 
The resultant pale yellow reaction mixture was stirred at 0˚C for 15 min, treated over 15 
min with a solution of 3-butyn-1-ol (350 mg, 5 mmol) in CH2Cl2 (2 mL), slowly warmed 
to room temperature, stirred for 14 h, and cooled to -23˚C for 15 min before addition of 
NCS (800 mg, 6.0 mmol, 1.2 equiv). The mixture was stirred at -23˚C for 30 min, slowly 
warmed to room temperature and stirred for 15 min before the reaction was quenched by 
the slow, dropwise addition of 1 M HCl (20 mL). The solution was extracted with 
CH2Cl2 (2 x 20 mL). The organic layer was washed with water (1 x 20 mL) and brine (1 
x 20 mL), dried (Na2SO4) and concentrated in vacuo to afford the alcohol 23 as a pale 
yellow oil. Purification by chromatography on SiO2 (10% EtOAc/hexanes, followed by 
20% EtOAc/hexanes) gave 23 (362 mg, 60%) as a colorless oil. A solution of alcohol 23 
(30.1 mg, 0.25 mmol, 1.0 equiv) in acetone (1 mL) was cooled to 0˚C in an ice-bath for 
15 min, treated with Jones reagent (0.25 mL, 0.63 mmol) and stirred at 0˚C for 20 min. 
After the addition of 2-propanol (400 μL), the reaction mixture was poured into a 
separatory funnel containing ether (5 mL) and water (5 mL). The aqueous layer was 
re-extracted with ether (2 x 5 mL). The combined organic layers were washed with brine 
(1 x 20 mL), dried (Na2SO4), and concentrated in vacuo. The resulting brown oil was 
purified by chromatography on SiO2 (1% MeOH/CH2Cl2 containing 0.5% AcOH) to give 
the desired acid 24 (22.8 mg, 68%) as a pale yellow oil. 
(E)-N-Butyl-4-chloro-3-methylbut-3-enamide (25): To a solution of the chloro acid 24 
(34 mg, 0.25 mmol) in CH2Cl2 (0.5 mL) was added EDC•HCl (58 mg, 0.30 mmol, 1.2 
equiv), triethylamine (38.4 mg, 0.379 mmol, 1.5 equiv) and butylamine (22.2 mg, 0.303 
mmol, 1.2 equiv). The reaction mixture was stirred at room temperature for 14 h, poured 
into a separatory funnel containing 1 M HCl (1 mL) and ether (2 mL), and the organic 
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layer was washed with water (1 x 2 mL) and brine (1 x 2 mL) dried (Na2SO4) and 
concentrated in vacuo. The yellow oily residue was purified by chromatography on SiO2 
(10% EtOAc/hexanes, followed by 20% EtOAc/hexanes) to afford the desired amide 25 
(20 mg, 41%) as a colorless oil: IR (neat) 3429, 1636, 1556 cm-1; 1H NMR (300 MHz, 
CDCl3) δ 6.03-6.00 (m, 1 H), 5.61 (br s, 1 H), 3.30-3.19 (m, 2 H), 2.98 (s, 2 H), 1.85 (br 
d, 3 H, J = 1.2 Hz), 1.54-1.43 (m, 2 H), 1.39-1.29 (m, 2 H), 0.92 (t, 3 H, J = 7.2 Hz); 13C 
NMR (75 MHz, CDCl3) δ 169.1, 133.5, 116.6, 44.8, 39.4, 31.6, 20.0, 16.7, 13.7; MS (ESI) 
calculated for [M+H]+ 189.09, found 189.10. (Performed by Amol Kulkarni) 
Spectroscopic data and chemical synthesis of 
(Z)-N-butyl-4-chloro-3-methylbut-3-enamide (28).  
(Z)-4-Chloro-3-methylbut-3-enoic acid (27). A solution of Cp2ZrCl2 (0.292 g, 1.0 mmol, 
1.0 equiv) in 1,2-DCE (1 mL) in a 50 mL 3-necked flask was stirred at 0˚C for 15 min, 
treated with a solution of AlMe3 (0.216 g, 3.0 mmol, 3.0 equiv) in 1,2-DCE (2 mL) and 
stirred at 0˚C for 15 min. To the reaction mixture was added a solution of 3-butyn-1-ol 
(70 mg, 1.0 mmol,1 equiv) in 1,2-DCE (1 mL) over 15 min. The mixture was slowly 
warmed to room temperature, stirred for 14 h, slowly heated to reflux and maintained at a 
reflux temperature for 3 d. The solution was cooled to 0˚C and subsequently to -23˚C for 
15 min before addition of NCS (127 mg, 1.20 mmol, 1.2 equiv). The reaction mixture 
was stirred at -23˚C for an additional 30 min, slowly warmed to room temperature, stirred 
for 15 min, and quenched by a slow, dropwise addition of 1 M HCl (10 mL). The solution 
was extracted with ether (5 x 20 mL), and the combined organic layers were washed with 
brine (1 x 50 mL), dried (Na2SO4) and concentrated in vacuo to afford the desired alcohol 
26 as a pale yellow oil. Purification of the crude compound by chromatography on SiO2 
(10% EtOAc/hexanes, followed by 20% EtOAc/hexanes) provided alcohol 26 (61 mg, 
51%) as a pale yellow oil. A solution 26 (61 mg, 0.51 mmol, 1.0 equiv) in acetone (2 mL) 
was cooled to 0˚C for 15 min, treated with Jones reagent (0.51 mL, 1.28 mmol) and 
stirred for 20 min at 0˚C. The mixture was diluted with 2-propanol (400 μL), poured into 
a separatory funnel containing ether (5 mL) and water (5 mL), and the aqueous layer was 
washed with ether (2 x 5 mL). The combined organic layers were washed with brine (1 x 
20 mL), dried (Na2SO4) and concentrated in vacuo. The brown oily residue was purified 
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by chromatography on SiO2 (1% MeOH/CH2Cl2 containing 0.5% AcOH) to give the 
desired acid 27 (44.3 mg, 65%) as a pale yellow oil. 
(Z)-N-Butyl-4-chloro-3-methylbut-3-enamide (28). To a solution of acid 27 (11.0 mg, 
0.08 mmol, 1.0 equiv) in THF (1 mL) were added sequentially at 0˚C diphenylphosphinic 
chloride (19.3 mg, 0.082 mmol, 1.0 equiv), N-methylmorpholine (34.7 mg, 0.343 mmol, 
4.2 equiv) and butylamine (5.9 mg, 0.08 mmol, 1.0 equiv). The reaction mixture was 
stirred at 0˚C for 1 h, concentrated and purified by chromatography on SiO2 (20% 
EtOAc/hexanes) to give amide 28 (5.0 mg 32%) as a colorless oil: IR (neat) 3428, 1649, 
1555, 1440 cm-1; 1H NMR (300 MHz, CDCl3) δ 6.00 (app d, 1 H, J = 1.5 Hz), 5.61 (br s, 
1 H), 3.28-3.21 (m, 2 H), 3.16 (s, 2 H), 1.86 (d, 3 H, J = 1.2 Hz), 1.53-1.43 (m, 2 H), 
1.40-1.25 (m, 2 H), 0.92 (t, 3 H, J = 7.2 Hz); 13C NMR (75 MHz, CDCl3) δ 168.6, 134.0, 
114.9, 40.4, 39.4, 31.6, 21.4, 20.0, 13.7; MS (ESI) calculated for [M+H]+ 189.09, found 
189.10. (Performed by Amol Kulkarni) 
Spectroscopic data and chemical synthesis of N-butyl-4-chloro-3-methylbutanamide 
(31). 
N-Butyl-4-chloro-3-methylbutanamide (31). To a solution of lactone 29 (100 mg, 1.0 
mmol, 1.0 equiv) in thionyl chloride (0.13 g, 1.0 equiv) was added freshly fused ZnCl2 
(6.8 mg, 0.05 mmol, 0.05 equiv). The reaction mixture was slowly heated to reflux, 
maintained at reflux for 8 h, and then slowly cooled to room temperature. The mixture 
was concentrated in vacuo and a solution of the brown oily residue in THF (0.5 mL) was 
cooled to 0˚C, treated with a mixture of triethylamine (0.15 g, 0.15 mmol, 1.5 equiv) and 
butylamine (80 mg, 1.1 mmol, 1.1 equiv), stirred at 0˚C for 30 min, warmed to room 
temperature, stirred for 30 min, and poured into a separatory funnel containing 1 M HCl 
(2 mL) and CH2Cl2 (2 mL). The organic layer was washed with brine (1 x 2 mL), dried 
(Na2SO4) and concentrated in vacuo to afford a pale brown oil that was purified by 
chromatography on SiO2 (20% EtOAc/hexanes followed by 50% EtOAc/hexanes) to give 
amide 31 (70.7 mg, 37%) as a yellow oil: IR (neat) 3422, 1644, 1559, 1459, 1379 cm-1; 
1H NMR (300 MHz, CDCl3) δ 5.92 (br s, 1 H), 3.59-3.48 (m, 2 H), 3.24 (app q, 2 H, J = 
6.6 Hz), 2.50-2.30 (m, 2 H), 2.10 (dd, 1 H, J = 14.1, 7.2 Hz), 1.52-1.43 (m, 2 H), 
1.37-1.27 (m, 2 H), 1.04 (d, 3 H, J = 6.6 Hz), 0.91 (t, 3 H, J = 7.2 Hz); 13C NMR (75 
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MHz, CDCl3) δ 171.3, 50.6, 40.6, 39.3, 32.6, 31.6, 20.0, 17.6, 13.7; MS (ESI) calculated 
for [M+H]+ 191.11, found 191.10. (Performed by Amol Kulkarni) 
Chemical synthesis of 6-CoA. The chemical synthesis of 6-CoA was described in our 
previous work (12). 
Enzymatic synthesis of 1-CoA. 1-CoA was enzymatically generated by HMG-CoA 
reductase as previously described (12, 45). The reaction mixture was separated by a 
self-packed DEAE Sepharose column (1 cm x 30 cm, GE Healthcare)) equilibrated with 
0.1 M HCO2NH4, pH 4.4. 1-CoA was eluted with 0.4 M HCO2NH4, pH 4.4 (45). 1-CoA 
was further purified using XBridge Preparative C18 column (10 x 250 mm, 5 μm) and an 
elution gradient of 3-60% CH3OH/H2O (10 mM NH4OAc). The fractions were pooled 
and lyophilized, and 1-CoA purity was measured by HPLC to be >98%. 
Enzymatic synthesis of 2-CoA. 2-CoA was enzymatically generated from 1-CoA by Cur 
ECH1 as previously described (34). 
Bacterial strains, media and culture conditions. Escherichia coli DH5α MCR 
(Invitrogen) was used for DNA propagation. Escherichia coli BL21 (DE3) transformed 
with the derivatives of pET20b, pET24b, pET28b, and pET41a (Novagen) were used for 
protein overexpression in Luria-Bertani (LB) medium. Ampicillin (100 μg/mL), 
carbenecillin (100 μg/mL), kanamycin (50 μg/mL), chloramphenicol (25 μg/mL), and 
apramycin (50 μg/mL) were used for the corresponding plasmid construct resistance 
marker selection in E. coli cultures. 
Plasmid construction and site mutagenesis. The primers for the plasmid construction 
were listed in Table S1. The expression plasmids for CurB ACPIV, CurE ECH1 and CurF 
ECH2 were constructed in our previous work (12). CurA Hal, Hal-ACP3 and CurF ER 
genes were amplified from the cosmid pLM54 (16). JamI ECH1, JamJ ECH2 and JamJ ER 
genes were amplified from cosmid pJam3 (14). CurA Hal and Hal-ACP3 genes were 
inserted into pET28b plasmid using NdeI/XhoI restriction sites. JamI ECH1 gene was 
inserted into pET24b plasmid using NdeI/XhoI restriction sites. JamJ ECH2 gene was 
inserted into pET20b plasmid using NdeI/XhoI restriction sites. CurF ER and JamJ ER 
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genes were inserted into pET41a plasmid using SacII/XhoI restriction sites. The CurA 
ACP3, ACPI, ACPII and ACPIII expression plasmids derived from a synthetic ACP3 gene 
were provided by Professor Christopher Walsh and Dr. Christopher Calderone at Harvard 
Medical School. CurA ACP3 (1946-2248) gene was inserted into pET28a plasmid using 
NdeI/XhoI restriction sites. CurA ACPI (1946-2031), ACPII (2057-2146) and ACPIII 
(2161-2248) genes were inserted into pET29a plasmid using NdeI/XhoI restriction sites. 
CurF ECH2 mutants, H240A, H240Q, K86A, K86Q and Y82F, were made in our previous 
work (34). All the constructs and mutations were verified by DNA sequencing. 
Protein overexpression. The protein expression conditions for CurB ACPIV, CurE ECH1, 
CurF ECH2 and the corresponding mutants were described in our previous work (12, 34). A) 
CurA (apo) ACP3, (apo) ACPI, (apo) ACPII, (apo) ACPIII, JamI ECH1, and JamJ 
ECH2: E. coli BL21 (DE3) was transformed by the pET28a::ACP3 (pCC111) plasmid to 
overexpress the N-terminal His-tagged protein, and by pET29a::ACPI (pCC112), 
pET29a::ACPII (pCC113), pET29a::ACPIII (pCC114), pET24b::Jam ECH1 and 
pET20b::Jam ECH2 to overexpress the C-terminal His-tagged proteins. Cells were grown at 
35˚C to an OD (590 nm) = 0.5-0.6, and then cooled to 18˚C prior to addition of 1 mM 
isopropyl-β-D-galactopyranoside (IPTG). The cultures were grown at 18˚C for another 
12-15 h before harvesting. B) CurA Hal and (apo) Hal-ACP3: E. coli BL21 (DE3) was 
transformed by pET28b::Cur Hal and pET28b::Cur Hal-ACP3 plasmids to overexpress the 
N-terminal His-tagged proteins. Cells were grown at 30˚C to an OD (590 nm) = 0.5-0.6, 
and then cooled to 15˚C prior to the addition of 1 mM IPTG. The cultures were grown at 
15˚C for another 18-20 h before harvesting. C) CurF ER and JamJ ER: E. coli BL21 
(DE3) was transformed by pET41b::Cur ER and pET41b::Jam ER to overexpress the 
N-terminal GST-tagged and C-terminal His-tagged proteins. Cells were grown at 30˚C to 
an OD (590 nm) = 0.5-0.6, and then cooled to 18˚C prior to the addition of 1 mM IPTG. 
The cultures were grown at 18˚C for another 12-15 h before harvesting. 
Protein purification. Protein purifications were performed at 4˚C. In general, the first 
step Ni-affinity purifications for all His-tagged proteins were performed under the same 
conditions. E. coli cells were harvested by centrifugation (5,000 g, 20 min, 4˚C), 
resuspended in ice cold lysis buffer A (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 10 
 106
mM imidazole, 20% glycerol) and disrupted by sonication on ice. The cell debris was 
removed by centrifugation at 15,000 g for 50 min. The supernatant was gently removed 
and loaded onto the 5 mL HisTrap column (GE Healthcare) preequilibrated with lysis 
buffer A. The resin was washed successively with ~10 column volumes of washing 
buffer B (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole, 10% glycerol) to 
remove nonspecifically bound contaminants. Bound proteins were eluted with imidazole 
by a linear gradient of the elution buffer C (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 
250 mM imidazole, 20% glycerol). The fractions of the eluate were checked for purity by 
SDS-PAGE, pooled and concentrated using Amicon Ultra-15 (30 kDa, 10 kDa or 5 kDa) 
centrifugal devices (Millipore). The follow-up purification and buffer exchange for 
different proteins are described below:  
A) CurA (apo) ACP3, (apo) ACPI, (apo) ACPII, (apo) ACPIII, CurB (apo) ACPIV, 
CurF ECH2 WT and the mutants, CurF ER, JamI ECH1, JamJ ECH2 and JamJ ER: 
the concentrated eluate was loaded onto HiPrep 26/10 Desalting column (GE Healthcare) 
equilibrated with the storage buffer D (50 mM PBS buffer, pH 7.5, 200 mM NaCl, 20% 
glycerol), The fractions were pooled, concentrated, flash-frozen in 50-200 μL aliquots by 
liquid N2, and stored at -80˚C. B) CurE ECH1: CurE ECH1 is prone to precipitate after its 
elution from HisTrap column. So the eluted protein was immediately desalted by PD10 
column (GE Healthcare) equilibrated with the storage buffer D. The protein was 
flash-frozen in 100 μL aliquots by liquid N2 and stored at -80˚C. 
Anaerobic purification of Cur Hal and (apo) Hal-ACP3. The FeII-, α-KG- and 
O2-dependent halogenases were reported to be sensitive to O2, and anaerobic purification 
was performed to remain their activities (19, 20). The purification was performed under 
inert atmosphere by using ÄKTA FPLC (GE Healthcare) companied with a glove box 
(Coy Laboratory Products), which is similar to the system previously described (46). All 
the buffers were sparged with argon and equilibrated in glove box for two days. E. coli 
cells were resuspended in buffer A and disrupted by sonication on ice. Then the cell 
lysate was equilibrated with argon for ~1 hour, transferred to gas-tight tubes in glove box, 
and centrifuged at 15,000 g for 50 min. The Ni-affinity purification for Hal and 
Hal-ACP3 was performed as described above. After elution from HisTrap column, the 
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proteins were exchanged into buffer D using HiPrep 26/10 Desalting column. The 
N-terminal His-tag of Hal was removed by thrombin for metal analysis (19, 20). The 
biotinylated thrombin (Novagen) was added into Hal in buffer D, and the reaction was 
incubated at room temperature for overnight to achieve a complete His-tag cleavage. The 
biotinylated thrombin was removed from the reaction mixture by using 1 mL HiTrap 
Streptavidin HP column (GE Healthcare). The flow-through was loaded onto HiLoad 
26/60 Superdex 200 column (GE Healthcare) equilibrated with the storage buffer D. Cur 
Hal was eluted as a dimer from size-exclusion columns. The fractions were pooled, 
concentrated, flash-frozen in 50 μL aliquots by liquid N2, and stored at -80˚C. 
Metal analysis of Cur Hal. To determine which metal bound to Hal, His-tag cleaved Cur 
Hal was anaerobically reconstituted with 1 mM α-KG and a metal mixture containing 25 
μM Fe2+, Co2+, Ni2+, Cu2+ and Zn2+ for 10 min before desalted by PD10 column 
equilibrated with buffer E (50 mM Tris-HCl buffer, pH 7.5, 150 mM NaCl, 10% 
glycerol). The metal content of Cur Hal was measured by ICP-MS (Finnigan). The buffer 
E was applied as blank for analysis. For ~2.0 μM Cur Hal, the metal concentrations were 
measured to be 1.81 ± 0.09 μM Fe (blank 0.09 ± 0.02), < 0.0031 μM Co (blank < 0.0027), 
< 0.0017 μM Ni (blank < 0.0015), < 0.0019 μM Cu (blank < 0.0017), and 0.067 ± 0.003 
μM Zn (blank 0.039 ± 0.003). Based on this result, the reconstitution of with α-KG and 
Fe(NH4)2(SO4)2 were performed for its activity assay described below. 
Substrate loading onto (apo) ACPs. The ACP-linked substrates were generated by 
loading the corresponding CoA substrates onto (apo) ACPs by using recombinant 
Bacillus subtilis Sfp (12, 47). Typically, 500 μM acyl-CoA and 50 μM (apo) ACP were 
incubated with 2 μM Sfp, and 10 μM MgCl2 in 50 mM Tris-HCl buffer, pH 8.1, at room 
temperature for ~2 h. Reaction mixtures were desalted by PD10 column equilibrated with 
the buffer E. The desalted (holo) ACPs were concentrated by using Amicon Ultra-4 (5 
kDa, Millipore), flash-frozen in 10-50 μL aliquots in liquid N2, and stored at -80˚C. For 
substrate loading onto (apo) Hal-ACP3, the reagents were equilibrated with argon prior to 
use. The substrate loading onto (apo) Hal-ACP3 was manipulated in glove box. The 
substrate-loaded ACP samples were analyzed by reverse-phase HPLC using a Jupiter C4 
column (250 x 2.0 mm, 5 μm, 300 Å, Phenomenex), and a linear elution gradient from 5% 
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to 90% of CH3CN (0.1% CF3CO2H)/H2O (0.1% CF3CO2H). 
Cur Hal activity assays & enzymatic generation of γ-Cl-1-ACPII. Cur Hal acitivity 
was tested by using ACPIV or ACPII-linked substrates including malonyl-ACPIV, 
acetyl-ACPIV, 1-ACPII, 2-ACPII, 3-ACPII, 4-ACPII and 6-ACPII. The chlorination product 
was only detected for 1-ACPII. As such, the follow-up chlorination assays were 
performed by incubating the enzyme with 1-ACPII or 1-ACP3. Typically, 200 μl reaction 
mixture containing 50 μM 1-ACPII or 1-ACP3, 5 μM Cur Hal, 50 μM fresh 
Fe(NH4)2(SO4)2, and 0.5 mM α-KG in 50 mM Tris-HCl buffer (pH 7.5) was prepared in 
glove box. The reaction was initiated by exposing the reaction mixture to air, and 
incubated at 30˚C for 2 h to achieve a full conversion to γ-Cl-1-ACPII. The γ-Cl-1-ACPII 
was served as substrate for ECH1/ECH2/ER reactions. FTICR-MS and IRMPD were 
employed to detect the products. 
α-KG and O2 dependence of Hal chlorination. The α-KG and O2 dependence of Cur 
Hal chlorination was investigated by incubating the enzyme with 1-ACPII in the absence 
of α-KG or O2 under the uniform reaction condition described above. For Hal 
chlorination without O2, the reaction mixture was prepared in glove box, and capped 
during its incubation.  
ECH1 and ECH2 acitivity assays. ECH1 and ECH2 assays were performed as previously 
described (34). Briefly, ~50 μM 1-ACPII or γ-Cl-1-ACPII was added with 1 μM ECH1 or 
ECH1/ECH2 in 50 mM Tris-HCl buffer (pH 7.5), and incubated at 30˚C. After quenched 
by addition of 10% formic acid, the reactions were analyzed by reverse-phase HPLC 
using Jupiter C4 column. FTICR-MS and IRMPD were applied to detect the products. 
ER activity assays. The chlorinated substrate, γ-Cl-3-ACPII, was generated from 
γ-Cl-1-ACPII by Cur ECH1/ECH2, and the non-chlorinated substrate, 3-ACPII was 
generated by loading (apo) ACPII with 3-CoA. Typically, ER reactions were performed 
by incubating ~50 μM γ-Cl-3-ACPII or 3-ACPII with 1 μM ER and 0.5 mM NADPH in 
50 mM Tris-HCl buffer (pH 7.5) at 30˚C. Alternatively, ER reaction was coupled with 
ECH1/ECH2 dehydration and decarboxylation by serving γ-Cl-1-ACPII or 1-ACPII as the 
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substrate. FTICR-MS and IRMPD were applied to detect the products. 
One-pot reactions with Cur Hal-ACP3 or ACP3-linked substrate. The one-pot 
reactions were conducted tο confirm the products of ECH1/ECH2, Hal/ECH1/ECH2, 
ECH1/ECH2/ER, and Hal/ECH1/ECH2/ER coupled reactions. The ACP3-linked HMG 
substrates were generated by loading Cur (apo) Hal-ACP3 and ACP3 with 1-CoA as 
described above. The substrate loading of (apo) Hal-ACP3 was manipulated in glove box. 
Typically, the one-pot reactions were performed by incubating ~50 μM ACP3 or 
Hal-ACP3-linked HMG substrate with ~10 μM enzymes and their corresponding 
cofactors at 30˚C for 5 min. The reactions were initiated by exposing the reaction mixture 
to O2, and quenched by addition of 10% formic acid. Hal-ACP3 and ACP3 were purified 
from their reaction mixtures by reverse-phase HPLC before subjected to butylamine 
aminolysis as described below. 
Butylamine aminolysis. To determine the structures of products linked to the ACP3 and 
Hal-ACP3 PPant arms, the acyl groups were cleaved by butylamine aminolysis to 
generate the butylamide derivatives, which were analyzed by GC/MS (39) and compared 
with the authentic standards. To remove contaminants, the ACP3 and Hal-ACP3 were 
purified from their reaction mixtures by reverse-phase HPLC using the Source 15PRC 
column. The proteins were eluted using a linear gradient from 30% to 70% of CH3CN 
(0.1% CF3COOH)/H2O (0.1% CF3COOH), and pooled in glass vials before 
lyophilization. The aminolysis reaction was performed by adding 160 μl H2O, 100 μl 
hexane and 40 μl butylamine into ~5 nmol lyophilized ACP3 or Hal-ACP3 samples. The 
reaction mixture was incubated at 30˚C for 30 min, quenched by 66 μl 12 M HCl, and 
extracted with 2 x 2 mL ethyl acetate. The extracts were dried under nitrogen, and the 
butylamides were redissolved in 100 μl hexane before GC/MS analysis. 
GC/EI-MS analysis. The samples and authentic standards were analyzed by a Hewlett 
Packard 6890 gas chromatograph equipped with a 5973 mass selective quadrupole 
detector. The butylamides were separated on a DB-VRX (Agilent J&W) capillary column 
(60 m x 253 μm x 1.40 μm), which was operated with helium-carrier gas and splitless 
injection. Both the injector and detector temperatures were set as 250˚C. After initial 6 
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min at 45˚C, the oven temperature was raised to 140˚C at 8˚C/min and held for 10 
minutes, and then to 225˚C at 30˚C/min and held for 25 minutes. Total ion 
chromatograms were recorded using a mass range of 35-270 amu, and the selective ion 
chromatograms were recoded by monitoring 2-3 most abundant masses plus the parent 
masses of target compounds. 
Analysis of ACP samples by electrospray ionization (ESI)-FTICR-MS. The observed 
and calculated masses for all ACPII samples are listed in Table S2. The ESI-FTICR-MS 
samples were prepared by separating ACPII from the reaction mixtures using the Source 
15PRC reverse phase column as previously described (47). All samples were freshly 
prepared and analyzed with an actively shielded 7 Tesla quadrupole- FTICR mass 
spectrometer (APEX-Q, Bruker Daltonics, Billerica, MA). Target analytes in electrospray 
solution (1:1 CH3CN:H2O with 0.1% HCOOH) were directly infused into an electrospray 
ionization (ESI) source (Apollo II, Bruker Daltonics) operating in positive ion mode at a 
flow rate of 70 µL/h and a voltage of - 3.8 kV. A counterflow of hot (240°C) nitrogen gas 
was applied to assist desolvation of ESI droplets. Multiply protonated ions generated by 
ESI were externally accumulated in a hexapole and transferred via high voltage ion optics 
to the ICR cell for analysis. For IRMPD, precursor ions were mass-selectively 
accumulated in the hexapole with a 5-10 m/z quadrupole isolation window, transferred to 
the ICR cell, and irradiated for 100-300 ms by 10.6 μm photons at 10 W laser power (25 
W CO2 laser, Synrad, Mukilteo, WA). All data were acquired with XMASS software 
(version 6.1, Bruker Daltonics) in broadband mode from m/z = 200 to 2000 with 512k 
data points and summed over 10-30 scans. Mass spectra were analyzed with the MIDAS 
analysis software (48). For accurate mass determination, apomyoglobin (Sigma, St. Louis, 
MO) peaks on charge state of 19-20 (apomyoglobin was spiked into the ESI solution 
prior to analysis), or known y-type product ions (y22) generated from IRMPD of the same 
protein were used as internal calibrants. Once the exact mass of a protein had been 
determined, its two most abundant charge states were selected as internal standards for 
further calibration (apomyoglobin was not spiked into all reactions). All 
frequency-to-m/z calibrations were performed with a two-term calibration equation (49). 
(Performed by Bo Wang and Liangcai Gu) 
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IRMPD-based quantification. Peak abundances of PPant ejection products (PEPs) 
generated by IRMPD (38) were measured to quantify the yields of the ER catalyzed α,β 
C=C saturation and cyclopropanation reactions for time-course studies, or site 
mutagenesis assays. In ER α,β C=C saturation reaction, an addition of two hydrogens to 
the substrate is unlikely to affect ESI efficiency. Furthermore, products and substrates 
were observed with the same charge state distribution patterns, allowing a single charge 
state to be used for analysis (50). For Cur ER cyclopropanation, quantification of 5-ACPII 
was achieved by using 4-ACPII as an internal standard. No desaturation product of 
4-ACPII, which would interfere with 5-ACPII measurement, was detected. The ratio of 
these acyl-ACPII species with 2 Dalton mass difference can be straightforwardly 
measured by analyzing their PEPs. With IRMPD, quantification results from a single 
charge state (+12) were identical to those based on an average of the entire charge state 
distribution. Thus, we chose to utilize the +12 charge state for IRMPD quantification 
analysis. The ratio of PEPs with 2 Dalton mass difference was calculated by measuring 
the abundance of the n and n+2 product ion peaks (the n+2 peak abundance was adjusted 
by subtracting the natural n+2 isotopic abundance for peak n). For saturation reactions, 
yields were calculated by measuring the ratios of substrates with respect to products 
whereas, for cyclopropanation reactions, yields were calculated by measuring the ratios 
of products with respect to the internal standard. (Performed by Bo Wang and Liangcai 
Gu) 
Time-course studies of ER saturation and cyclopropanation. The time-course studies 
were performed to compare the catalytic efficiencies of Cur ER cyclopropanation and 
saturation, and Jam ER saturation. γ-Cl-3-ACPII was applied as the substrate for Cur ER 
cyclopropanation and Jam ER saturation, and 3-ACPII as the substrate for Cur and Jam 
ER saturation. All the reactions were performed in triplicate under the uniform reaction 
condition. ~200 μM γ-Cl-3-ACPII or 3-ACPII was incubated with 2 μM Jam or Cur ER, 
and 1 mM NADPH in 50 mM Tris-HCl buffer (pH 7.5) at 30˚C. For Cur ER 
cyclopropanation, ~100 μM 4-ACPII, which was generated from (apo) ACPII and 4-CoA, 
was added as the internal standard for 5-ACPII. No desaturation product of 4-CoA was 
observed under the tested conditions. After certain amounts of reaction time, ~20 μl 
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aliquots were removed from the reaction mixture, added with 50 μl 10% formic acid to 
quench the reaction, and flash-frozen by liquid N2. The ACPII samples were purified by 
reverse-phase HPLC, and immediately subjected to the IRMPD-based quantification 
analysis.  
Quantification of regiochemical products of the ECH2 WT and mutants. The ratios 
of α,β and β,γ C=C products of the ECH2 decarboxylation were measured for Cur ECH2 
WT and mutants, and Jam ECH2 WT. The products were generated from γ-Cl-1-ACPII by 
ECH1/ECH2 coupled dehydration and decarboxylation. 50 μM γ-Cl-1-ACPII was 
incubated with 2 μM Cur ECH1 and 2 μM Cur or Jam ECH2 in 50 mM Tris-HCl buffer 
(pH 7.5) at 30˚C for 45 min. Next, the reaction mixtures were treated with 2 μM Jam ER 
with 0.5 mM NADPH for 45 min before an addition of 10% formic acid to quench the 
reactions. The ratio of γ-Cl-4-ACPII and γ-Cl-6-ACPII were measured by IRMPD-based 
quantification as described above. (Performed by Bo Wang and Liangcai Gu) 
Modeling the PPant arm of (4S)-γ-Cl-2-ACPII into Cur ECH2 structure. Initial 
atomic coordinates and topology files for the PPant arm of (4S)-γ-Cl-2-ACPII were 
generated using the PRODRG2 server (51). The PPant arm was initially positioned into 
Cur ECH2 (PDB code 2Q34) as previously described (34). Any overlapping waters were 
removed before energy minimization after the addition of hydrogens using the program 
CNS 1.2 (52) in 1080 steps of conjugate gradient minimization using no experimental 
energy terms and full harmonic restraints. (Performed by Todd Geders) 
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4.6  SUPPLEMENTAR FIGURES AND TABLES 
 
 
Figure 4-S1. Alignment of AT domains of the sequenced pathways from L. majuscula, 







Figure 4-S2. Phylogenetic trees for a, AT, b, KS and c, DH domain sequences of curacin, 
jamaicamide, barbamide and putative carmabin pathways from L. majuscula. The 





Figure 4-S3. Coomassie blue-stained SDS-PAGE of purified Cur and Jam enzymes. JamJ 
ER and CurF ER were expressed as N-terminal GST-tagged proteins to increase their solubility. 
CurE ECH1 was coexpressed with chaperones to increase its solubility and coeluted with them 
from the Ni-affinity column. His-tag cleaved CurA Hal was prepared for metal content analysis. 





Figure 4-S4. HPLC analysis of HMG substrate loading onto a, (apo) ACP3, b, (apo) ACPII. 




Figure 4-S5. a, b, HMG substrate chirality preference of Cur Hal and ECH1; c, O2 and 
α-KG dependence of Cur Hal. Partial FTICR mass spectra for ECH1 and Hal reactions with a, 
(S)-HMG-ACPII substrate, and b, (R,S)-HMG-ACPII substrate. c, Partial FTICR mass spectra for 
Hal reactions without O2 or α-KG. For Hal reaction without O2, the reaction mixture was 

























































Figure 4-S6. Feeding experiment to demonstrate that Hal chlorination precedes ECH2 
decarboxylation. The β-branching carbon forming the cyclopropane was labeled with only one 
deuterium atom by [2H3,2-13C]acetate supplied in the growth media of L. majuscula. If Hal 
chlorination happens after ECH2 decarboxylation, the β-branching carbon would be labeled 




Figure 4-S7. HPLC analysis of ECH1/ECH2 coupled dehydration and decarboxylation to 
compare the rates for the chlorinated and non-chlorinated substrate. The reactions were 




Figure 4-S8. FTICR mass spectra and IRMPD spectra for Jam enzyme reactions. a, Partial 
FTICR mass spectra for Jam ECH1, ECH2 and ER reactions. 1-ACPII was chlorinated by Cur Hal 
for 1 h to generate γ-Cl-1-ACPII substrate. The reactions were incubated at 30oC for 2 h for the 
1-ACPII substrate and 30 min for the γ-Cl-1-ACPII substrate. b, IRMPD spectra for the PEPs of 
6-ACPII and γ-Cl-6-ACPII before Jam ER saturation (above) and after Jam ER saturation (below). 
A small amount of saturated product with its PEP indicated by red arrow was observed to be 
mixed with the 6-ACPII. Based on the butylamine cleavage analysis, 3-ACPII was inferred to be 




Figure 4-S9. The UV absorption difference for Cur and Jam ECH2 decarboxylation 
products. a, HPLC traces showing the separation of γ-Cl-1-ACPII and its decarboxylation 
products catalyzed by Cur and Jam ECH1/ECH2. b, UV spectra (220-310 nm) of Cur (red) and 
















































































































Figure 4-S10. Natural products with different β-branching-associated C=C positions via 
ECH2 regiochemical control. a, Two groups of natural products with the α,β and β,γ C=Cs 
adjacent to their β-branching carbons. The C=Cs of curacin A and myxovirescin A have been 




Figure 4-S11. IRMPD-based quantification to measure the yields of a, Cur ER 
cyclopropanation, b, Jam ER saturation, and c, the ratio of α,β and β,γ C=C products of 
ECH2s. Because the ACPII species with two Dalton mass difference are equally distributed over 
different charge states, we focused on the +12 change state to record IRMPD spectra. a, To 
measure the yield of Cur ER cyclopropanation, 4-ACPII was added as internal standard for 
5-ACPII. b, The yield of Jam ER saturation was measured by the ratio of γ-Cl-3-ACPII substrate 
and γ-Cl-4-ACPII product. c, To measure the ratio of α,β and β,γ C=C products, the α,β C=C 
product was reduced by Jam ER by treating the mixtures of α,β and β,γ C=C products with Jam 




Figure 4-S12. Comparison of Cur and Jam ER saturation by using 3-ACPII substrate. 
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Figure 4-S13. Synthesis of butylamide derivatives as GC-MS authentic standards.
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Table 4-S1. Primers for expression constructs. 
The restriction sites are underlined. 
Primer name Sequences (5’ to 3’)  
CurA-Hal-for CATATGAACCGGGAACAAGTTGAACAA (NdeI) 
CurA-Hal-rev CTCGAGTTACGAAGAGATGCTTGGTGTTTC (XhoI) 
CurA-ACP3-rev CTCGAGCTCCTAAACTGTAACCTGTTT (XhoI ) 
CurF-ER-for CCGCGGGTATACACCAGGTAACCTTTAAC (SacII) 
CurF-ER-rev CTCGAGATTTTTCTTTGTTGGGGA (XhoI) 
JamI-ECH1-for CATATGTATTACCAAACCCTAAAA (NdeI) 
JamI-ECH1-rev CTCGAGGCTTTGCCATGGATATAAC (XhoI) 
JamJ-ECH2-for CATATGGCAAAGCTGAACTTGAATC (NdeI) 
JamJ-ECH2-rev CTCGAGCTGCTGGAAGGTTTTTTC (XhoI) 
JamJ-ER-for CCGCGGGTATACATCAAACCACTAGTCAA (SacII) 
JamJ-ER-rev CTCGAGTTCTTTTGTCGATTCTGGTTC (XhoI) 
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Table 4-S2.  ESI-FTICR-MS analysis. 
 
Masses are in Daltons. Calc., calculated; Obs., observed. 
PEP, PPant ejection product. 
ESI-FTICR-MS IRMPD (PEP) 
ACPII samples Obs. avg mass Calc. avg mass Obs. [M + H]+ Calc. [M + H]+ 
apo-ACPII 11300.7 11300.8   
1-ACPII 11785.9 11785.9 387.164 387.159 
2-ACPII 11767.9 11767.9 405.174 405.170 
3-ACPII 11723.9 11723.9 343.174 343.169 
6-ACPII 11723.9 11723.9 343.163 343.169 
4-ACPII 11725.9 11725.9 345.190 345.185 
γ-Cl-1-ACPII 11819.8 11819.9 439.128 439.131 
γ-Cl-2-ACPII 11802.0 11801.9 421.110 421.120 
γ-Cl-3-ACPII 11757.8 11757.9 377.140 377.130 
γ-Cl-6-ACPII 11757.8 11757.9 377.141 377.130 
γ-Cl-4-ACPII 11759.8 11759.9 379.156 379.146 
5-ACPII 11723.9 11723.9 343.169 343.169 
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DECARBOXYLATIVE CHAIN TERMINATION 
5.1  SUMMARY 
In this chapter, a novel chain termination module that mediates a decarboxylative 
chain termination leading to the formation of terminal olefin in the curacin A pathway is 
biochemically assessed. First, we identified the correct curM sequence by sequencing the 
thioesterase (TE) region in the selected cosmids from the genomic library of Lyngbya 
majuscula. Next, the acyl carrier protein (ACP), sulfotransferase (ST) and thioesterase 
domains from CurM chain extension and termination modules were overexpressed, 
purified and biochemically assessed. The ST domain was demonstrated to transfer a 
sulfuryl group from adenosine 3′-phosphate 5′-phosphosulfate (PAPS) to the β-hydroxyl 
group of the model substrates. The TE domain was proved to release the acyl chain by 
cleaving the thioester bond. New model substrates were designed to facilitate the 
detection of the terminal olefin products in ST/TE coupled assays. This ST-TE chain 
termination model can serve as an important engineering tool to generate a hydrophobic 
end in polyketide products to improve their physicochemical properties. 
5.2  INTRODUCTION 
Modular polyketide synthases (PKSs) are giant biosynthetic machines that catalyze 
programmed metabolic pathways to assemble short-chain acyl-CoA building blocks into 
complex polyketide products by one step of chain initiation followed by multiple steps of 
chain elongation and one step of chain releasing. So far, three major strategies have been 
reported for cleavage of the thioester bond between the thiol group of ACP/peptidyl 
carrier protein (PCP) PPant arm and PKS/non-ribosomal peptide synthase (NRPS) 
acyl/peptidyl chain after the final step of chain extension completes (1). The first strategy 
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is to hydrolyze the full-length acyl, peptidyl, or hybrid chain from carrier protein PPant 
thiol to release the free acid via formation of an acyl-O-TE intermediate and releasing the 
acyl group by nucleophilic attack with H2O (1). The second strategy and the one of most 
medicinal interest is to use an intramolecular nucleophile within the acyl chain to release 
the acyl group from the acyl-O-TE intermediate (1). This intramolecular nucleophile can 
be N-terminal or side chain -NH2s that give cyclic lactams, or side chain -OHs that result 
in macrolactones. The last strategy of chain release is to employ a reductase (Red) 
domain rather than the TE domain that utilizes NAD(P)H as a hydride-transfer 
cosubstrate (1). Usually, the most downstream catalytic domain in such assembly lines is 
a reductase domain instead of a TE domain. The two-electron reduction of an acyl 
thioester generates the thioacetal, which spotaneously decomposes to release an aldehyde 
product. In some cases, the aldehyde can undergo a second round of reduction to give an 
alcohol. 
Curacin A is a potent antimitotic agent isolated from L. majuscula (2, 3). As a mixed 
polyketide/non-ribosomal peptide, it has unusually high hydrophobicity. All the keto 
groups from the chain extension steps are reduced to hydroxyl groups, which are 
removed by the dehydratase (DH)-catalyzed dehydration or modified by 
O-methyltransferase (OM)-catalyzed methylation. More interestingly, the curacin A has 
an unusual terminal olefin instead of a carboxyl, aldehyde or alcohol group. The 
identification of curacin A biosynthetic gene cluster (3) revealed that the terminal olefin 
group is most likely generated from the decarboxylation/dehydration catalyzed by an 
unprecedented ST-TE chain termination module. Based on the feeding study and the 
pathway annotation (3), a TE and ST-mediated decarboxylative chain termination 
mechanism was proposed (Figure 5-1). 
Sulfotransferases are enzymes that catalyze the transfer of a sulfuryl group from the 
donor, PAPS, to the receptors ranging from proteins to compounds (4). Two classes of 
STs have been identified and characterized: cytosolic STs and membrane-associated STs. 
Cytosolic STs sulfonate small endogenous and exogenous compounds, such as hormones, 
bioamines, drugs, and various xenobiotic compounds, which are involved in 
detoxification, hormone regulation, and drug metabolism (4). Membrane-associated STs, 
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many of which have been implicated recently in crucial biological processes, sulfonate 
larger biomolecules, such as carbohydrates and proteins, and play key roles in a number 
of molecular-recognition events and biochemical signaling pathways (4). Here, CurM ST 
is unprecedented in that it is embedded in PKS modules and recruited for polyketide 
chain termination process. 
The sulfotransferase superfamily members have a conserved structural fold, a core 
of four to five parallel beta-strands flanked by alpha helices. The PAPS binding region is 
highly conserved both in primary and tertiary structures (4). Given the diverse nature of 
sulfuryl group receptor, it is expected that the substrate-binding region has the most 
variation (4). Mechanistic insights have been derived from the solved X-ray structures of 
some STs and their biochemical studies. It was demonstrated that the sulfonation 
reactions proceed by an in-line attack of the nucleophile at the sulfate group of PAPS. 
However, it is yet to be confirmed that whether the conserved active-site histidine residue 
assists in the reaction by deprotonating the substrate hydroxyl group, or acts as a 
nucleophile to form an unstable protein-sulfate complex (5). 
 
Figure 5-1. The terminal olefin formation via decarboxylative elimination mechanisms. A. 
MDD-catalyzed decarboxylative elimination. B. Proposed chain termination mechanism in 
curacin A pathway. 
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This unusual decarboxylative chain termination chemistry provides us an useful tool 
to generate a terminal olefin into polyketide-related compounds. Presumably, the 
ST-catalyzed sulfonation of β-hydroxyl group can promote the decarboxylative 
elimination by recruiting the sulfate as an excellent leaving group. However, the timing 
of sulfonation and TE cleavage, as well as the enzyme that mediates the decarboxylative 
elimination is not evident. Notably, similar strategy to generate the terminal olefin was 
observed in the mevalonate pathway in isoprenoid biosynthesis. A kinase, 
mevalonate-5-diphosphate decarboxylase (MDD), was proved to convert β-hydroxyl 
group in mevalonate-5-diphosphate to phosphate group, which also serves as a leaving 
group, and catalyze successive decarboxylative elimination leading to a isopentenyl 
diphosphate product (Figure 5-1) (6). However, a similar terminal olefin in tautomycetin 
(TMC), a polyketide metabolite isolated from Streptomyces sp. CK4412 and identified as 
an immunosuppressor of activated T cells, is likely generated by a distinct unknown 
mechanism (7). In tautomycetin biosynthetic pathway, only TE was observed in the chain 
termination module, and some tailoring enzymes, such as a P450 and decarboxylase, 
were suggested to mediate the terminal olefin formation (7). 
The ST-TE chain termination module provides us a useful bioengineering tool to 
generate a highly hydrophobic functional group in the polyketide-related compounds, 
which might optimize the physicochemical properties of some natural products. 
5.3  RESULTS 
5.3.1  Resequencing of CurM TE Domain 
Based on the bioinformatic analysis and protein expression results, the previously 
published sequence of the end of curacin A pathway that starts from the middle of CurM 
TE region (3) was predicted to be incorrect. Only a part of thioesterase domain was found 
in this TE region based on the Conserved Domain (CD) searching and sequence 
alignment. No soluble protein expression was achieved for any CurM TE-containing 
constructs, such as ACP-ST-TE, ST-TE and TE. 
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We sought to identify the cosmids that contain the correct curacin A downstream 
pathway. Thus, the selected cosmids from the genomic library (8) that contain PKS or 
NRPS modules were screened by PCR using a primer pair that amplifies curM ST gene. 
The pLM19 and pLM14 cosmids (3) were detected to contain curM ST gene. These two 
cosmids were further sequenced by the primer walking from CurM TE to ~300 base pair 
downstream. Our results confirmed that the published sequence (3) of CurM TE and its 
downstream regions in pLM17 does not belong to the curacin A pathway. This finding is 
supported by the result from the L. majuscula single cell genome sequencing project 
provided by William Gerwick lab at UCSD (Figure 5-2). 
Based on the corrected sequence of curacin A downstream pathway, this pathway 
ends at curM, and no curN (3) was found in the downstream region. The new CurM TE 
sequence was predicted to contain a full conserved region for thioesterases. 
5.3.2  CurM ST Assays 
CurM ST was biochemically assessed to identify and characterize its activities. The 
ST was produced as an N-terminal His-tagged protein (Figure 5-3). Two long chain (C14) 
model substrates with (R) or (S) β-hydroxyl and δ-methoxyl groups were synthesized as the 
CoA and SNAC thioesters. The CoA substrates were also loaded onto (apo) CurM ACP to 
generated ACP-linked substrates. All CoA, SNAC and ACP-linked substrates were proved 
to be sulfonated by CurM ST. Thus, we focused on the substrates in CoA thioester form to 
examine the stereoselectivity for the β-hydroxyl group. The CurM ST transfers sulfuryl 
group from PAPS to both substrates with (R) and (S) β-hydroxyl groups (Figure 5-4). 
Figure 5-2. The updated curacin A downstream pathway from L. majuscular genome 












amount of α, β 
dehydration product was observed for the (S) β-hydroxyl group substrate, which suggests 
that (S) β-sulfate group might serve as a leaving group for ST-catalyzed dehydration. 
5.3.3  CurM TE Assays 
The CurM TE was produced as a partially soluble C-terminal His-tagged protein 
(Figure 5-3). The model 
substrates in the CoA 
thioester form were 
examined for the TE 
stereoselectivity of the 
β-hydroxyl group. The 
CurM TE was proved to 
cleave the thioester bond 
of both model substrates 
with the (R) and (S) 
β-hydroxyl groups 
(Figure 5-4). However, 
according to our 
preliminary HPLC 
 
Figure 5-3. Ni-NTA purifications of CurM ACP, TE and ST. 
Figure 5-4. HPLC analysis for the ST and TE assays. 
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analysis, the CurM TE shows a higher catalytic acitivity for the (R) β-hydroxyl group 
substrate than (S) β-hydroxyl group substrate, suggesting that the native substrate of CurM 
ST should contain a (R) β-hydroxyl group. 
5.4  FUTURE DIRECTIONS 
The terminal olefin products of the chain model substrates can only be detected by 
GC-MS, which is not facile method for the follow-up kinetic assays. Thus, we decided to 
introduce a hydrophilic imidazole 
group as a chromophore into the 
model substrates (Figure 5-5) to 
facilitate the HPLC analysis. These 
substrates will be synthesized by Peter 
Wipf group at University of 
Pittsburgh. 
Given our results from the CurM 
ST and TE assays, some questions are 
yet to be answered: (1) the timing of 
ST-catalyzed sulfonation. Does it 
happen before or after the TE 
cleavage? We need to test whether 
CurM ST can catalyze the sulfonation 
of the carboxylic acids after the TE 
cleavage. (2) Which enzyme catalyzes 
the decarboxylative elimination, ST or 
TE? The ST-catalyzed dehydration of the CoA thioesters implies that the activity of ST 
might not be limited to the β-hydroxyl sulfonation. The new designed 
imidazole-containing model substrates will enable us to trace their intermediates and 
products in ST/TE-coupled assays. 
5.5  MATERIAL AND METHODS 

















Figure 5-5. Imidazole-containing model 
substrates and the authentic standard for the 
HPLC analysis of terminal olefin products. 
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Chemicals. PAPS was from Sigma-Aldrich (>60% purity). The model substrates in 
carboxyl acid forms were synthesized by Peter Wipf group at University of Pittsburgh. 
The CoA or SNAC thioesters of the model substrates were synthesized as described in 
chapter 4. All other chemicals were from Sigma-Aldrich. 
Bacterial strains, media and culture conditions. Escherichia coli DH5α MCR 
(Invitrogen) was used for DNA propagation. Escherichia coli BL21 (DE3) transformed 
with the derivatives of pET24b and pET28b were used for protein overexpression in 
Luria-Bertani (LB) medium. Ampicillin (100 μg/mL), carbenecillin (100 μg/mL), 
kanamycin (50 μg/mL), and apramycin (50 μg/mL) were used for the corresponding 
plasmid construct resistance marker selection in E. coli cultures. 
Resequencing of curM. The selected cosmids from the cosmid library (8) of L. majuscula 
were screened by PCR using a pair of primers to amplify CurM ST gene: (F) GGA TGC 
GGA TGC AAA AAC TTG, and (R) CGG ATG CAA AAA CTT GTC GGG. According 
to the PCR results, pLM19 and pLM14, as well as pLM17 (8) were detected to contain 
curM ST gene. The restriction enzyme digestion patterns of these cosmids were found to 
be similar, suggesting that they share the DNA fragments from the digested genomic 
DNA of L. majuscula. The two cosmids, pLM19 and pLM14, were further sequenced by 
primer walking in the CurM TE and the downstream regions. Our sequencing results 
confirmed that the previously published sequences (3) of CurM TE and also its 




Plasmid construction and site mutagenesis. The primers used for the plasmid 
construction and site-directed mutagenesis were listed in table 5-1. CurM ACP, ST and TE 
genes were amplified from cosmid pLM14 or pLM19. The CurM ACP, ST-TE and 
ACP-ST-TE genes were inserted into pET24b plasmid with NdeI and NotI restriction sites. 
The CurM ST gene was inserted into pET28b plasmid with NdeI and BamHI restriction 
sites. All the constructs were verified by DNA sequencing. 
Protein overexpression. E. coli BL21 (DE3) was transformed by the pET24b::CurM ACP, 
and pET24b::CurM TE plasmids to overexpress C-terminal His-tagged proteins, and by 
pET28b::CurM ST plasmid to overexpress N-terminal His-tagged protein. CurM ACP was 
overexpressed in the apo form. Cells were grown at 30oC to an OD (590 nm) = 0.5-0.6, and 
then cooled to 15oC prior to the addition of 1 mM isopropyl-β-D-galactopyranoside (IPTG). 
The cultures were grown at 15oC for another 18-20 h before harvesting. 
Protein purification. Protein purifications were performed at 4oC. Generally, the first 
step Ni-affinity purifications for all His-tagged proteins were performed under the same 
conditions. E. coli cells were harvested by centrifugation (4,000 g, 15 min, 4oC), 
resuspended in the ice cold lysis buffer A (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 10 
mM imidazole, 20% glycerol) and disrupted by sonication on ice. The cell debris was 
removed by centrifugation at 15,000 g for 50 min. The supernatant was gently removed 
and loaded onto the 5 ml HisTrap column (GE Healthcare) preequilibrated with lysis 
buffer A. The resin was washed successively with ~ 10 column volumes of the washing 
buffer B (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 20 mM imidazole, 10% glycerol) to 
remove nonspecifically bound contaminants. Bound proteins were eluted with imidazole 
by a linear gradient of the elution buffer C (50 mM PBS buffer, pH 8.0, 300 mM NaCl, 
250 mM imidazole, 20% glycerol). The eluate was checked by SDS-PAGE for purity, 
pooled and concentrated using Amicon Ultra-15 (10 kDa or 5 kDa) centrifugal devices 
(Millipore). The concentrated eluate was loaded onto HiPrep 26/10 Desalting column 
equilibrated with the storage buffer D (50 mM PBS buffer, pH 7.5, 200 mM NaCl, 20% 
glycerol). The fractions were pooled, concentrated, flash-frozen in 50-200 μl aliquots in 
liquid N2, and stored at -80oC for further use. The purity of the proteins was analyzed by 
SDS-PAGE and the protein concentrations were determined using the Bradford assay 
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(Bio-Rad). 
The preparation of CurM ACP-linked model substrates. The model substrates were 
firstly coupled to CoASH to generate CoA thioesters, which were loaded onto (apo) 
CurM ACP using sfp or svp protocol described previously (9). 
HPLC analysis of the ST-catalyzed sulfonation on the model substrates. HPLC 
analysis of the ST-catalyzed sulfonation was performed using XBridge C18 column (4.6 
x 250 mm, 5 μm, Waters) on the Gold HPLC system equipped with an autosampler and 
controlled by 32 Karat software (Beckman Coulter). The CoA samples were eluted with a 
linear gradient from 3% to 100% of MeOH/H2O (10 mM CH3CO2NH4). The SNAC 
samples were eluted with linear gradient from 5% to 100% of CH3CN/H2O (0.1% 
CF3COOH). For the sulfonation assays, 200 μM CoA or SNAC model substrates were 
incubated with 20 μM CurM ST, and 1 mM PAPS in 50 mM Tris-HCl, pH 7.5, for 2 
hours at room temperature. DMSO (1%) was added to increase solubility of SNAC 
substrates. The reaction mixtures were filtrated by Microcon YM-10 (Millipore), and 
analyzed by HPLC. 
HPLC analysis of the TE-catalyzed sulfonation on the model substrates. The HPLC 
analysis conditions for the TE assays were similar to those of the ST assays described 
above. The CoA samples were eluted with a linear gradient from 3% to 100% of 
MeOH/H2O (10 mM CH3CO2NH4). The SNAC samples were eluted with linear gradient 
from 5% to 100% of CH3CN/H2O (0.1% CF3COOH). For the TE assays, 200 μM CoA or 
SNAC model substrates were incubated with 10 μM CurM TE in 50 mM Tris-HCl, pH 
7.5, for 1 hours at room temperature. DMSO (1%) was added to increase solubility of 
SNAC substrates. The reaction mixtures were filtrated by Microcon YM-10 (Millipore), 
and analyzed by HPLC. 
Analysis of CurM ACP samples by ESI-FTICR-MS. CurM ACP samples were 
prepared by loading the reaction mixtures on Source 15PRC reverse phase column. The 
proteins were eluted with a linear gradient from 30% to 70% CH3CN (0.05% HCOOH 
and 0.05% CF3COOH)/H2O (0.05% HCOOH and 0.05% CF3COOH). Mass 
spectrometric analysis was performed with an actively shielded 7 Tesla 
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quadrupole-Fourier transform ion cyclotron resonance mass spectrometer (APEX-Q, 
Bruker Daltonics, Billerica, MA). Target analytes were diluted in an electrospray solution 
(1:1 CH3CN:H2O with 0.1% HCOOH) and directly infused into an electrospray 
ionization (ESI) source (Apollo II, Bruker Daltonics) at a flow rate of 70 µL/h and a 
voltage of - 3.8 kV. A counterflow of hot (240°C) nitrogen gas was applied to assist 
desolvation of ESI droplets. For accurate mass determination, up to 10 picomoles of 
apomyoglobin (Sigma, St. Louis, MO) was spiked into the ESI solution as internal 
calibrant.  Multiply protonated ions generated from ESI were externally accumulated in 
a hexapole for 1 s and transferred via high voltage ion optics to the ICR cell for analysis. 
All data were acquired with XMASS software (version 6.1, Bruker Daltonics) in 
broadband mode from m/z = 200 to 2000 with 512k data points and summed over 20-30 
scans. Mass spectra were analyzed with the MIDAS analysis software (10). When needed, 
external frequency-to-m/z calibration was performed with a two-term calibration 
equation (11) using two calibration standards (m/z = 622.02895 and 922.00979, from the 
calibration mix G2421A, Agilent Technologies, Palo Alto, CA). For infrared multiphoton 
dissociation (IRMPD), precursor ions were mass-selectively accumulated in a hexapole 
with a 3-5 m/z quadrupole isolation window, transferred to the ICR cell, and irradiated 
for 100-300 ms by 10.6 μm photons at 10 W laser power (25 W CO2 laser, Synrad, 
Mukilteo, WA) for 30-50 scans. 
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6.1  NATURAL PRODUCT ASSEMBLY LINES IN EVOLUTION 
Natural product biosynthetic pathways are comprised of gene sets whose architecture 
reflects an ongoing evolutionary process. In bacterial type I PKS and NRPS systems, the 
metabolic pathway includes a series of modules that specify the nature of the starter unit, 
extender unit and termination processes to generate a core molecule. Within this 
biosynthetic framework numerous genetic determinants ultimately translate into the order, 
nature and number of catalytic domains within the PKS or NRPS multifunctional proteins. 
In turn, this determines the chemical outcome relating to each step during polyketide or 
non-ribosomal peptide assembly. As chain elongation progresses, keto group processing 
reactions determine the fate of the β-carbonyl group, stereochemistry of the resulting 
hydroxyl, or configuration of the double bond. In essence, each reaction operates 
independently, yet the catalytic event driving it has evolved within the scope of an 
extremely complex biosynthetic machine whose parts operate together efficiently. 
The driving forces that determine co-evolution of multiple catalytic domains or 
enzymes within a secondary metabolic pathway remain largely unknown. Thus, although 
the biological role of many chemically diverse natural products is understood with 
respect to human cell targets, their natural or indigenous targets may never be definitively 
revealed. On the other hand, we assume that pathways of secondary metabolism evolve 
and expand by mechanisms similar to those recognized for primary metabolic pathways. 
However, tracing the ancestral forms of multiple genes as a functional collective is 
elusive, especially when they are dispersed in the genome. Biosynthetic genes from 
microbial hosts are usually clustered in their genomes, and as such are ideal for 
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evolutionary studies (1). 
6.2  DIFFERENT TYPES OF MEATABOLIC PATHWAY 
EVOLUTION 
The curacin A pathway enabled us to witness the innovation on a polyketide 
assembly line by different types of metabolic pathway evolution. This pathway is largely 
constructed by the canonical PKS and NRPS modules. However, in its chain initiation, 
extension and termination modules, some unusual catalytic elements were incorporated 
and catalyze the unprecedented reactions on the polyketide assembly line. These 
interesting catalytic enzymes and domains in canonical PKS module offer us a precious 
chance to reveal the evolution events that enabled the formation of curacin A pathway. 
The biochemical, bioinformatic and structural studies described in this dissertation 
demonstrated that these different types of pathway evolution are widely employed and 
significantly promote the chemical diversity of natural products. 
6.2.1  Insertion of Gene Assembly by Homologous Recombination 
The type I PKS and NRPS are highly modularized biosynthetic machinery. They 
serve as a paradigm for secondary metabolic systems that are successful in natural 
selection to expand chemical diversity. It is well know that the evolution of metabolic 
pathways proceeds by patterns of gene duplication, insertion and mutation. Recent 
bioinformatic studies suggest that some highly conserved sequences in PKS modules can 
facilitate domain replacement by homologous recombination (2, 3). As such, the 
conserved regions in these highly modularized systems give us a good reason to explain 
why these complex biosynthetic machines are chosen by nature to expand chemical 
diversity in secondary metabolism. In chapter 4, our comparative studies of the Cur and 
Jam pathways indicate that a whole gene assembly is inserted into polyketide pathway by 
the “di-AT” replacement. This type of the replacement might frequently happen in PKS 
pathway to achieve pathway expansion and contraction via an economic way. As more 
and more genome sequencing data become available, we will have enough samples to 
study the roles of homologous recombination in construction of new biosynthetic 
pathways. We also expect that this genetic strategy can be employed to the pathway 
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engineering in laboratory.  
6.2.2  Recruitment of New Enzymes to Change Biochemical Schemes 
In this dissertation, there are two perfect examples to show how new enzymes are 
recruited into the biosynthetic pathway and then significantly revise the biochemical 
schemes. In chapter 4, the Cur and Jam Hal domain are revealed to be introduced into the 
HMG enzyme assembly to catalyze the chlorination of (S)-HMG-ACP3. This chlorination 
step revised the scheme of HMG β-branching modification. Without the chlorination step, 
an isovaleryl-ACP3 is generated, but after the chlorination, the Cur ER catalyzes a 
cyclopropanation step instead of α,β saturation to form 
2-methylcyclopropane-1-carboxyl-ACP3. In chapter 5, another example is the terminal 
olefin formation in the chain termination of curacin A pathway. A sulfotransferase is 
incorporated into the chain termination module, and catalyzes the β-hydroxyl sulfonation 
to generate a good leaving group. Without the sulfotransferase, the thioesterase just 
cleaves the acyl chain from ACP to yield the product with a carboxylic end. Instead, the 
sulfonated product undergoes a decarboxylative chain termination to produce the terminal 
olefin. These two elegant biochemistries show us the tremendous capability of nature to 
innovate biosynthetic mechanisms from the existing ones. 
6.2.3  Development of New Functions from Old Enzyme Scaffolds 
The biosynthetic enzymes in secondary metabolism show significant substrate 
tolerance and catalytic promiscuity (4, 5), which can facilitate the generation of new 
functions from the same protein scaffold. In chapter 2, the GNATL domain in the chain 
initiation module of curacin A pathway was proved to be a member of GNAT 
superfamily. GNATs normally catalyze the N-acetyltransfer from acetyl-CoA to the 
primary amine groups on small molecules or proteins. However, the GNATL domain was 
demonstrated to catalyze the unprecedented S-acetyltransfer and decarboxylation 
reactions. Similarly, in chapter 4, the Cur ER domain shows the highest sequence identity 
to the Jam ER domain. Unexpectedly, the Cur ER catalyzes a cyclopropanation step of 
the chlorinated substrate, but the Jam ER domain only catalyzes the canonical saturation 
reaction. It is proposed that some mutations happen in the active site of Cur ER to 
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remove proton source from the α-carbanion in favor of the cyclopropanation via an 
intramolecular nucleophilic substitution. The GNATL and ER domains well exemplify 
the intriguing protein evolution events that develop new functions from the same enzyme 
scaffolds. Our undergoing structural studies will let us know more details about the 
sequence variation that can yield these new activities. 
6.2.4  Diversification of Regiochemical Control for Pathway Ramification 
In chapter 4, we show that the change of the decarboxylation regiochemical control 
can diversify pathway to produce the distinct functional groups in the final products. In 
HMG enzyme cassette, the ECH2 domain normally generates decarboxylation products 
with a α,β C=C. However, the regiochemical control of Jam ECH2 domain is 
differentiated to form the β,γ C=C product which can not be reduced by Jam ER. Some 
residues in a hypervariable region are suggested to contribute to the ECH2 
regioselectivity. Thus, our results suggest that the ECH2 regiochemical control might be 
easily effected by the mutations happen in this hypervariable region, which might be a 
facile way to diversify biosynthetic pathways to form distinct functional groups.  
6.2.5  Synergized Co-Evolution in Multienzyme System 
In natural product assembly lines, the changes on upstream enzymes will evidently 
effect downstream enzymes. If the downstream enzymes cannot effectively respond to 
upstream biochemical variations, the whole pathway will be nullified. In chapter 4, the 
introduction of a chlorination step renders the functional diversification of the Cur ER 
domain. The chlorination step can increase hydrophobicity of the final product. Given the 
unusually high hydrophobicity of curacin structure, which is successfully constructed to 
serve its host, the increase of the hydrophobicity might not be beneficial for the 
biological activity of final product. The Cur ER domain seems to respond to this change 
by eliminating the chlorine group to increase the hydrophobicity. Thus, this could be nice 
example for synergized co-evolution in multi-enzyme system. 
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